pathway_name,pathway_id,pathway_url,gene_symbol,ensg_id,chembl_id,drug_name,phase,status,disease_id,disease_name,mechanismOfAction,smiles
Transcriptional activation of mitochondrial biogenesis,R-HSA-2151201,https://reactome.org/PathwayBrowser/#/R-HSA-2151201,IDH2,ENSG00000182054,CHEMBL3989931,ENASIDENIB MESYLATE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O
Transcriptional activation of mitochondrial biogenesis,R-HSA-2151201,https://reactome.org/PathwayBrowser/#/R-HSA-2151201,IDH2,ENSG00000182054,CHEMBL3989908,ENASIDENIB,3.0,Completed,EFO_0000565,leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1
Transcriptional activation of mitochondrial biogenesis,R-HSA-2151201,https://reactome.org/PathwayBrowser/#/R-HSA-2151201,IDH2,ENSG00000182054,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Citric acid cycle (TCA cycle),R-HSA-71403,https://reactome.org/PathwayBrowser/#/R-HSA-71403,IDH2,ENSG00000182054,CHEMBL3989931,ENASIDENIB MESYLATE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O
Citric acid cycle (TCA cycle),R-HSA-71403,https://reactome.org/PathwayBrowser/#/R-HSA-71403,IDH2,ENSG00000182054,CHEMBL3989908,ENASIDENIB,3.0,Completed,EFO_0000565,leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1
Citric acid cycle (TCA cycle),R-HSA-71403,https://reactome.org/PathwayBrowser/#/R-HSA-71403,IDH2,ENSG00000182054,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Mitochondrial protein degradation,R-HSA-9837999,https://reactome.org/PathwayBrowser/#/R-HSA-9837999,IDH2,ENSG00000182054,CHEMBL3989931,ENASIDENIB MESYLATE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O
Mitochondrial protein degradation,R-HSA-9837999,https://reactome.org/PathwayBrowser/#/R-HSA-9837999,IDH2,ENSG00000182054,CHEMBL3989908,ENASIDENIB,3.0,Completed,EFO_0000565,leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1
Mitochondrial protein degradation,R-HSA-9837999,https://reactome.org/PathwayBrowser/#/R-HSA-9837999,IDH2,ENSG00000182054,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Maturation of TCA enzymes and regulation of TCA cycle,R-HSA-9854311,https://reactome.org/PathwayBrowser/#/R-HSA-9854311,IDH2,ENSG00000182054,CHEMBL3989931,ENASIDENIB MESYLATE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O
Maturation of TCA enzymes and regulation of TCA cycle,R-HSA-9854311,https://reactome.org/PathwayBrowser/#/R-HSA-9854311,IDH2,ENSG00000182054,CHEMBL3989908,ENASIDENIB,3.0,Completed,EFO_0000565,leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1
Maturation of TCA enzymes and regulation of TCA cycle,R-HSA-9854311,https://reactome.org/PathwayBrowser/#/R-HSA-9854311,IDH2,ENSG00000182054,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
PIP3 activates AKT signaling,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Downstream signal transduction,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Signaling by PDGF,R-HSA-186797,https://reactome.org/PathwayBrowser/#/R-HSA-186797,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Constitutive Signaling by Aberrant PI3K in Cancer,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL1738797,ALECTINIB,4.0,,EFO_0000616,neoplasm,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL4559134,SELPERCATINIB,4.0,,EFO_0000616,neoplasm,,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL4582651,PRALSETINIB,4.0,,EFO_0000616,neoplasm,,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL3707320,ALECTINIB HYDROCHLORIDE,4.0,,EFO_0003060,non-small cell lung carcinoma,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL4650296,BOS-589,2.0,Completed,EFO_0000555,irritable bowel syndrome,,
RAF/MAP kinase cascade,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,R-HSA-198933,https://reactome.org/PathwayBrowser/#/R-HSA-198933,CD33,ENSG00000105383,CHEMBL1201506,GEMTUZUMAB OZOGAMICIN,4.0,,EFO_0000222,acute myeloid leukemia,,
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,R-HSA-198933,https://reactome.org/PathwayBrowser/#/R-HSA-198933,CD33,ENSG00000105383,CHEMBL2108342,GEMTUZUMAB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,R-HSA-198933,https://reactome.org/PathwayBrowser/#/R-HSA-198933,CD33,ENSG00000105383,CHEMBL2109150,LINTUZUMAB,3.0,Unknown status,EFO_0000565,leukemia,,
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,R-HSA-198933,https://reactome.org/PathwayBrowser/#/R-HSA-198933,CD33,ENSG00000105383,CHEMBL2109267,M195,1.0,Completed,EFO_0000198,myelodysplastic syndrome,,
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,R-HSA-198933,https://reactome.org/PathwayBrowser/#/R-HSA-198933,CD33,ENSG00000105383,CHEMBL2109266,AVE-9633,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,CD33,ENSG00000105383,CHEMBL1201506,GEMTUZUMAB OZOGAMICIN,4.0,,EFO_0000222,acute myeloid leukemia,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,CD33,ENSG00000105383,CHEMBL2108342,GEMTUZUMAB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,CD33,ENSG00000105383,CHEMBL2109150,LINTUZUMAB,3.0,Unknown status,EFO_0000565,leukemia,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,CD33,ENSG00000105383,CHEMBL2109267,M195,1.0,Completed,EFO_0000198,myelodysplastic syndrome,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,CD33,ENSG00000105383,CHEMBL2109266,AVE-9633,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL3989958,IVOSIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4297610,OLUTASIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4167360,IDH305,2.0,Withdrawn,EFO_1000453,Paraganglioma,,Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4651002,SAFUSIDENIB,2.0,Recruiting,EFO_1000453,Paraganglioma,,Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4650282,DS-1001B,2.0,"Active, not recruiting",MONDO_0021639,grade II glioma,,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4206033,BAY1436032,1.0,Completed,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Neutrophil degranulation,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
PI3K Cascade,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
FLT3 Signaling,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
STAT5 Activation,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
FLT3 mutants bind TKIs,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
STAT5 activation downstream of FLT3 ITD mutants,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
KW2449-resistant FLT3 mutants,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
semaxanib-resistant FLT3 mutants,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
crenolanib-resistant FLT3 mutants,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
gilteritinib-resistant FLT3 mutants,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
lestaurtinib-resistant FLT3 mutants,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
midostaurin-resistant FLT3 mutants,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
pexidartinib-resistant FLT3 mutants,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
ponatinib-resistant FLT3 mutants,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
quizartinib-resistant FLT3 mutants,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
sorafenib-resistant FLT3 mutants,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
sunitinib-resistant FLT3 mutants,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
tandutinib-resistant FLT3 mutants,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
linifanib-resistant FLT3 mutants,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
tamatinib-resistant FLT3 mutants,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Signaling by FLT3 ITD and TKD mutants,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Negative regulation of FLT3,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
FLT3 signaling through SRC family kinases,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
FLT3 signaling by CBL mutants,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Regulation of actin dynamics for phagocytic cup formation,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Role of ABL in ROBO-SLIT signaling,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Myogenesis,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
RHO GTPases Activate WASPs and WAVEs,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
HDR through Single Strand Annealing (SSA),R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Cyclin D associated events in G1,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
RUNX1 regulates transcription of genes involved in differentiation of HSCs,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
RUNX2 regulates osteoblast differentiation,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
FCGR3A-mediated phagocytosis,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Factors involved in megakaryocyte development and platelet production,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Apoptotic cleavage of cellular proteins,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Apoptotic cleavage of cellular proteins,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Apoptotic cleavage of cellular proteins,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Apoptotic cleavage of cellular proteins,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Apoptotic cleavage of cellular proteins,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Apoptotic cleavage of cellular proteins,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Apoptotic cleavage of cellular proteins,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Apoptotic cleavage of cellular proteins,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Apoptotic cleavage of cellular proteins,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Calmodulin induced events,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Calmodulin induced events,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Calmodulin induced events,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Calmodulin induced events,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Calmodulin induced events,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Calmodulin induced events,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Calmodulin induced events,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Calmodulin induced events,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Calmodulin induced events,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Calmodulin induced events,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCE,ENSG00000171132,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCE,ENSG00000171132,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCE,ENSG00000171132,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCE,ENSG00000171132,CHEMBL4297775,KAI-1678,2.0,Completed,HP_0012531,Pain,,
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCE,ENSG00000171132,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCH,ENSG00000027075,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCH,ENSG00000027075,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCH,ENSG00000027075,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCH,ENSG00000027075,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Effects of PIP2 hydrolysis,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCE,ENSG00000171132,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCE,ENSG00000171132,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCE,ENSG00000171132,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCE,ENSG00000171132,CHEMBL4297775,KAI-1678,2.0,Completed,HP_0012531,Pain,,
SHC1 events in ERBB2 signaling,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCE,ENSG00000171132,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
DAG and IP3 signaling,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
DAG and IP3 signaling,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
DAG and IP3 signaling,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
DAG and IP3 signaling,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
DAG and IP3 signaling,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
DAG and IP3 signaling,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCE,ENSG00000171132,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
DAG and IP3 signaling,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCE,ENSG00000171132,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
DAG and IP3 signaling,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCE,ENSG00000171132,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
DAG and IP3 signaling,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCE,ENSG00000171132,CHEMBL4297775,KAI-1678,2.0,Completed,HP_0012531,Pain,,
DAG and IP3 signaling,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCE,ENSG00000171132,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Role of phospholipids in phagocytosis,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Role of phospholipids in phagocytosis,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Role of phospholipids in phagocytosis,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Role of phospholipids in phagocytosis,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Role of phospholipids in phagocytosis,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Role of phospholipids in phagocytosis,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCE,ENSG00000171132,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Role of phospholipids in phagocytosis,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCE,ENSG00000171132,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Role of phospholipids in phagocytosis,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCE,ENSG00000171132,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Role of phospholipids in phagocytosis,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCE,ENSG00000171132,CHEMBL4297775,KAI-1678,2.0,Completed,HP_0012531,Pain,,
Role of phospholipids in phagocytosis,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCE,ENSG00000171132,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCE,ENSG00000171132,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCE,ENSG00000171132,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCE,ENSG00000171132,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCE,ENSG00000171132,CHEMBL4297775,KAI-1678,2.0,Completed,HP_0012531,Pain,,
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCE,ENSG00000171132,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCH,ENSG00000027075,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCH,ENSG00000027075,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCH,ENSG00000027075,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCH,ENSG00000027075,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling events,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
HuR (ELAVL1) binds and stabilizes mRNA,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
HuR (ELAVL1) binds and stabilizes mRNA,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
HuR (ELAVL1) binds and stabilizes mRNA,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
HuR (ELAVL1) binds and stabilizes mRNA,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
HuR (ELAVL1) binds and stabilizes mRNA,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
HuR (ELAVL1) binds and stabilizes mRNA,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
HuR (ELAVL1) binds and stabilizes mRNA,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
HuR (ELAVL1) binds and stabilizes mRNA,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
HuR (ELAVL1) binds and stabilizes mRNA,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
HuR (ELAVL1) binds and stabilizes mRNA,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
VEGFR2 mediated cell proliferation,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
CLEC7A (Dectin-1) signaling,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
CLEC7A (Dectin-1) signaling,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
CLEC7A (Dectin-1) signaling,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
CLEC7A (Dectin-1) signaling,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
CLEC7A (Dectin-1) signaling,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RHO GTPases Activate NADPH Oxidases,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RHO GTPases Activate NADPH Oxidases,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
RHO GTPases Activate NADPH Oxidases,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RHO GTPases Activate NADPH Oxidases,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RHO GTPases Activate NADPH Oxidases,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RHO GTPases Activate NADPH Oxidases,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RHO GTPases Activate NADPH Oxidases,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
RHO GTPases Activate NADPH Oxidases,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RHO GTPases Activate NADPH Oxidases,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RHO GTPases Activate NADPH Oxidases,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Interferon gamma signaling,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
KEAP1-NFE2L2 pathway,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
KEAP1-NFE2L2 pathway,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
KEAP1-NFE2L2 pathway,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
KEAP1-NFE2L2 pathway,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
KEAP1-NFE2L2 pathway,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Inhibition of replication initiation of damaged DNA by RB1/E2F1,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Inhibition of replication initiation of damaged DNA by RB1/E2F1,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Inhibition of replication initiation of damaged DNA by RB1/E2F1,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F1,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F1,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F1,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F1,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switching on the C-strand of the telomere,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switching on the C-strand of the telomere,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switching on the C-strand of the telomere,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switching on the C-strand of the telomere,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomere,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomere,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switching on the C-strand of the telomere,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Telomere C-strand synthesis initiation,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Telomere C-strand synthesis initiation,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Telomere C-strand synthesis initiation,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Telomere C-strand synthesis initiation,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand synthesis initiation,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand synthesis initiation,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Telomere C-strand synthesis initiation,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
DNA replication initiation,R-HSA-68952,https://reactome.org/PathwayBrowser/#/R-HSA-68952,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
DNA replication initiation,R-HSA-68952,https://reactome.org/PathwayBrowser/#/R-HSA-68952,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
DNA replication initiation,R-HSA-68952,https://reactome.org/PathwayBrowser/#/R-HSA-68952,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
DNA replication initiation,R-HSA-68952,https://reactome.org/PathwayBrowser/#/R-HSA-68952,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiation,R-HSA-68952,https://reactome.org/PathwayBrowser/#/R-HSA-68952,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiation,R-HSA-68952,https://reactome.org/PathwayBrowser/#/R-HSA-68952,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
DNA replication initiation,R-HSA-68952,https://reactome.org/PathwayBrowser/#/R-HSA-68952,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Activation of the pre-replicative complex,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Activation of the pre-replicative complex,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Activation of the pre-replicative complex,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Activation of the pre-replicative complex,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative complex,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative complex,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Activation of the pre-replicative complex,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switching,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switching,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switching,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switching,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switching,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediate,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediate,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediate,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediate,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediate,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediate,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediate,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the lagging strand,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the lagging strand,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the lagging strand,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the lagging strand,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging strand,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging strand,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the lagging strand,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
G1/S-Specific Transcription,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
G1/S-Specific Transcription,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
G1/S-Specific Transcription,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
G1/S-Specific Transcription,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
G1/S-Specific Transcription,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
G1/S-Specific Transcription,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
G1/S-Specific Transcription,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Defective pyroptosis,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Defective pyroptosis,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Defective pyroptosis,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Defective pyroptosis,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Defective pyroptosis,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Defective pyroptosis,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Defective pyroptosis,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Defective pyroptosis,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Defective pyroptosis,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Defective pyroptosis,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Defective pyroptosis,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL38,TRETINOIN,4.0,Unknown status,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL1131,ACITRETIN,4.0,Completed,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL1265,ADAPALENE,4.0,"Active, not recruiting",EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL38,TRETINOIN,4.0,,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL1131,ACITRETIN,4.0,"Active, not recruiting",EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL1657,TAZAROTENE,4.0,Completed,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL3707313,TRIFAROTENE,4.0,,EFO_0003894,acne,,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathway,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL2105648,PALOVAROTENE,4.0,,MONDO_0007606,fibrodysplasia ossificans progressiva,,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL38,TRETINOIN,4.0,Unknown status,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL1131,ACITRETIN,4.0,Completed,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL1265,ADAPALENE,4.0,"Active, not recruiting",EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL38,TRETINOIN,4.0,,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL1131,ACITRETIN,4.0,"Active, not recruiting",EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL1657,TAZAROTENE,4.0,Completed,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL3707313,TRIFAROTENE,4.0,,EFO_0003894,acne,,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Acid,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL2105648,PALOVAROTENE,4.0,,MONDO_0007606,fibrodysplasia ossificans progressiva,,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL38,TRETINOIN,4.0,Unknown status,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL1131,ACITRETIN,4.0,Completed,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL1265,ADAPALENE,4.0,"Active, not recruiting",EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL38,TRETINOIN,4.0,,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL1131,ACITRETIN,4.0,"Active, not recruiting",EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL1657,TAZAROTENE,4.0,Completed,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL3707313,TRIFAROTENE,4.0,,EFO_0003894,acne,,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesis,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL2105648,PALOVAROTENE,4.0,,MONDO_0007606,fibrodysplasia ossificans progressiva,,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21
Activation of NOXA and translocation to mitochondria,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Activation of NOXA and translocation to mitochondria,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Activation of NOXA and translocation to mitochondria,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Activation of NOXA and translocation to mitochondria,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Activation of NOXA and translocation to mitochondria,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Activation of NOXA and translocation to mitochondria,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Activation of NOXA and translocation to mitochondria,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Activation of NOXA and translocation to mitochondria,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Activation of NOXA and translocation to mitochondria,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Activation of PUMA and translocation to mitochondria,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Activation of PUMA and translocation to mitochondria,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Activation of PUMA and translocation to mitochondria,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Activation of PUMA and translocation to mitochondria,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Activation of PUMA and translocation to mitochondria,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Activation of PUMA and translocation to mitochondria,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Activation of PUMA and translocation to mitochondria,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Activation of PUMA and translocation to mitochondria,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Activation of PUMA and translocation to mitochondria,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Pre-NOTCH Transcription and Translation,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Pre-NOTCH Transcription and Translation,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Pre-NOTCH Transcription and Translation,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Pre-NOTCH Transcription and Translation,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Pre-NOTCH Transcription and Translation,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Pre-NOTCH Transcription and Translation,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Pre-NOTCH Transcription and Translation,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Pre-NOTCH Transcription and Translation,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Pre-NOTCH Transcription and Translation,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Oxidative Stress Induced Senescence,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Oxidative Stress Induced Senescence,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Oxidative Stress Induced Senescence,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Oxidative Stress Induced Senescence,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Oxidative Stress Induced Senescence,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Oxidative Stress Induced Senescence,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Oxidative Stress Induced Senescence,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Oxidative Stress Induced Senescence,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Oxidative Stress Induced Senescence,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Formation of Senescence-Associated Heterochromatin Foci (SAHF),R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Formation of Senescence-Associated Heterochromatin Foci (SAHF),R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Formation of Senescence-Associated Heterochromatin Foci (SAHF),R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Formation of Senescence-Associated Heterochromatin Foci (SAHF),R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Formation of Senescence-Associated Heterochromatin Foci (SAHF),R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Formation of Senescence-Associated Heterochromatin Foci (SAHF),R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Formation of Senescence-Associated Heterochromatin Foci (SAHF),R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Formation of Senescence-Associated Heterochromatin Foci (SAHF),R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Formation of Senescence-Associated Heterochromatin Foci (SAHF),R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Oncogene Induced Senescence,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Oncogene Induced Senescence,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Oncogene Induced Senescence,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Oncogene Induced Senescence,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Oncogene Induced Senescence,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Oncogene Induced Senescence,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Oncogene Induced Senescence,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Oncogene Induced Senescence,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Oncogene Induced Senescence,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
DNA Damage/Telomere Stress Induced Senescence,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
DNA Damage/Telomere Stress Induced Senescence,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
DNA Damage/Telomere Stress Induced Senescence,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
DNA Damage/Telomere Stress Induced Senescence,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
DNA Damage/Telomere Stress Induced Senescence,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
DNA Damage/Telomere Stress Induced Senescence,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
DNA Damage/Telomere Stress Induced Senescence,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
DNA Damage/Telomere Stress Induced Senescence,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
DNA Damage/Telomere Stress Induced Senescence,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
SUMOylation of transcription factors,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
SUMOylation of transcription factors,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
SUMOylation of transcription factors,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
SUMOylation of transcription factors,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
SUMOylation of transcription factors,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
SUMOylation of transcription factors,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
SUMOylation of transcription factors,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
SUMOylation of transcription factors,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
SUMOylation of transcription factors,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Autodegradation of the E3 ubiquitin ligase COP1,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Autodegradation of the E3 ubiquitin ligase COP1,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Autodegradation of the E3 ubiquitin ligase COP1,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Autodegradation of the E3 ubiquitin ligase COP1,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Autodegradation of the E3 ubiquitin ligase COP1,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Autodegradation of the E3 ubiquitin ligase COP1,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Autodegradation of the E3 ubiquitin ligase COP1,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Autodegradation of the E3 ubiquitin ligase COP1,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Autodegradation of the E3 ubiquitin ligase COP1,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Association of TriC/CCT with target proteins during biosynthesis,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Association of TriC/CCT with target proteins during biosynthesis,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Association of TriC/CCT with target proteins during biosynthesis,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Association of TriC/CCT with target proteins during biosynthesis,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Association of TriC/CCT with target proteins during biosynthesis,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Association of TriC/CCT with target proteins during biosynthesis,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Association of TriC/CCT with target proteins during biosynthesis,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Association of TriC/CCT with target proteins during biosynthesis,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Association of TriC/CCT with target proteins during biosynthesis,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Pyroptosis,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Metabolic Genes,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Metabolic Genes,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Metabolic Genes,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Metabolic Genes,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Metabolic Genes,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Metabolic Genes,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Metabolic Genes,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Metabolic Genes,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Metabolic Genes,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Ub-specific processing proteases,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Ub-specific processing proteases,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Ub-specific processing proteases,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Ub-specific processing proteases,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Ub-specific processing proteases,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Ub-specific processing proteases,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Ub-specific processing proteases,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Ub-specific processing proteases,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Ub-specific processing proteases,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Ovarian tumor domain proteases,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Ovarian tumor domain proteases,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Ovarian tumor domain proteases,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Ovarian tumor domain proteases,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Ovarian tumor domain proteases,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Ovarian tumor domain proteases,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Ovarian tumor domain proteases,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Ovarian tumor domain proteases,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Ovarian tumor domain proteases,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Interleukin-4 and Interleukin-13 signaling,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Transcription of DNA Repair Genes,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of DNA Repair Genes,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of DNA Repair Genes,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of DNA Repair Genes,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of DNA Repair Genes,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of DNA Repair Genes,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of DNA Repair Genes,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of DNA Repair Genes,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of DNA Repair Genes,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Transcription of Caspase Activators and Caspases,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of Caspase Activators and Caspases,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of Caspase Activators and Caspases,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of Caspase Activators and Caspases,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of Caspase Activators and Caspases,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of Caspase Activators and Caspases,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of Caspase Activators and Caspases,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of Caspase Activators and Caspases,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of Caspase Activators and Caspases,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Transcription of Death Receptors and Ligands,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of Death Receptors and Ligands,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of Death Receptors and Ligands,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of Death Receptors and Ligands,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of Death Receptors and Ligands,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of Death Receptors and Ligands,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of Death Receptors and Ligands,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of Death Receptors and Ligands,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of Death Receptors and Ligands,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of TP53 Expression,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Expression,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Expression,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Expression,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Expression,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Expression,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Expression,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Expression,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Expression,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of TP53 Activity through Phosphorylation,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Activity through Phosphorylation,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Activity through Phosphorylation,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Activity through Phosphorylation,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Activity through Phosphorylation,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Activity through Phosphorylation,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Activity through Phosphorylation,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Activity through Phosphorylation,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Activity through Phosphorylation,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of TP53 Degradation,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Degradation,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Degradation,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Degradation,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Degradation,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Degradation,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Degradation,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Degradation,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Degradation,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of TP53 Activity through Acetylation,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Activity through Acetylation,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Activity through Acetylation,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Activity through Acetylation,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Activity through Acetylation,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Activity through Acetylation,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Activity through Acetylation,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Activity through Acetylation,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Activity through Acetylation,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of TP53 Activity through Association with Co-factors,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Activity through Association with Co-factors,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Activity through Association with Co-factors,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Activity through Association with Co-factors,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Activity through Association with Co-factors,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Activity through Association with Co-factors,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Activity through Association with Co-factors,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Activity through Association with Co-factors,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Activity through Association with Co-factors,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of TP53 Activity through Methylation,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Activity through Methylation,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Activity through Methylation,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Activity through Methylation,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Activity through Methylation,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Activity through Methylation,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Activity through Methylation,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Activity through Methylation,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Activity through Methylation,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
PI5P Regulates TP53 Acetylation,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
PI5P Regulates TP53 Acetylation,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
PI5P Regulates TP53 Acetylation,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
PI5P Regulates TP53 Acetylation,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
PI5P Regulates TP53 Acetylation,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
PI5P Regulates TP53 Acetylation,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
PI5P Regulates TP53 Acetylation,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
PI5P Regulates TP53 Acetylation,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
PI5P Regulates TP53 Acetylation,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
G2/M DNA damage checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
G2/M DNA damage checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
G2/M DNA damage checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
G2/M DNA damage checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
G2/M DNA damage checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
G2/M DNA damage checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
G2/M DNA damage checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
G2/M DNA damage checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
G2/M DNA damage checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
G2/M Checkpoints,R-HSA-69481,https://reactome.org/PathwayBrowser/#/R-HSA-69481,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
G2/M Checkpoints,R-HSA-69481,https://reactome.org/PathwayBrowser/#/R-HSA-69481,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
G2/M Checkpoints,R-HSA-69481,https://reactome.org/PathwayBrowser/#/R-HSA-69481,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
G2/M Checkpoints,R-HSA-69481,https://reactome.org/PathwayBrowser/#/R-HSA-69481,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
G2/M Checkpoints,R-HSA-69481,https://reactome.org/PathwayBrowser/#/R-HSA-69481,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
G2/M Checkpoints,R-HSA-69481,https://reactome.org/PathwayBrowser/#/R-HSA-69481,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
G2/M Checkpoints,R-HSA-69481,https://reactome.org/PathwayBrowser/#/R-HSA-69481,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
G2/M Checkpoints,R-HSA-69481,https://reactome.org/PathwayBrowser/#/R-HSA-69481,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
G2/M Checkpoints,R-HSA-69481,https://reactome.org/PathwayBrowser/#/R-HSA-69481,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Stabilization of p53,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Stabilization of p53,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Stabilization of p53,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Stabilization of p53,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Stabilization of p53,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Stabilization of p53,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Stabilization of p53,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Stabilization of p53,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Stabilization of p53,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Transcriptional activation of cell cycle inhibitor p21,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Transcriptional activation of cell cycle inhibitor p21,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Transcriptional activation of cell cycle inhibitor p21,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Transcriptional activation of cell cycle inhibitor p21,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Transcriptional activation of cell cycle inhibitor p21,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Transcriptional activation of cell cycle inhibitor p21,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Transcriptional activation of cell cycle inhibitor p21,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Transcriptional activation of cell cycle inhibitor p21,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Transcriptional activation of cell cycle inhibitor p21,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
The role of GTSE1 in G2/M progression after G2 checkpoint,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Transcriptional Regulation by VENTX,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Transcriptional Regulation by VENTX,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Transcriptional Regulation by VENTX,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Transcriptional Regulation by VENTX,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Transcriptional Regulation by VENTX,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Transcriptional Regulation by VENTX,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Transcriptional Regulation by VENTX,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Transcriptional Regulation by VENTX,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Transcriptional Regulation by VENTX,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
RUNX3 regulates CDKN1A transcription,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
RUNX3 regulates CDKN1A transcription,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
RUNX3 regulates CDKN1A transcription,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
RUNX3 regulates CDKN1A transcription,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
RUNX3 regulates CDKN1A transcription,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
RUNX3 regulates CDKN1A transcription,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
RUNX3 regulates CDKN1A transcription,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
RUNX3 regulates CDKN1A transcription,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
RUNX3 regulates CDKN1A transcription,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of PTEN gene transcription,R-HSA-8943724,https://reactome.org/PathwayBrowser/#/R-HSA-8943724,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of PTEN gene transcription,R-HSA-8943724,https://reactome.org/PathwayBrowser/#/R-HSA-8943724,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of PTEN gene transcription,R-HSA-8943724,https://reactome.org/PathwayBrowser/#/R-HSA-8943724,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of PTEN gene transcription,R-HSA-8943724,https://reactome.org/PathwayBrowser/#/R-HSA-8943724,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of PTEN gene transcription,R-HSA-8943724,https://reactome.org/PathwayBrowser/#/R-HSA-8943724,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of PTEN gene transcription,R-HSA-8943724,https://reactome.org/PathwayBrowser/#/R-HSA-8943724,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of PTEN gene transcription,R-HSA-8943724,https://reactome.org/PathwayBrowser/#/R-HSA-8943724,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of PTEN gene transcription,R-HSA-8943724,https://reactome.org/PathwayBrowser/#/R-HSA-8943724,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of PTEN gene transcription,R-HSA-8943724,https://reactome.org/PathwayBrowser/#/R-HSA-8943724,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Loss of function of TP53 in cancer due to loss of tetramerization ability,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Loss of function of TP53 in cancer due to loss of tetramerization ability,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Loss of function of TP53 in cancer due to loss of tetramerization ability,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Loss of function of TP53 in cancer due to loss of tetramerization ability,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Loss of function of TP53 in cancer due to loss of tetramerization ability,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Loss of function of TP53 in cancer due to loss of tetramerization ability,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Loss of function of TP53 in cancer due to loss of tetramerization ability,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Loss of function of TP53 in cancer due to loss of tetramerization ability,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Loss of function of TP53 in cancer due to loss of tetramerization ability,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Signaling by ALK fusions and activated point mutants,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of NF-kappa B signaling,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Zygotic genome activation (ZGA),R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Zygotic genome activation (ZGA),R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Zygotic genome activation (ZGA),R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Zygotic genome activation (ZGA),R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Zygotic genome activation (ZGA),R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Zygotic genome activation (ZGA),R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Zygotic genome activation (ZGA),R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Zygotic genome activation (ZGA),R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Zygotic genome activation (ZGA),R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
PKR-mediated signaling,,,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
PKR-mediated signaling,,,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
PKR-mediated signaling,,,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
PKR-mediated signaling,,,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
PKR-mediated signaling,,,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
PKR-mediated signaling,,,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
PKR-mediated signaling,,,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
PKR-mediated signaling,,,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
PKR-mediated signaling,,,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL1738797,ALECTINIB,4.0,,EFO_0000616,neoplasm,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL4559134,SELPERCATINIB,4.0,,EFO_0000616,neoplasm,,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL4582651,PRALSETINIB,4.0,,EFO_0000616,neoplasm,,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL3707320,ALECTINIB HYDROCHLORIDE,4.0,,EFO_0003060,non-small cell lung carcinoma,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL4650296,BOS-589,2.0,Completed,EFO_0000555,irritable bowel syndrome,,
RET signaling,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL1738797,ALECTINIB,4.0,,EFO_0000616,neoplasm,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL4559134,SELPERCATINIB,4.0,,EFO_0000616,neoplasm,,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL4582651,PRALSETINIB,4.0,,EFO_0000616,neoplasm,,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL3707320,ALECTINIB HYDROCHLORIDE,4.0,,EFO_0003060,non-small cell lung carcinoma,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL4650296,BOS-589,2.0,Completed,EFO_0000555,irritable bowel syndrome,,
NPAS4 regulates expression of target genes,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL1738797,ALECTINIB,4.0,,EFO_0000616,neoplasm,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL4559134,SELPERCATINIB,4.0,,EFO_0000616,neoplasm,,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL4582651,PRALSETINIB,4.0,,EFO_0000616,neoplasm,,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL3707320,ALECTINIB HYDROCHLORIDE,4.0,,EFO_0003060,non-small cell lung carcinoma,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL4650296,BOS-589,2.0,Completed,EFO_0000555,irritable bowel syndrome,,
Formation of the nephric duct,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL1738797,ALECTINIB,4.0,,EFO_0000616,neoplasm,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL4559134,SELPERCATINIB,4.0,,EFO_0000616,neoplasm,,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL4582651,PRALSETINIB,4.0,,EFO_0000616,neoplasm,,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL3707320,ALECTINIB HYDROCHLORIDE,4.0,,EFO_0003060,non-small cell lung carcinoma,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL4650296,BOS-589,2.0,Completed,EFO_0000555,irritable bowel syndrome,,
Formation of the ureteric bud,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL1201567,FILGRASTIM,4.0,,EFO_0000544,infection,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL1201568,PEGFILGRASTIM,4.0,,EFO_0000544,infection,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL2109128,LENOGRASTIM,4.0,,EFO_0000616,neoplasm,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL3833384,EFLAPEGRASTIM,4.0,,EFO_0000616,neoplasm,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL4297950,EFBEMALENOGRASTIM ALFA,4.0,,EFO_0000616,neoplasm,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL4594230,LIPEGFILGRASTIM,4.0,,EFO_0000616,neoplasm,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL2107881,REGRAMOSTIM,3.0,Completed,EFO_0000756,melanoma,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL4297800,PEGTEOGRASTIM,2.0,,EFO_0000616,neoplasm,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL2108572,BALUGRASTIM,2.0,,EFO_0000616,neoplasm,,
Other interleukin signaling,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL4650461,ANUMIGILIMAB,2.0,Withdrawn,MONDO_0100096,COVID-19,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL1201567,FILGRASTIM,4.0,,EFO_0000544,infection,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL1201568,PEGFILGRASTIM,4.0,,EFO_0000544,infection,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL2109128,LENOGRASTIM,4.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL3833384,EFLAPEGRASTIM,4.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL4297950,EFBEMALENOGRASTIM ALFA,4.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL4594230,LIPEGFILGRASTIM,4.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL2107881,REGRAMOSTIM,3.0,Completed,EFO_0000756,melanoma,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL4297800,PEGTEOGRASTIM,2.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL2108572,BALUGRASTIM,2.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL4650461,ANUMIGILIMAB,2.0,Withdrawn,MONDO_0100096,COVID-19,,
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Transcriptional regulation of granulopoiesis,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL1201567,FILGRASTIM,4.0,,EFO_0000544,infection,,
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL1201568,PEGFILGRASTIM,4.0,,EFO_0000544,infection,,
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL2109128,LENOGRASTIM,4.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL3833384,EFLAPEGRASTIM,4.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL4297950,EFBEMALENOGRASTIM ALFA,4.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL4594230,LIPEGFILGRASTIM,4.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL2107881,REGRAMOSTIM,3.0,Completed,EFO_0000756,melanoma,,
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL4297800,PEGTEOGRASTIM,2.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL2108572,BALUGRASTIM,2.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL4650461,ANUMIGILIMAB,2.0,Withdrawn,MONDO_0100096,COVID-19,,
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by CSF3 (G-CSF),R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL1201567,FILGRASTIM,4.0,,EFO_0000544,infection,,
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL1201568,PEGFILGRASTIM,4.0,,EFO_0000544,infection,,
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL2109128,LENOGRASTIM,4.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL3833384,EFLAPEGRASTIM,4.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL4297950,EFBEMALENOGRASTIM ALFA,4.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL4594230,LIPEGFILGRASTIM,4.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL2107881,REGRAMOSTIM,3.0,Completed,EFO_0000756,melanoma,,
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL4297800,PEGTEOGRASTIM,2.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL2108572,BALUGRASTIM,2.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL4650461,ANUMIGILIMAB,2.0,Withdrawn,MONDO_0100096,COVID-19,,
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Inactivation of CSF3 (G-CSF) signaling,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Activation of BAD and translocation to mitochondria,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Activation of BAD and translocation to mitochondria,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
Activation of BAD and translocation to mitochondria,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
Activation of BAD and translocation to mitochondria,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
Activation of BAD and translocation to mitochondria,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
Activation of BAD and translocation to mitochondria,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
Activation of BAD and translocation to mitochondria,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
The NLRP1 inflammasome,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
The NLRP1 inflammasome,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
The NLRP1 inflammasome,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
The NLRP1 inflammasome,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
The NLRP1 inflammasome,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
The NLRP1 inflammasome,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
The NLRP1 inflammasome,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
Estrogen-dependent gene expression,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Estrogen-dependent gene expression,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
Estrogen-dependent gene expression,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
Estrogen-dependent gene expression,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
Estrogen-dependent gene expression,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
Estrogen-dependent gene expression,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
Estrogen-dependent gene expression,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
Estrogen-dependent nuclear events downstream of ESR-membrane signaling,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Estrogen-dependent nuclear events downstream of ESR-membrane signaling,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
Estrogen-dependent nuclear events downstream of ESR-membrane signaling,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
Estrogen-dependent nuclear events downstream of ESR-membrane signaling,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
Estrogen-dependent nuclear events downstream of ESR-membrane signaling,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
Estrogen-dependent nuclear events downstream of ESR-membrane signaling,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
Estrogen-dependent nuclear events downstream of ESR-membrane signaling,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
NFE2L2 regulating tumorigenic genes,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
NFE2L2 regulating tumorigenic genes,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
NFE2L2 regulating tumorigenic genes,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
NFE2L2 regulating tumorigenic genes,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
NFE2L2 regulating tumorigenic genes,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
NFE2L2 regulating tumorigenic genes,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
NFE2L2 regulating tumorigenic genes,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
Regulation of MITF-M-dependent genes involved in apoptosis,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Regulation of MITF-M-dependent genes involved in apoptosis,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
Regulation of MITF-M-dependent genes involved in apoptosis,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
Regulation of MITF-M-dependent genes involved in apoptosis,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
Regulation of MITF-M-dependent genes involved in apoptosis,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
Regulation of MITF-M-dependent genes involved in apoptosis,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of MITF-M-dependent genes involved in apoptosis,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
Downstream TCR signaling,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Downstream TCR signaling,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Downstream TCR signaling,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Downstream TCR signaling,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
"Inactivation, recovery and regulation of the phototransduction cascade",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"Inactivation, recovery and regulation of the phototransduction cascade",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
"Inactivation, recovery and regulation of the phototransduction cascade",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
"Inactivation, recovery and regulation of the phototransduction cascade",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
"Inactivation, recovery and regulation of the phototransduction cascade",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
"Inactivation, recovery and regulation of the phototransduction cascade",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"Inactivation, recovery and regulation of the phototransduction cascade",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
"Inactivation, recovery and regulation of the phototransduction cascade",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
"Inactivation, recovery and regulation of the phototransduction cascade",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
FCERI mediated NF-kB activation,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
FCERI mediated NF-kB activation,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
FCERI mediated NF-kB activation,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
FCERI mediated NF-kB activation,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Netrin-1 signaling,R-HSA-373752,https://reactome.org/PathwayBrowser/#/R-HSA-373752,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Netrin-1 signaling,R-HSA-373752,https://reactome.org/PathwayBrowser/#/R-HSA-373752,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Netrin-1 signaling,R-HSA-373752,https://reactome.org/PathwayBrowser/#/R-HSA-373752,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Netrin-1 signaling,R-HSA-373752,https://reactome.org/PathwayBrowser/#/R-HSA-373752,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,R-HSA-8936459,https://reactome.org/PathwayBrowser/#/R-HSA-8936459,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,R-HSA-8936459,https://reactome.org/PathwayBrowser/#/R-HSA-8936459,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,R-HSA-8936459,https://reactome.org/PathwayBrowser/#/R-HSA-8936459,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,R-HSA-8936459,https://reactome.org/PathwayBrowser/#/R-HSA-8936459,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RAS processing,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAS processing,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RAS processing,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RAS processing,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL359744,DOXORUBICIN HYDROCHLORIDE,4.0,,EFO_0000183,Hodgkins lymphoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1200976,IDARUBICIN HYDROCHLORIDE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O.Cl
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL178,DAUNORUBICIN,4.0,,EFO_0000222,acute myeloid leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1096885,VALRUBICIN,4.0,,EFO_0000313,carcinoma,,CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1200778,DEXRAZOXANE HYDROCHLORIDE,4.0,,EFO_0000318,cardiomyopathy,,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1.Cl
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1117,IDARUBICIN,4.0,,EFO_0000616,neoplasm,,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL44657,ETOPOSIDE,4.0,,EFO_0000616,neoplasm,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL58,MITOXANTRONE,4.0,,EFO_0000616,neoplasm,,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL43,AMSACRINE,4.0,,EFO_0000616,neoplasm,,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL452231,TENIPOSIDE,4.0,,EFO_0000616,neoplasm,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL53463,DOXORUBICIN,4.0,,EFO_0000616,neoplasm,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1563,DAUNORUBICIN HYDROCHLORIDE,4.0,,EFO_0004289,lymphoid leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1417019,MITOXANTRONE HYDROCHLORIDE,4.0,,MONDO_0008315,prostate cancer,,Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1738,DEXRAZOXANE,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1200645,ETOPOSIDE PHOSPHATE,3.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL68117,VOSAROXIN,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CN[C@H]1CN(c2ccc3c(=O)c(C(=O)O)cn(-c4nccs4)c3n2)C[C@@H]1OC
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1186894,AMRUBICIN,3.0,,EFO_0000616,neoplasm,,CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL481958,AMRUBICIN HYDROCHLORIDE,3.0,Terminated,EFO_0000702,small cell lung carcinoma,,CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O.Cl
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL240163,PAZUFLOXACIN,3.0,,EFO_0000771,bacterial disease,,C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL2107818,ALDOXORUBICIN,3.0,Completed,EFO_1001968,soft tissue sarcoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL2107313,BECATECARIN,3.0,Terminated,MONDO_0003060,biliary tract cancer,,CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL2110580,BERUBICIN,2.0,"Active, not recruiting",EFO_0000519,glioblastoma multiforme,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1200475,DAUNORUBICIN CITRATE,2.0,Completed,EFO_0000565,leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL3833344,GANCOTAMAB,2.0,Terminated,MONDO_0007254,breast cancer,,
Transcription of E2F targets under negative control by DREAM complex,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL2103796,BERUBICIN HYDROCHLORIDE,1.0,Terminated,EFO_0000313,carcinoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1.Cl
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL359744,DOXORUBICIN HYDROCHLORIDE,4.0,,EFO_0000183,Hodgkins lymphoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1200976,IDARUBICIN HYDROCHLORIDE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O.Cl
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL178,DAUNORUBICIN,4.0,,EFO_0000222,acute myeloid leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1096885,VALRUBICIN,4.0,,EFO_0000313,carcinoma,,CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1200778,DEXRAZOXANE HYDROCHLORIDE,4.0,,EFO_0000318,cardiomyopathy,,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1.Cl
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1117,IDARUBICIN,4.0,,EFO_0000616,neoplasm,,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL44657,ETOPOSIDE,4.0,,EFO_0000616,neoplasm,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL58,MITOXANTRONE,4.0,,EFO_0000616,neoplasm,,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL43,AMSACRINE,4.0,,EFO_0000616,neoplasm,,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL452231,TENIPOSIDE,4.0,,EFO_0000616,neoplasm,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL53463,DOXORUBICIN,4.0,,EFO_0000616,neoplasm,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1563,DAUNORUBICIN HYDROCHLORIDE,4.0,,EFO_0004289,lymphoid leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1417019,MITOXANTRONE HYDROCHLORIDE,4.0,,MONDO_0008315,prostate cancer,,Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1738,DEXRAZOXANE,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1200645,ETOPOSIDE PHOSPHATE,3.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL68117,VOSAROXIN,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CN[C@H]1CN(c2ccc3c(=O)c(C(=O)O)cn(-c4nccs4)c3n2)C[C@@H]1OC
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1186894,AMRUBICIN,3.0,,EFO_0000616,neoplasm,,CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL481958,AMRUBICIN HYDROCHLORIDE,3.0,Terminated,EFO_0000702,small cell lung carcinoma,,CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O.Cl
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL240163,PAZUFLOXACIN,3.0,,EFO_0000771,bacterial disease,,C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL2107818,ALDOXORUBICIN,3.0,Completed,EFO_1001968,soft tissue sarcoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL2107313,BECATECARIN,3.0,Terminated,MONDO_0003060,biliary tract cancer,,CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL2110580,BERUBICIN,2.0,"Active, not recruiting",EFO_0000519,glioblastoma multiforme,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1200475,DAUNORUBICIN CITRATE,2.0,Completed,EFO_0000565,leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL3833344,GANCOTAMAB,2.0,Terminated,MONDO_0007254,breast cancer,,
SUMOylation of DNA replication proteins,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL2103796,BERUBICIN HYDROCHLORIDE,1.0,Terminated,EFO_0000313,carcinoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1.Cl
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL3989958,IVOSIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4297610,OLUTASIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4167360,IDH305,2.0,Withdrawn,EFO_1000453,Paraganglioma,,Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4651002,SAFUSIDENIB,2.0,Recruiting,EFO_1000453,Paraganglioma,,Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4650282,DS-1001B,2.0,"Active, not recruiting",MONDO_0021639,grade II glioma,,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4206033,BAY1436032,1.0,Completed,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1
NADPH regeneration,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL3989958,IVOSIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
NADPH regeneration,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4297610,OLUTASIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
NADPH regeneration,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
NADPH regeneration,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4167360,IDH305,2.0,Withdrawn,EFO_1000453,Paraganglioma,,Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1
NADPH regeneration,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4651002,SAFUSIDENIB,2.0,Recruiting,EFO_1000453,Paraganglioma,,Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
NADPH regeneration,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4650282,DS-1001B,2.0,"Active, not recruiting",MONDO_0021639,grade II glioma,,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
NADPH regeneration,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4206033,BAY1436032,1.0,Completed,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1
Peroxisomal protein import,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL3989958,IVOSIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
Peroxisomal protein import,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4297610,OLUTASIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
Peroxisomal protein import,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Peroxisomal protein import,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4167360,IDH305,2.0,Withdrawn,EFO_1000453,Paraganglioma,,Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1
Peroxisomal protein import,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4651002,SAFUSIDENIB,2.0,Recruiting,EFO_1000453,Paraganglioma,,Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Peroxisomal protein import,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4650282,DS-1001B,2.0,"Active, not recruiting",MONDO_0021639,grade II glioma,,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Peroxisomal protein import,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4206033,BAY1436032,1.0,Completed,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1
NFE2L2 regulating TCA cycle genes,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL3989958,IVOSIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
NFE2L2 regulating TCA cycle genes,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4297610,OLUTASIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
NFE2L2 regulating TCA cycle genes,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
NFE2L2 regulating TCA cycle genes,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4167360,IDH305,2.0,Withdrawn,EFO_1000453,Paraganglioma,,Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1
NFE2L2 regulating TCA cycle genes,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4651002,SAFUSIDENIB,2.0,Recruiting,EFO_1000453,Paraganglioma,,Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
NFE2L2 regulating TCA cycle genes,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4650282,DS-1001B,2.0,"Active, not recruiting",MONDO_0021639,grade II glioma,,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
NFE2L2 regulating TCA cycle genes,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4206033,BAY1436032,1.0,Completed,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by PDGFRA extracellular domain mutants,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Imatinib-resistant PDGFR mutants,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Sunitinib-resistant PDGFR mutants,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Regorafenib-resistant PDGFR mutants,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Sorafenib-resistant PDGFR mutants,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
PDGFR mutants bind TKIs,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
"Interleukin-3, Interleukin-5 and GM-CSF signaling",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
Surfactant metabolism,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Defective CSF2RB causes SMDP5,R-HSA-5688849,https://reactome.org/PathwayBrowser/#/R-HSA-5688849,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
Defective CSF2RB causes SMDP5,R-HSA-5688849,https://reactome.org/PathwayBrowser/#/R-HSA-5688849,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Defective CSF2RA causes SMDP4,R-HSA-5688890,https://reactome.org/PathwayBrowser/#/R-HSA-5688890,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
Defective CSF2RA causes SMDP4,R-HSA-5688890,https://reactome.org/PathwayBrowser/#/R-HSA-5688890,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin receptor SHC signaling,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-6 signaling,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
MAPK3 (ERK1) activation,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
MAPK1 (ERK2) activation,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Prolactin receptor signaling,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Signaling by SCF-KIT,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by Leptin,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
RMTs methylate histone arginines,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
RAF activation,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
IL-6-type cytokine receptor ligand interactions,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by moderate kinase activity BRAF mutants,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by BRAF and RAF1 fusions,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Paradoxical activation of RAF signaling by kinase inactive BRAF,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Regulation of IFNG signaling,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-20 family signaling,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-35 Signalling,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by Erythropoietin,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-12 signaling,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-23 signaling,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-27 signaling,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K),R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Erythropoietin activates Phospholipase C gamma (PLCG),R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Erythropoietin activates STAT5,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Erythropoietin activates RAS,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling downstream of RAS mutants,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by RAF1 mutants,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Potential therapeutics for SARS,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
IFNG signaling activates MAPKs,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Growth hormone receptor signaling,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Class B/2 (Secretin family receptors),R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL4297534,GLASDEGIB MALEATE,4.0,,EFO_0000222,acute myeloid leukemia,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O
Class B/2 (Secretin family receptors),R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL2043437,GLASDEGIB,4.0,,EFO_0000616,neoplasm,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
Class B/2 (Secretin family receptors),R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL2105737,SONIDEGIB,4.0,,EFO_0000616,neoplasm,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
Class B/2 (Secretin family receptors),R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL473417,VISMODEGIB,4.0,,EFO_0000616,neoplasm,,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
Class B/2 (Secretin family receptors),R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL3137317,SONIDEGIB PHOSPHATE,4.0,,EFO_0004193,basal cell carcinoma,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O
Class B/2 (Secretin family receptors),R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL538867,PATIDEGIB,3.0,Terminated,MONDO_0007187,nevoid basal cell carcinoma syndrome,,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
Class B/2 (Secretin family receptors),R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL3545403,BMS-833923,2.0,Terminated,EFO_0000565,leukemia,,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1
Class B/2 (Secretin family receptors),R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL2142592,TALADEGIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1
Class B/2 (Secretin family receptors),R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL2205230,TAK-441,1.0,Completed,EFO_0004193,basal cell carcinoma,,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1
Class B/2 (Secretin family receptors),R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL3133037,LEQ506,1.0,Completed,EFO_0002939,medulloblastoma,,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL4297534,GLASDEGIB MALEATE,4.0,,EFO_0000222,acute myeloid leukemia,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL2043437,GLASDEGIB,4.0,,EFO_0000616,neoplasm,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL2105737,SONIDEGIB,4.0,,EFO_0000616,neoplasm,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL473417,VISMODEGIB,4.0,,EFO_0000616,neoplasm,,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL3137317,SONIDEGIB PHOSPHATE,4.0,,EFO_0004193,basal cell carcinoma,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL538867,PATIDEGIB,3.0,Terminated,MONDO_0007187,nevoid basal cell carcinoma syndrome,,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL3545403,BMS-833923,2.0,Terminated,EFO_0000565,leukemia,,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL2142592,TALADEGIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL2205230,TAK-441,1.0,Completed,EFO_0004193,basal cell carcinoma,,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1
Hedgehog 'off' state,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL3133037,LEQ506,1.0,Completed,EFO_0002939,medulloblastoma,,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C
BBSome-mediated cargo-targeting to cilium,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL4297534,GLASDEGIB MALEATE,4.0,,EFO_0000222,acute myeloid leukemia,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O
BBSome-mediated cargo-targeting to cilium,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL2043437,GLASDEGIB,4.0,,EFO_0000616,neoplasm,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
BBSome-mediated cargo-targeting to cilium,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL2105737,SONIDEGIB,4.0,,EFO_0000616,neoplasm,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
BBSome-mediated cargo-targeting to cilium,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL473417,VISMODEGIB,4.0,,EFO_0000616,neoplasm,,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
BBSome-mediated cargo-targeting to cilium,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL3137317,SONIDEGIB PHOSPHATE,4.0,,EFO_0004193,basal cell carcinoma,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O
BBSome-mediated cargo-targeting to cilium,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL538867,PATIDEGIB,3.0,Terminated,MONDO_0007187,nevoid basal cell carcinoma syndrome,,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
BBSome-mediated cargo-targeting to cilium,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL3545403,BMS-833923,2.0,Terminated,EFO_0000565,leukemia,,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1
BBSome-mediated cargo-targeting to cilium,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL2142592,TALADEGIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1
BBSome-mediated cargo-targeting to cilium,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL2205230,TAK-441,1.0,Completed,EFO_0004193,basal cell carcinoma,,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1
BBSome-mediated cargo-targeting to cilium,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL3133037,LEQ506,1.0,Completed,EFO_0002939,medulloblastoma,,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C
Hedgehog 'on' state,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL4297534,GLASDEGIB MALEATE,4.0,,EFO_0000222,acute myeloid leukemia,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O
Hedgehog 'on' state,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL2043437,GLASDEGIB,4.0,,EFO_0000616,neoplasm,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
Hedgehog 'on' state,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL2105737,SONIDEGIB,4.0,,EFO_0000616,neoplasm,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
Hedgehog 'on' state,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL473417,VISMODEGIB,4.0,,EFO_0000616,neoplasm,,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
Hedgehog 'on' state,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL3137317,SONIDEGIB PHOSPHATE,4.0,,EFO_0004193,basal cell carcinoma,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O
Hedgehog 'on' state,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL538867,PATIDEGIB,3.0,Terminated,MONDO_0007187,nevoid basal cell carcinoma syndrome,,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
Hedgehog 'on' state,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL3545403,BMS-833923,2.0,Terminated,EFO_0000565,leukemia,,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1
Hedgehog 'on' state,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL2142592,TALADEGIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1
Hedgehog 'on' state,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL2205230,TAK-441,1.0,Completed,EFO_0004193,basal cell carcinoma,,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1
Hedgehog 'on' state,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL3133037,LEQ506,1.0,Completed,EFO_0002939,medulloblastoma,,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C
Activation of SMO,R-HSA-5635838,https://reactome.org/PathwayBrowser/#/R-HSA-5635838,SMO,ENSG00000128602,CHEMBL4297534,GLASDEGIB MALEATE,4.0,,EFO_0000222,acute myeloid leukemia,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O
Activation of SMO,R-HSA-5635838,https://reactome.org/PathwayBrowser/#/R-HSA-5635838,SMO,ENSG00000128602,CHEMBL2043437,GLASDEGIB,4.0,,EFO_0000616,neoplasm,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
Activation of SMO,R-HSA-5635838,https://reactome.org/PathwayBrowser/#/R-HSA-5635838,SMO,ENSG00000128602,CHEMBL2105737,SONIDEGIB,4.0,,EFO_0000616,neoplasm,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
Activation of SMO,R-HSA-5635838,https://reactome.org/PathwayBrowser/#/R-HSA-5635838,SMO,ENSG00000128602,CHEMBL473417,VISMODEGIB,4.0,,EFO_0000616,neoplasm,,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
Activation of SMO,R-HSA-5635838,https://reactome.org/PathwayBrowser/#/R-HSA-5635838,SMO,ENSG00000128602,CHEMBL3137317,SONIDEGIB PHOSPHATE,4.0,,EFO_0004193,basal cell carcinoma,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O
Activation of SMO,R-HSA-5635838,https://reactome.org/PathwayBrowser/#/R-HSA-5635838,SMO,ENSG00000128602,CHEMBL538867,PATIDEGIB,3.0,Terminated,MONDO_0007187,nevoid basal cell carcinoma syndrome,,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
Activation of SMO,R-HSA-5635838,https://reactome.org/PathwayBrowser/#/R-HSA-5635838,SMO,ENSG00000128602,CHEMBL3545403,BMS-833923,2.0,Terminated,EFO_0000565,leukemia,,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1
Activation of SMO,R-HSA-5635838,https://reactome.org/PathwayBrowser/#/R-HSA-5635838,SMO,ENSG00000128602,CHEMBL2142592,TALADEGIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1
Activation of SMO,R-HSA-5635838,https://reactome.org/PathwayBrowser/#/R-HSA-5635838,SMO,ENSG00000128602,CHEMBL2205230,TAK-441,1.0,Completed,EFO_0004193,basal cell carcinoma,,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1
Activation of SMO,R-HSA-5635838,https://reactome.org/PathwayBrowser/#/R-HSA-5635838,SMO,ENSG00000128602,CHEMBL3133037,LEQ506,1.0,Completed,EFO_0002939,medulloblastoma,,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C
Sphingolipid de novo biosynthesis,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD3,ENSG00000115825,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sphingolipid de novo biosynthesis,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD3,ENSG00000115825,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Sphingolipid de novo biosynthesis,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD3,ENSG00000115825,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Sphingolipid de novo biosynthesis,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD3,ENSG00000115825,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
SUMOylation of intracellular receptors,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
TGFBR3 expression,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
TGFBR3 expression,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
TGFBR3 expression,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
TGFBR3 expression,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
TGFBR3 expression,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
TGFBR3 expression,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
TGFBR3 expression,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
TGFBR3 expression,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
TGFBR3 expression,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,AXL,ENSG00000167601,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,AXL,ENSG00000167601,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,AXL,ENSG00000167601,CHEMBL3809489,BEMCENTINIB,2.0,Completed,EFO_0000571,lung adenocarcinoma,,Nc1nc(Nc2ccc3c(c2)CC[C@@H](N2CCCC2)CC3)nn1-c1cc2c(nn1)-c1ccccc1CCC2
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,AXL,ENSG00000167601,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,AXL,ENSG00000167601,CHEMBL3545236,BPI-9016,1.0,Completed,EFO_0000616,neoplasm,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
VEGFA-VEGFR2 Pathway,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
Transcriptional regulation of testis differentiation,R-HSA-9690406,https://reactome.org/PathwayBrowser/#/R-HSA-9690406,WT1,ENSG00000184937,CHEMBL3833386,GALINPEPIMUT-S,3.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,
Transcriptional regulation of testis differentiation,R-HSA-9690406,https://reactome.org/PathwayBrowser/#/R-HSA-9690406,WT1,ENSG00000184937,CHEMBL4297235,OMBIPEPIMUT-S,3.0,Completed,EFO_0000519,glioblastoma multiforme,,
Nephron development,R-HSA-9831926,https://reactome.org/PathwayBrowser/#/R-HSA-9831926,WT1,ENSG00000184937,CHEMBL3833386,GALINPEPIMUT-S,3.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,
Nephron development,R-HSA-9831926,https://reactome.org/PathwayBrowser/#/R-HSA-9831926,WT1,ENSG00000184937,CHEMBL4297235,OMBIPEPIMUT-S,3.0,Completed,EFO_0000519,glioblastoma multiforme,,
Stimuli-sensing channels,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Stimuli-sensing channels,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Stimuli-sensing channels,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Stimuli-sensing channels,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Stimuli-sensing channels,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Stimuli-sensing channels,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Stimuli-sensing channels,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Stimuli-sensing channels,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Stimuli-sensing channels,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Stimuli-sensing channels,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Rap1 signalling,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Rap1 signalling,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Rap1 signalling,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Rap1 signalling,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Rap1 signalling,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Rap1 signalling,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Rap1 signalling,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Rap1 signalling,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Rap1 signalling,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Rap1 signalling,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
GP1b-IX-V activation signalling,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
GP1b-IX-V activation signalling,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
GP1b-IX-V activation signalling,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
GP1b-IX-V activation signalling,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
GP1b-IX-V activation signalling,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
GP1b-IX-V activation signalling,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
GP1b-IX-V activation signalling,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
GP1b-IX-V activation signalling,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
GP1b-IX-V activation signalling,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
GP1b-IX-V activation signalling,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
CD209 (DC-SIGN) signaling,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
CD209 (DC-SIGN) signaling,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
CD209 (DC-SIGN) signaling,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
CD209 (DC-SIGN) signaling,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
CD209 (DC-SIGN) signaling,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
CD209 (DC-SIGN) signaling,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
CD209 (DC-SIGN) signaling,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
CD209 (DC-SIGN) signaling,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
CD209 (DC-SIGN) signaling,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
CD209 (DC-SIGN) signaling,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
MAP2K and MAPK activation,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Negative feedback regulation of MAPK pathway,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Negative regulation of MAPK pathway,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by high-kinase activity BRAF mutants,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
SHOC2 M1731 mutant abolishes MRAS complex function,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Gain-of-function MRAS complexes activate RAF signaling,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
PRC2 methylates histones and DNA,R-HSA-212300,https://reactome.org/PathwayBrowser/#/R-HSA-212300,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
PRC2 methylates histones and DNA,R-HSA-212300,https://reactome.org/PathwayBrowser/#/R-HSA-212300,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
PRC2 methylates histones and DNA,R-HSA-212300,https://reactome.org/PathwayBrowser/#/R-HSA-212300,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
PRC2 methylates histones and DNA,R-HSA-212300,https://reactome.org/PathwayBrowser/#/R-HSA-212300,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
NoRC negatively regulates rRNA expression,R-HSA-427413,https://reactome.org/PathwayBrowser/#/R-HSA-427413,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
NoRC negatively regulates rRNA expression,R-HSA-427413,https://reactome.org/PathwayBrowser/#/R-HSA-427413,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
SUMOylation of DNA methylation proteins,R-HSA-4655427,https://reactome.org/PathwayBrowser/#/R-HSA-4655427,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
SUMOylation of DNA methylation proteins,R-HSA-4655427,https://reactome.org/PathwayBrowser/#/R-HSA-4655427,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
SUMOylation of DNA methylation proteins,R-HSA-4655427,https://reactome.org/PathwayBrowser/#/R-HSA-4655427,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
SUMOylation of DNA methylation proteins,R-HSA-4655427,https://reactome.org/PathwayBrowser/#/R-HSA-4655427,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
DNA methylation,R-HSA-5334118,https://reactome.org/PathwayBrowser/#/R-HSA-5334118,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
DNA methylation,R-HSA-5334118,https://reactome.org/PathwayBrowser/#/R-HSA-5334118,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
DNA methylation,R-HSA-5334118,https://reactome.org/PathwayBrowser/#/R-HSA-5334118,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
DNA methylation,R-HSA-5334118,https://reactome.org/PathwayBrowser/#/R-HSA-5334118,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
STAT3 nuclear events downstream of ALK signaling,R-HSA-9701898,https://reactome.org/PathwayBrowser/#/R-HSA-9701898,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
STAT3 nuclear events downstream of ALK signaling,R-HSA-9701898,https://reactome.org/PathwayBrowser/#/R-HSA-9701898,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Nuclear events stimulated by ALK signaling in cancer,R-HSA-9725371,https://reactome.org/PathwayBrowser/#/R-HSA-9725371,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Nuclear events stimulated by ALK signaling in cancer,R-HSA-9725371,https://reactome.org/PathwayBrowser/#/R-HSA-9725371,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Regulation of KIT signaling,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Dasatinib-resistant KIT mutants,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Imatinib-resistant KIT mutants,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
KIT mutants bind TKIs,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Masitinib-resistant KIT mutants,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Nilotinib-resistant KIT mutants,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Regorafenib-resistant KIT mutants,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by kinase domain mutants of KIT,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Sunitinib-resistant KIT mutants,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by juxtamembrane domain KIT mutants,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Sorafenib-resistant KIT mutants,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by extracellular domain mutants of KIT,R-HSA-9680187,https://reactome.org/PathwayBrowser/#/R-HSA-9680187,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Transcriptional and post-translational regulation of MITF-M expression and activity,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Disinhibition of SNARE formation,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Disinhibition of SNARE formation,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Disinhibition of SNARE formation,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Disinhibition of SNARE formation,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Disinhibition of SNARE formation,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
EGFR Transactivation by Gastrin,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
EGFR Transactivation by Gastrin,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
EGFR Transactivation by Gastrin,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
EGFR Transactivation by Gastrin,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
EGFR Transactivation by Gastrin,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Syndecan interactions,R-HSA-3000170,https://reactome.org/PathwayBrowser/#/R-HSA-3000170,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Syndecan interactions,R-HSA-3000170,https://reactome.org/PathwayBrowser/#/R-HSA-3000170,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Syndecan interactions,R-HSA-3000170,https://reactome.org/PathwayBrowser/#/R-HSA-3000170,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Syndecan interactions,R-HSA-3000170,https://reactome.org/PathwayBrowser/#/R-HSA-3000170,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Syndecan interactions,R-HSA-3000170,https://reactome.org/PathwayBrowser/#/R-HSA-3000170,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Acetylcholine regulates insulin secretion,R-HSA-399997,https://reactome.org/PathwayBrowser/#/R-HSA-399997,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Acetylcholine regulates insulin secretion,R-HSA-399997,https://reactome.org/PathwayBrowser/#/R-HSA-399997,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Acetylcholine regulates insulin secretion,R-HSA-399997,https://reactome.org/PathwayBrowser/#/R-HSA-399997,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Acetylcholine regulates insulin secretion,R-HSA-399997,https://reactome.org/PathwayBrowser/#/R-HSA-399997,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Acetylcholine regulates insulin secretion,R-HSA-399997,https://reactome.org/PathwayBrowser/#/R-HSA-399997,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Ca2+ pathway,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Ca2+ pathway,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Ca2+ pathway,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Ca2+ pathway,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Ca2+ pathway,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Trafficking of GluR2-containing AMPA receptors,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Trafficking of GluR2-containing AMPA receptors,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Trafficking of GluR2-containing AMPA receptors,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Trafficking of GluR2-containing AMPA receptors,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Trafficking of GluR2-containing AMPA receptors,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Depolymerization of the Nuclear Lamina,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Depolymerization of the Nuclear Lamina,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Depolymerization of the Nuclear Lamina,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Depolymerization of the Nuclear Lamina,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Depolymerization of the Nuclear Lamina,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
WNT5A-dependent internalization of FZD4,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
WNT5A-dependent internalization of FZD4,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
WNT5A-dependent internalization of FZD4,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
WNT5A-dependent internalization of FZD4,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
WNT5A-dependent internalization of FZD4,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Response to elevated platelet cytosolic Ca2+,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Response to elevated platelet cytosolic Ca2+,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Response to elevated platelet cytosolic Ca2+,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Response to elevated platelet cytosolic Ca2+,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Response to elevated platelet cytosolic Ca2+,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
ROBO receptors bind AKAP5,R-HSA-9010642,https://reactome.org/PathwayBrowser/#/R-HSA-9010642,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
ROBO receptors bind AKAP5,R-HSA-9010642,https://reactome.org/PathwayBrowser/#/R-HSA-9010642,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
ROBO receptors bind AKAP5,R-HSA-9010642,https://reactome.org/PathwayBrowser/#/R-HSA-9010642,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
ROBO receptors bind AKAP5,R-HSA-9010642,https://reactome.org/PathwayBrowser/#/R-HSA-9010642,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
ROBO receptors bind AKAP5,R-HSA-9010642,https://reactome.org/PathwayBrowser/#/R-HSA-9010642,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Spry regulation of FGF signaling,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Frs2-mediated activation,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
ARMS-mediated activation,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signalling to p38 via RIT and RIN,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs),R-HSA-9845323,https://reactome.org/PathwayBrowser/#/R-HSA-9845323,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs),R-HSA-9845323,https://reactome.org/PathwayBrowser/#/R-HSA-9845323,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL502835,NINTEDANIB,3.0,Completed,EFO_0000768,idiopathic pulmonary fibrosis,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL101253,VATALANIB,3.0,Completed,EFO_1000657,rectum cancer,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2109602,IMC-3C5,1.0,Completed,EFO_0000616,neoplasm,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3109738,JNJ-26483327,1.0,Completed,MONDO_0004992,cancer,,COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
VEGF binds to VEGFR leading to receptor dimerization,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL502835,NINTEDANIB,3.0,Completed,EFO_0000768,idiopathic pulmonary fibrosis,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL101253,VATALANIB,3.0,Completed,EFO_1000657,rectum cancer,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2109602,IMC-3C5,1.0,Completed,EFO_0000616,neoplasm,,
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
NOTCH4 Intracellular Domain Regulates Transcription,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3109738,JNJ-26483327,1.0,Completed,MONDO_0004992,cancer,,COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL502835,NINTEDANIB,3.0,Completed,EFO_0000768,idiopathic pulmonary fibrosis,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL101253,VATALANIB,3.0,Completed,EFO_1000657,rectum cancer,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2109602,IMC-3C5,1.0,Completed,EFO_0000616,neoplasm,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3109738,JNJ-26483327,1.0,Completed,MONDO_0004992,cancer,,COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
Neurophilin interactions with VEGF and VEGFR,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
Integrin cell surface interactions,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
Fanconi Anemia Pathwa,R-HSA-6783310,https://reactome.org/PathwayBrowser/#/R-HSA-6783310,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Fanconi Anemia Pathwa,R-HSA-6783310,https://reactome.org/PathwayBrowser/#/R-HSA-6783310,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Fanconi Anemia Pathwa,R-HSA-6783310,https://reactome.org/PathwayBrowser/#/R-HSA-6783310,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
PKR-mediated signalin,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,NPM1,ENSG00000181163,CHEMBL601719,CRIZOTINIB,4.0,,EFO_0000616,neoplasm,,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
PKR-mediated signalin,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,NPM1,ENSG00000181163,CHEMBL2403108,CERITINIB,4.0,,EFO_0000616,neoplasm,,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
PKR-mediated signalin,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
PKR-mediated signalin,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
PKR-mediated signalin,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
PKR-mediated signalin,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
PKR-mediated signalin,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
PKR-mediated signalin,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
PKR-mediated signalin,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
PKR-mediated signalin,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
PKR-mediated signalin,R-HSA-9833482,https://reactome.org/PathwayBrowser/#/R-HSA-9833482,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
PRC2 methylates histones and DN,R-HSA-212300,https://reactome.org/PathwayBrowser/#/R-HSA-212300,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
PRC2 methylates histones and DN,R-HSA-212300,https://reactome.org/PathwayBrowser/#/R-HSA-212300,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
PRC2 methylates histones and DN,R-HSA-212300,https://reactome.org/PathwayBrowser/#/R-HSA-212300,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
PRC2 methylates histones and DN,R-HSA-212300,https://reactome.org/PathwayBrowser/#/R-HSA-212300,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
PRC2 methylates histones and DN,R-HSA-212300,https://reactome.org/PathwayBrowser/#/R-HSA-212300,EZH2,ENSG00000106462,CHEMBL4594260,TAZEMETOSTAT HYDROBROMIDE,4.0,,EFO_0000691,sarcoma,,Br.CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
PRC2 methylates histones and DN,R-HSA-212300,https://reactome.org/PathwayBrowser/#/R-HSA-212300,EZH2,ENSG00000106462,CHEMBL3414621,TAZEMETOSTAT,4.0,,EFO_0000616,neoplasm,,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
PRC2 methylates histones and DN,R-HSA-212300,https://reactome.org/PathwayBrowser/#/R-HSA-212300,EZH2,ENSG00000106462,CHEMBL3287735,GSK2816126,1.0,Terminated,EFO_0000616,neoplasm,,CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
RMTs methylate histone arginine,R-HSA-3214858,https://reactome.org/PathwayBrowser/#/R-HSA-3214858,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
SUMOylation of DNA methylation protein,R-HSA-4655427,https://reactome.org/PathwayBrowser/#/R-HSA-4655427,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
SUMOylation of DNA methylation protein,R-HSA-4655427,https://reactome.org/PathwayBrowser/#/R-HSA-4655427,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
SUMOylation of DNA methylation protein,R-HSA-4655427,https://reactome.org/PathwayBrowser/#/R-HSA-4655427,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
SUMOylation of DNA methylation protein,R-HSA-4655427,https://reactome.org/PathwayBrowser/#/R-HSA-4655427,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
DNA methylatio,R-HSA-5334118,https://reactome.org/PathwayBrowser/#/R-HSA-5334118,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
DNA methylatio,R-HSA-5334118,https://reactome.org/PathwayBrowser/#/R-HSA-5334118,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
DNA methylatio,R-HSA-5334118,https://reactome.org/PathwayBrowser/#/R-HSA-5334118,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
DNA methylatio,R-HSA-5334118,https://reactome.org/PathwayBrowser/#/R-HSA-5334118,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,EZH2,ENSG00000106462,CHEMBL4594260,TAZEMETOSTAT HYDROBROMIDE,4.0,,EFO_0000691,sarcoma,,Br.CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,EZH2,ENSG00000106462,CHEMBL3414621,TAZEMETOSTAT,4.0,,EFO_0000616,neoplasm,,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,EZH2,ENSG00000106462,CHEMBL3287735,GSK2816126,1.0,Terminated,EFO_0000616,neoplasm,,CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA2,ENSG00000014138,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA2,ENSG00000014138,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA2,ENSG00000014138,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA2,ENSG00000014138,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA2,ENSG00000014138,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA2,ENSG00000014138,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,POLA2,ENSG00000014138,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM1,ENSG00000198056,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM1,ENSG00000198056,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM1,ENSG00000198056,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM1,ENSG00000198056,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM1,ENSG00000198056,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM1,ENSG00000198056,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM1,ENSG00000198056,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM2,ENSG00000146143,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM2,ENSG00000146143,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM2,ENSG00000146143,CHEMBL803,CYTARABINE,4.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM2,ENSG00000146143,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM2,ENSG00000146143,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM2,ENSG00000146143,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Defective pyroptosi,R-HSA-9710421,https://reactome.org/PathwayBrowser/#/R-HSA-9710421,PRIM2,ENSG00000146143,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs,R-HSA-9845323,https://reactome.org/PathwayBrowser/#/R-HSA-9845323,DNMT3A,ENSG00000119772,CHEMBL1201129,DECITABINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs,R-HSA-9845323,https://reactome.org/PathwayBrowser/#/R-HSA-9845323,DNMT3A,ENSG00000119772,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Activation of BAD and translocation to mitochondri,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Activation of BAD and translocation to mitochondri,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
Activation of BAD and translocation to mitochondri,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
Activation of BAD and translocation to mitochondri,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
Activation of BAD and translocation to mitochondri,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
Activation of BAD and translocation to mitochondri,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
Activation of BAD and translocation to mitochondri,R-HSA-111447,https://reactome.org/PathwayBrowser/#/R-HSA-111447,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 member,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 member,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 member,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 member,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 member,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 member,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 member,R-HSA-111453,https://reactome.org/PathwayBrowser/#/R-HSA-111453,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Interleukin-4 and Interleukin-13 signalin,R-HSA-6785807,https://reactome.org/PathwayBrowser/#/R-HSA-6785807,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
The NLRP1 inflammasom,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
The NLRP1 inflammasom,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
The NLRP1 inflammasom,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
The NLRP1 inflammasom,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
The NLRP1 inflammasom,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
The NLRP1 inflammasom,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
The NLRP1 inflammasom,R-HSA-844455,https://reactome.org/PathwayBrowser/#/R-HSA-844455,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
Estrogen-dependent gene expressio,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Estrogen-dependent gene expressio,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
Estrogen-dependent gene expressio,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
Estrogen-dependent gene expressio,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
Estrogen-dependent gene expressio,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
Estrogen-dependent gene expressio,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
Estrogen-dependent gene expressio,R-HSA-9018519,https://reactome.org/PathwayBrowser/#/R-HSA-9018519,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
Estrogen-dependent nuclear events downstream of ESR-membrane signalin,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Estrogen-dependent nuclear events downstream of ESR-membrane signalin,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
Estrogen-dependent nuclear events downstream of ESR-membrane signalin,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
Estrogen-dependent nuclear events downstream of ESR-membrane signalin,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
Estrogen-dependent nuclear events downstream of ESR-membrane signalin,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
Estrogen-dependent nuclear events downstream of ESR-membrane signalin,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
Estrogen-dependent nuclear events downstream of ESR-membrane signalin,R-HSA-9634638,https://reactome.org/PathwayBrowser/#/R-HSA-9634638,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
NFE2L2 regulating tumorigenic gene,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
NFE2L2 regulating tumorigenic gene,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
NFE2L2 regulating tumorigenic gene,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
NFE2L2 regulating tumorigenic gene,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
NFE2L2 regulating tumorigenic gene,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
NFE2L2 regulating tumorigenic gene,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
NFE2L2 regulating tumorigenic gene,R-HSA-9818030,https://reactome.org/PathwayBrowser/#/R-HSA-9818030,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
Regulation of MITF-M-dependent genes involved in apoptosi,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL3137309,VENETOCLAX,4.0,,EFO_0000095,chronic lymphocytic leukemia,,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1
Regulation of MITF-M-dependent genes involved in apoptosi,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL2109229,OBLIMERSEN SODIUM,3.0,Completed,EFO_0000389,cutaneous melanoma,,
Regulation of MITF-M-dependent genes involved in apoptosi,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL408194,OBATOCLAX,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C
Regulation of MITF-M-dependent genes involved in apoptosi,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL443684,NAVITOCLAX,3.0,"Active, not recruiting",EFO_0002430,primary myelofibrosis,,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1
Regulation of MITF-M-dependent genes involved in apoptosi,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL2107358,OBATOCLAX MESYLATE,3.0,Withdrawn,EFO_0000702,small cell lung carcinoma,,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O
Regulation of MITF-M-dependent genes involved in apoptosi,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL4650374,APG-2575,2.0,Recruiting,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of MITF-M-dependent genes involved in apoptosi,R-HSA-9824594,https://reactome.org/PathwayBrowser/#/R-HSA-9824594,BCL2,ENSG00000171791,CHEMBL2108324,OBLIMERSEN,2.0,,EFO_0000616,neoplasm,,
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,PRKCI,ENSG00000163558,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,PRKCI,ENSG00000163558,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,PRKCI,ENSG00000163558,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,PRKCI,ENSG00000163558,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Pre-NOTCH Transcription and Translatio,R-HSA-1912408,https://reactome.org/PathwayBrowser/#/R-HSA-1912408,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of RUNX1 Expression and Activit,R-HSA-8934593,https://reactome.org/PathwayBrowser/#/R-HSA-8934593,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet functio,R-HSA-8936459,https://reactome.org/PathwayBrowser/#/R-HSA-8936459,KMT2A,ENSG00000118058,CHEMBL4650827,REVUMENIB,2.0,Not yet recruiting,EFO_0000222,acute myeloid leukemia,,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet functio,R-HSA-8936459,https://reactome.org/PathwayBrowser/#/R-HSA-8936459,KMT2A,ENSG00000118058,CHEMBL4650278,REVUMENIB SESQUIFUMARATE,1.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet functio,R-HSA-8936459,https://reactome.org/PathwayBrowser/#/R-HSA-8936459,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet functio,R-HSA-8936459,https://reactome.org/PathwayBrowser/#/R-HSA-8936459,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet functio,R-HSA-8936459,https://reactome.org/PathwayBrowser/#/R-HSA-8936459,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet functio,R-HSA-8936459,https://reactome.org/PathwayBrowser/#/R-HSA-8936459,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,KMT2A,ENSG00000118058,CHEMBL4650827,REVUMENIB,2.0,Not yet recruiting,EFO_0000222,acute myeloid leukemia,,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,KMT2A,ENSG00000118058,CHEMBL4650278,REVUMENIB SESQUIFUMARATE,1.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
RUNX1 regulates transcription of genes involved in differentiation of HSC,R-HSA-8939236,https://reactome.org/PathwayBrowser/#/R-HSA-8939236,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
RUNX1 regulates transcription of genes involved in differentiation of myeloid cell,R-HSA-8939246,https://reactome.org/PathwayBrowser/#/R-HSA-8939246,PRKCB,ENSG00000166501,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RUNX1 regulates transcription of genes involved in differentiation of myeloid cell,R-HSA-8939246,https://reactome.org/PathwayBrowser/#/R-HSA-8939246,PRKCB,ENSG00000166501,CHEMBL300138,ENZASTAURIN,3.0,Completed,EFO_0000403,diffuse large B-cell lymphoma,,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
RUNX1 regulates transcription of genes involved in differentiation of myeloid cell,R-HSA-8939246,https://reactome.org/PathwayBrowser/#/R-HSA-8939246,PRKCB,ENSG00000166501,CHEMBL91829,RUBOXISTAURIN,3.0,Completed,EFO_0003770,diabetic retinopathy,,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
RUNX1 regulates transcription of genes involved in differentiation of myeloid cell,R-HSA-8939246,https://reactome.org/PathwayBrowser/#/R-HSA-8939246,PRKCB,ENSG00000166501,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RUNX1 regulates transcription of genes involved in differentiation of myeloid cell,R-HSA-8939246,https://reactome.org/PathwayBrowser/#/R-HSA-8939246,PRKCB,ENSG00000166501,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RUNX1 regulates transcription of genes involved in differentiation of myeloid cell,R-HSA-8939246,https://reactome.org/PathwayBrowser/#/R-HSA-8939246,PRKCB,ENSG00000166501,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RUNX3 regulates p14-AR,R-HSA-8951936,https://reactome.org/PathwayBrowser/#/R-HSA-8951936,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
RUNX3 regulates p14-AR,R-HSA-8951936,https://reactome.org/PathwayBrowser/#/R-HSA-8951936,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL1201567,FILGRASTIM,4.0,,EFO_0000544,infection,,
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL1201568,PEGFILGRASTIM,4.0,,EFO_0000544,infection,,
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL2109128,LENOGRASTIM,4.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL3833384,EFLAPEGRASTIM,4.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL4297950,EFBEMALENOGRASTIM ALFA,4.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL4594230,LIPEGFILGRASTIM,4.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL2107881,REGRAMOSTIM,3.0,Completed,EFO_0000756,melanoma,,
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL4297800,PEGTEOGRASTIM,2.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL2108572,BALUGRASTIM,2.0,,EFO_0000616,neoplasm,,
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,CSF3R,ENSG00000119535,CHEMBL4650461,ANUMIGILIMAB,2.0,Withdrawn,MONDO_0100096,COVID-19,,
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,KMT2A,ENSG00000118058,CHEMBL4650827,REVUMENIB,2.0,Not yet recruiting,EFO_0000222,acute myeloid leukemia,,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,KMT2A,ENSG00000118058,CHEMBL4650278,REVUMENIB SESQUIFUMARATE,1.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Transcriptional regulation of granulopoiesi,R-HSA-9616222,https://reactome.org/PathwayBrowser/#/R-HSA-9616222,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
SARS-CoV-1 activates/modulates innate immune response,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-1 activates/modulates innate immune response,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-1 activates/modulates innate immune response,R-HSA-9692916,https://reactome.org/PathwayBrowser/#/R-HSA-9692916,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL359744,DOXORUBICIN HYDROCHLORIDE,4.0,,EFO_0000183,Hodgkins lymphoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1200976,IDARUBICIN HYDROCHLORIDE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O.Cl
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL178,DAUNORUBICIN,4.0,,EFO_0000222,acute myeloid leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1096885,VALRUBICIN,4.0,,EFO_0000313,carcinoma,,CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1200778,DEXRAZOXANE HYDROCHLORIDE,4.0,,EFO_0000318,cardiomyopathy,,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1.Cl
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1117,IDARUBICIN,4.0,,EFO_0000616,neoplasm,,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL44657,ETOPOSIDE,4.0,,EFO_0000616,neoplasm,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL58,MITOXANTRONE,4.0,,EFO_0000616,neoplasm,,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL43,AMSACRINE,4.0,,EFO_0000616,neoplasm,,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL452231,TENIPOSIDE,4.0,,EFO_0000616,neoplasm,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL53463,DOXORUBICIN,4.0,,EFO_0000616,neoplasm,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1563,DAUNORUBICIN HYDROCHLORIDE,4.0,,EFO_0004289,lymphoid leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1417019,MITOXANTRONE HYDROCHLORIDE,4.0,,MONDO_0008315,prostate cancer,,Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1738,DEXRAZOXANE,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1200645,ETOPOSIDE PHOSPHATE,3.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL68117,VOSAROXIN,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CN[C@H]1CN(c2ccc3c(=O)c(C(=O)O)cn(-c4nccs4)c3n2)C[C@@H]1OC
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1186894,AMRUBICIN,3.0,,EFO_0000616,neoplasm,,CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL481958,AMRUBICIN HYDROCHLORIDE,3.0,Terminated,EFO_0000702,small cell lung carcinoma,,CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O.Cl
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL240163,PAZUFLOXACIN,3.0,,EFO_0000771,bacterial disease,,C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL2107818,ALDOXORUBICIN,3.0,Completed,EFO_1001968,soft tissue sarcoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL2107313,BECATECARIN,3.0,Terminated,MONDO_0003060,biliary tract cancer,,CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL2110580,BERUBICIN,2.0,"Active, not recruiting",EFO_0000519,glioblastoma multiforme,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL1200475,DAUNORUBICIN CITRATE,2.0,Completed,EFO_0000565,leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL3833344,GANCOTAMAB,2.0,Terminated,MONDO_0007254,breast cancer,,
Transcription of E2F targets under negative control by DREAM comple,R-HSA-1362277,https://reactome.org/PathwayBrowser/#/R-HSA-1362277,TOP2A,ENSG00000131747,CHEMBL2103796,BERUBICIN HYDROCHLORIDE,1.0,Terminated,EFO_0000313,carcinoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1.Cl
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL359744,DOXORUBICIN HYDROCHLORIDE,4.0,,EFO_0000183,Hodgkins lymphoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1200976,IDARUBICIN HYDROCHLORIDE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O.Cl
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL178,DAUNORUBICIN,4.0,,EFO_0000222,acute myeloid leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1096885,VALRUBICIN,4.0,,EFO_0000313,carcinoma,,CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1200778,DEXRAZOXANE HYDROCHLORIDE,4.0,,EFO_0000318,cardiomyopathy,,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1.Cl
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1117,IDARUBICIN,4.0,,EFO_0000616,neoplasm,,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL44657,ETOPOSIDE,4.0,,EFO_0000616,neoplasm,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL58,MITOXANTRONE,4.0,,EFO_0000616,neoplasm,,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL43,AMSACRINE,4.0,,EFO_0000616,neoplasm,,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL452231,TENIPOSIDE,4.0,,EFO_0000616,neoplasm,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL53463,DOXORUBICIN,4.0,,EFO_0000616,neoplasm,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1563,DAUNORUBICIN HYDROCHLORIDE,4.0,,EFO_0004289,lymphoid leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1417019,MITOXANTRONE HYDROCHLORIDE,4.0,,MONDO_0008315,prostate cancer,,Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1738,DEXRAZOXANE,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1200645,ETOPOSIDE PHOSPHATE,3.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL68117,VOSAROXIN,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CN[C@H]1CN(c2ccc3c(=O)c(C(=O)O)cn(-c4nccs4)c3n2)C[C@@H]1OC
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1186894,AMRUBICIN,3.0,,EFO_0000616,neoplasm,,CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL481958,AMRUBICIN HYDROCHLORIDE,3.0,Terminated,EFO_0000702,small cell lung carcinoma,,CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O.Cl
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL240163,PAZUFLOXACIN,3.0,,EFO_0000771,bacterial disease,,C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL2107818,ALDOXORUBICIN,3.0,Completed,EFO_1001968,soft tissue sarcoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL2107313,BECATECARIN,3.0,Terminated,MONDO_0003060,biliary tract cancer,,CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL2110580,BERUBICIN,2.0,"Active, not recruiting",EFO_0000519,glioblastoma multiforme,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL1200475,DAUNORUBICIN CITRATE,2.0,Completed,EFO_0000565,leukemia,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL3833344,GANCOTAMAB,2.0,Terminated,MONDO_0007254,breast cancer,,
SUMOylation of DNA replication protein,R-HSA-4615885,https://reactome.org/PathwayBrowser/#/R-HSA-4615885,TOP2A,ENSG00000131747,CHEMBL2103796,BERUBICIN HYDROCHLORIDE,1.0,Terminated,EFO_0000313,carcinoma,,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](OCc2ccccc2)[C@H](C)O1.Cl
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCE,ENSG00000171132,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCE,ENSG00000171132,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCE,ENSG00000171132,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCE,ENSG00000171132,CHEMBL4297775,KAI-1678,2.0,Completed,HP_0012531,Pain,,
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCE,ENSG00000171132,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCH,ENSG00000027075,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCH,ENSG00000027075,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCH,ENSG00000027075,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCH,ENSG00000027075,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Effects of PIP2 hydrolysi,R-HSA-114508,https://reactome.org/PathwayBrowser/#/R-HSA-114508,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCB,ENSG00000166501,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCB,ENSG00000166501,CHEMBL300138,ENZASTAURIN,3.0,Completed,EFO_0000403,diffuse large B-cell lymphoma,,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCB,ENSG00000166501,CHEMBL91829,RUBOXISTAURIN,3.0,Completed,EFO_0003770,diabetic retinopathy,,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCB,ENSG00000166501,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCB,ENSG00000166501,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCB,ENSG00000166501,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCE,ENSG00000171132,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCE,ENSG00000171132,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCE,ENSG00000171132,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCE,ENSG00000171132,CHEMBL4297775,KAI-1678,2.0,Completed,HP_0012531,Pain,,
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCE,ENSG00000171132,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCG,ENSG00000126583,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCG,ENSG00000126583,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCG,ENSG00000126583,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCG,ENSG00000126583,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCH,ENSG00000027075,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCH,ENSG00000027075,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCH,ENSG00000027075,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCH,ENSG00000027075,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
G alpha (z) signalling event,R-HSA-418597,https://reactome.org/PathwayBrowser/#/R-HSA-418597,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL38,TRETINOIN,4.0,Unknown status,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL1131,ACITRETIN,4.0,Completed,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL1265,ADAPALENE,4.0,"Active, not recruiting",EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARB,ENSG00000077092,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL38,TRETINOIN,4.0,,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL1131,ACITRETIN,4.0,"Active, not recruiting",EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL1657,TAZAROTENE,4.0,Completed,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL3707313,TRIFAROTENE,4.0,,EFO_0003894,acne,,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Nuclear Receptor transcription pathwa,R-HSA-383280,https://reactome.org/PathwayBrowser/#/R-HSA-383280,RARG,ENSG00000172819,CHEMBL2105648,PALOVAROTENE,4.0,,MONDO_0007606,fibrodysplasia ossificans progressiva,,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21
SUMOylation of intracellular receptor,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
SUMOylation of intracellular receptor,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
SUMOylation of intracellular receptor,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
SUMOylation of intracellular receptor,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
SUMOylation of intracellular receptor,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
SUMOylation of intracellular receptor,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
SUMOylation of intracellular receptor,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
SUMOylation of intracellular receptor,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
SUMOylation of intracellular receptor,R-HSA-4090294,https://reactome.org/PathwayBrowser/#/R-HSA-4090294,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL38,TRETINOIN,4.0,Unknown status,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL1131,ACITRETIN,4.0,Completed,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL1265,ADAPALENE,4.0,"Active, not recruiting",EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARB,ENSG00000077092,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL38,TRETINOIN,4.0,,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL1131,ACITRETIN,4.0,"Active, not recruiting",EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL1657,TAZAROTENE,4.0,Completed,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL3707313,TRIFAROTENE,4.0,,EFO_0003894,acne,,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Signaling by Retinoic Aci,R-HSA-5362517,https://reactome.org/PathwayBrowser/#/R-HSA-5362517,RARG,ENSG00000172819,CHEMBL2105648,PALOVAROTENE,4.0,,MONDO_0007606,fibrodysplasia ossificans progressiva,,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,EZH2,ENSG00000106462,CHEMBL4594260,TAZEMETOSTAT HYDROBROMIDE,4.0,,EFO_0000691,sarcoma,,Br.CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,EZH2,ENSG00000106462,CHEMBL3414621,TAZEMETOSTAT,4.0,,EFO_0000616,neoplasm,,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,EZH2,ENSG00000106462,CHEMBL3287735,GSK2816126,1.0,Terminated,EFO_0000616,neoplasm,,CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL38,TRETINOIN,4.0,Unknown status,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL1131,ACITRETIN,4.0,Completed,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL1265,ADAPALENE,4.0,"Active, not recruiting",EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARB,ENSG00000077092,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL38,TRETINOIN,4.0,,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000616,neoplasm,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL1131,ACITRETIN,4.0,"Active, not recruiting",EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL1657,TAZAROTENE,4.0,Completed,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL3707313,TRIFAROTENE,4.0,,EFO_0003894,acne,,CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
Activation of anterior HOX genes in hindbrain development during early embryogenesi,R-HSA-5617472,https://reactome.org/PathwayBrowser/#/R-HSA-5617472,RARG,ENSG00000172819,CHEMBL2105648,PALOVAROTENE,4.0,,MONDO_0007606,fibrodysplasia ossificans progressiva,,CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21
TGFBR3 expressio,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL38,TRETINOIN,4.0,Completed,EFO_0000224,acute promyelocytic leukemia,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
TGFBR3 expressio,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL1131,ACITRETIN,4.0,Unknown status,EFO_0000676,psoriasis,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C
TGFBR3 expressio,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL1657,TAZAROTENE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
TGFBR3 expressio,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL705,ALITRETINOIN,4.0,,EFO_0000558,Kaposi's sarcoma,,CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
TGFBR3 expressio,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL464,ETRETINATE,4.0,,EFO_0000676,psoriasis,,CCOC(=O)/C=C(C)/C=C/C=C(C)/C=C/c1c(C)cc(OC)c(C)c1C
TGFBR3 expressio,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL1265,ADAPALENE,4.0,,EFO_0003894,acne,,COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
TGFBR3 expressio,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL547,ISOTRETINOIN,4.0,,EFO_0003894,acne,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
TGFBR3 expressio,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL25202,TAMIBAROTENE,3.0,Recruiting,EFO_0000198,myelodysplastic syndrome,,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(C(=O)O)cc3)ccc21
TGFBR3 expressio,R-HSA-9839394,https://reactome.org/PathwayBrowser/#/R-HSA-9839394,RARA,ENSG00000131759,CHEMBL107430,NRX195183,2.0,Withdrawn,EFO_0000224,acute promyelocytic leukemia,,CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
L13a-mediated translational silencing of Ceruloplasmin expressio,R-HSA-156827,https://reactome.org/PathwayBrowser/#/R-HSA-156827,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peptide chain elongatio,R-HSA-156902,https://reactome.org/PathwayBrowser/#/R-HSA-156902,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SRP-dependent cotranslational protein targeting to membran,R-HSA-1799339,https://reactome.org/PathwayBrowser/#/R-HSA-1799339,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Viral mRNA Translatio,R-HSA-192823,https://reactome.org/PathwayBrowser/#/R-HSA-192823,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Selenocysteine synthesi,R-HSA-2408557,https://reactome.org/PathwayBrowser/#/R-HSA-2408557,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Major pathway of rRNA processing in the nucleolus and cytoso,R-HSA-6791226,https://reactome.org/PathwayBrowser/#/R-HSA-6791226,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translation initiation complex formatio,R-HSA-72649,https://reactome.org/PathwayBrowser/#/R-HSA-72649,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of a pool of free 40S subunit,R-HSA-72689,https://reactome.org/PathwayBrowser/#/R-HSA-72689,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Formation of the ternary complex, and subsequently, the 43S comple",R-HSA-72695,https://reactome.org/PathwayBrowser/#/R-HSA-72695,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ribosomal scanning and start codon recognitio,R-HSA-72702,https://reactome.org/PathwayBrowser/#/R-HSA-72702,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GTP hydrolysis and joining of the 60S ribosomal subuni,R-HSA-72706,https://reactome.org/PathwayBrowser/#/R-HSA-72706,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Eukaryotic Translation Terminatio,R-HSA-72764,https://reactome.org/PathwayBrowser/#/R-HSA-72764,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of expression of SLITs and ROBO,R-HSA-9010553,https://reactome.org/PathwayBrowser/#/R-HSA-9010553,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Response of EIF2AK4 (GCN2) to amino acid deficienc,R-HSA-9633012,https://reactome.org/PathwayBrowser/#/R-HSA-9633012,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-1 modulates host translation machiner,R-HSA-9735869,https://reactome.org/PathwayBrowser/#/R-HSA-9735869,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-2 modulates host translation machiner,R-HSA-9754678,https://reactome.org/PathwayBrowser/#/R-HSA-9754678,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC,R-HSA-975956,https://reactome.org/PathwayBrowser/#/R-HSA-975956,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL11,ENSG00000142676,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL11,ENSG00000142676,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL11,ENSG00000142676,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL15,ENSG00000174748,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL15,ENSG00000174748,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL15,ENSG00000174748,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL23,ENSG00000125691,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL23,ENSG00000125691,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL23,ENSG00000125691,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL26,ENSG00000161970,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL26,ENSG00000161970,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL26,ENSG00000161970,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL31,ENSG00000071082,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL31,ENSG00000071082,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL31,ENSG00000071082,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL35A,ENSG00000182899,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL35A,ENSG00000182899,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL35A,ENSG00000182899,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL36,ENSG00000130255,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL36,ENSG00000130255,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL36,ENSG00000130255,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL5,ENSG00000122406,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL5,ENSG00000122406,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPL5,ENSG00000122406,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS10,ENSG00000124614,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS10,ENSG00000124614,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS10,ENSG00000124614,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS17,ENSG00000182774,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS17,ENSG00000182774,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS17,ENSG00000182774,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS19,ENSG00000105372,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS19,ENSG00000105372,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS19,ENSG00000105372,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS24,ENSG00000138326,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS24,ENSG00000138326,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS24,ENSG00000138326,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS26,ENSG00000197728,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS26,ENSG00000197728,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS26,ENSG00000197728,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS28,ENSG00000233927,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS28,ENSG00000233927,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS28,ENSG00000233927,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS29,ENSG00000213741,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS29,ENSG00000213741,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS29,ENSG00000213741,CHEMBL4297744,ELX-02,2.0,Completed,MONDO_0009061,cystic fibrosis,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC,R-HSA-975957,https://reactome.org/PathwayBrowser/#/R-HSA-975957,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
PI3K Cascad,R-HSA-109704,https://reactome.org/PathwayBrowser/#/R-HSA-109704,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
PIP3 activates AKT signalin,R-HSA-1257604,https://reactome.org/PathwayBrowser/#/R-HSA-1257604,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Constitutive Signaling by Aberrant PI3K in Cance,R-HSA-2219530,https://reactome.org/PathwayBrowser/#/R-HSA-2219530,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL1738797,ALECTINIB,4.0,,EFO_0000616,neoplasm,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL4559134,SELPERCATINIB,4.0,,EFO_0000616,neoplasm,,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL4582651,PRALSETINIB,4.0,,EFO_0000616,neoplasm,,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL3707320,ALECTINIB HYDROCHLORIDE,4.0,,EFO_0003060,non-small cell lung carcinoma,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL4650296,BOS-589,2.0,Completed,EFO_0000555,irritable bowel syndrome,,
RAF/MAP kinase cascad,R-HSA-5673001,https://reactome.org/PathwayBrowser/#/R-HSA-5673001,RET,ENSG00000165731,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signalin",R-HSA-6811558,https://reactome.org/PathwayBrowser/#/R-HSA-6811558,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
FLT3 Signalin,R-HSA-9607240,https://reactome.org/PathwayBrowser/#/R-HSA-9607240,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
STAT5 Activatio,R-HSA-9645135,https://reactome.org/PathwayBrowser/#/R-HSA-9645135,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
FLT3 mutants bind TKI,R-HSA-9702509,https://reactome.org/PathwayBrowser/#/R-HSA-9702509,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
STAT5 activation downstream of FLT3 ITD mutant,R-HSA-9702518,https://reactome.org/PathwayBrowser/#/R-HSA-9702518,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
KW2449-resistant FLT3 mutant,R-HSA-9702569,https://reactome.org/PathwayBrowser/#/R-HSA-9702569,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
semaxanib-resistant FLT3 mutant,R-HSA-9702577,https://reactome.org/PathwayBrowser/#/R-HSA-9702577,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
crenolanib-resistant FLT3 mutant,R-HSA-9702581,https://reactome.org/PathwayBrowser/#/R-HSA-9702581,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
gilteritinib-resistant FLT3 mutant,R-HSA-9702590,https://reactome.org/PathwayBrowser/#/R-HSA-9702590,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
lestaurtinib-resistant FLT3 mutant,R-HSA-9702596,https://reactome.org/PathwayBrowser/#/R-HSA-9702596,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
midostaurin-resistant FLT3 mutant,R-HSA-9702600,https://reactome.org/PathwayBrowser/#/R-HSA-9702600,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
pexidartinib-resistant FLT3 mutant,R-HSA-9702605,https://reactome.org/PathwayBrowser/#/R-HSA-9702605,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
ponatinib-resistant FLT3 mutant,R-HSA-9702614,https://reactome.org/PathwayBrowser/#/R-HSA-9702614,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
quizartinib-resistant FLT3 mutant,R-HSA-9702620,https://reactome.org/PathwayBrowser/#/R-HSA-9702620,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
sorafenib-resistant FLT3 mutant,R-HSA-9702624,https://reactome.org/PathwayBrowser/#/R-HSA-9702624,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
sunitinib-resistant FLT3 mutant,R-HSA-9702632,https://reactome.org/PathwayBrowser/#/R-HSA-9702632,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
tandutinib-resistant FLT3 mutant,R-HSA-9702636,https://reactome.org/PathwayBrowser/#/R-HSA-9702636,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
linifanib-resistant FLT3 mutant,R-HSA-9702998,https://reactome.org/PathwayBrowser/#/R-HSA-9702998,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
tamatinib-resistant FLT3 mutant,R-HSA-9703009,https://reactome.org/PathwayBrowser/#/R-HSA-9703009,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by FLT3 ITD and TKD mutant,R-HSA-9703648,https://reactome.org/PathwayBrowser/#/R-HSA-9703648,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Negative regulation of FLT,R-HSA-9706369,https://reactome.org/PathwayBrowser/#/R-HSA-9706369,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
FLT3 signaling through SRC family kinase,R-HSA-9706374,https://reactome.org/PathwayBrowser/#/R-HSA-9706374,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002430,primary myelofibrosis,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4650387,CDX-301,2.0,Terminated,EFO_0000756,melanoma,,
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4650283,FF-10101,1.0,Completed,EFO_0000222,acute myeloid leukemia,,CCCNc1nc(Nc2ccc(C#N)cc2)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)/C=C/CN(C)C
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4650288,FLYSYN,1.0,Completed,EFO_0000222,acute myeloid leukemia,,
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4650295,AMG553,1.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL4790100,AKN-028,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ncc(-c2ccncc2)nc1Nc1ccc2[nH]ccc2c1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,FLT3,ENSG00000122025,CHEMBL2109328,IMC-EB10,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
FLT3 signaling by CBL mutant,R-HSA-9706377,https://reactome.org/PathwayBrowser/#/R-HSA-9706377,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarat,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL3989958,IVOSIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarat,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4297610,OLUTASIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarat,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarat,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4167360,IDH305,2.0,Withdrawn,EFO_1000453,Paraganglioma,,Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarat,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4651002,SAFUSIDENIB,2.0,Recruiting,EFO_1000453,Paraganglioma,,Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarat,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4650282,DS-1001B,2.0,"Active, not recruiting",MONDO_0021639,grade II glioma,,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarat,R-HSA-2978092,https://reactome.org/PathwayBrowser/#/R-HSA-2978092,IDH1,ENSG00000138413,CHEMBL4206033,BAY1436032,1.0,Completed,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1
NADPH regeneratio,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL3989958,IVOSIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
NADPH regeneratio,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4297610,OLUTASIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
NADPH regeneratio,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
NADPH regeneratio,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4167360,IDH305,2.0,Withdrawn,EFO_1000453,Paraganglioma,,Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1
NADPH regeneratio,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4651002,SAFUSIDENIB,2.0,Recruiting,EFO_1000453,Paraganglioma,,Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
NADPH regeneratio,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4650282,DS-1001B,2.0,"Active, not recruiting",MONDO_0021639,grade II glioma,,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
NADPH regeneratio,R-HSA-389542,https://reactome.org/PathwayBrowser/#/R-HSA-389542,IDH1,ENSG00000138413,CHEMBL4206033,BAY1436032,1.0,Completed,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,CD33,ENSG00000105383,CHEMBL1201506,GEMTUZUMAB OZOGAMICIN,4.0,,EFO_0000222,acute myeloid leukemia,,
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,CD33,ENSG00000105383,CHEMBL2108342,GEMTUZUMAB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,CD33,ENSG00000105383,CHEMBL2109150,LINTUZUMAB,3.0,Unknown status,EFO_0000565,leukemia,,
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,CD33,ENSG00000105383,CHEMBL2109267,M195,1.0,Completed,EFO_0000198,myelodysplastic syndrome,,
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,CD33,ENSG00000105383,CHEMBL2109266,AVE-9633,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,ELANE,ENSG00000197561,CHEMBL4297879,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,4.0,,EFO_0000508,genetic disorder,,
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,ELANE,ENSG00000197561,CHEMBL76688,SIVELESTAT,3.0,Not yet recruiting,EFO_0003777,heart disease,,CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,ELANE,ENSG00000197561,CHEMBL3617964,ALVELESTAT,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL3989958,IVOSIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4297610,OLUTASIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4167360,IDH305,2.0,Withdrawn,EFO_1000453,Paraganglioma,,Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4651002,SAFUSIDENIB,2.0,Recruiting,EFO_1000453,Paraganglioma,,Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4650282,DS-1001B,2.0,"Active, not recruiting",MONDO_0021639,grade II glioma,,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,IDH1,ENSG00000138413,CHEMBL4206033,BAY1436032,1.0,Completed,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Neutrophil degranulatio,R-HSA-6798695,https://reactome.org/PathwayBrowser/#/R-HSA-6798695,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Peroxisomal protein impor,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL3989958,IVOSIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
Peroxisomal protein impor,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4297610,OLUTASIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
Peroxisomal protein impor,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Peroxisomal protein impor,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4167360,IDH305,2.0,Withdrawn,EFO_1000453,Paraganglioma,,Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1
Peroxisomal protein impor,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4651002,SAFUSIDENIB,2.0,Recruiting,EFO_1000453,Paraganglioma,,Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Peroxisomal protein impor,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4650282,DS-1001B,2.0,"Active, not recruiting",MONDO_0021639,grade II glioma,,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
Peroxisomal protein impor,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,IDH1,ENSG00000138413,CHEMBL4206033,BAY1436032,1.0,Completed,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1
Peroxisomal protein impor,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Peroxisomal protein impor,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Peroxisomal protein impor,R-HSA-9033241,https://reactome.org/PathwayBrowser/#/R-HSA-9033241,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
NFE2L2 regulating TCA cycle gene,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL3989958,IVOSIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,N#Cc1ccnc(N2C(=O)CC[C@H]2C(=O)N(c2cncc(F)c2)[C@H](C(=O)NC2CC(F)(F)C2)c2ccccc2Cl)c1
NFE2L2 regulating TCA cycle gene,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4297610,OLUTASIDENIB,4.0,,EFO_0000222,acute myeloid leukemia,,C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O
NFE2L2 regulating TCA cycle gene,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
NFE2L2 regulating TCA cycle gene,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4167360,IDH305,2.0,Withdrawn,EFO_1000453,Paraganglioma,,Cc1cc([C@H](C)Nc2nccc(N3C(=O)OC[C@@H]3[C@@H](C)F)n2)ncc1-c1ccnc(C(F)(F)F)c1
NFE2L2 regulating TCA cycle gene,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4651002,SAFUSIDENIB,2.0,Recruiting,EFO_1000453,Paraganglioma,,Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
NFE2L2 regulating TCA cycle gene,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4650282,DS-1001B,2.0,"Active, not recruiting",MONDO_0021639,grade II glioma,,CC(C)(C)N.Cc1cn(C(=O)c2c(-c3c(Cl)cc(Cl)cc3Cl)noc2C(C)(C)F)c2cccc(/C=C/C(=O)O)c12
NFE2L2 regulating TCA cycle gene,R-HSA-9818025,https://reactome.org/PathwayBrowser/#/R-HSA-9818025,IDH1,ENSG00000138413,CHEMBL4206033,BAY1436032,1.0,Completed,EFO_0000222,acute myeloid leukemia,,C[C@H]1C[C@@H](n2c(Nc3ccc(OC(F)(F)F)cc3)nc3cc(CCC(=O)O)ccc32)CC(C)(C)C1
Telomere Extension By Telomeras,R-HSA-171319,https://reactome.org/PathwayBrowser/#/R-HSA-171319,TERT,ENSG00000164362,CHEMBL2107856,IMETELSTAT,3.0,Recruiting,MONDO_0044903,myelofibrosis,,
Telomere Extension By Telomeras,R-HSA-171319,https://reactome.org/PathwayBrowser/#/R-HSA-171319,TERT,ENSG00000164362,CHEMBL2108702,IMETELSTAT SODIUM,2.0,Completed,MONDO_0007254,breast cancer,,
rRNA modification in the nucleus and cytoso,R-HSA-6790901,https://reactome.org/PathwayBrowser/#/R-HSA-6790901,RPS7,ENSG00000171863,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
rRNA modification in the nucleus and cytoso,R-HSA-6790901,https://reactome.org/PathwayBrowser/#/R-HSA-6790901,RPS7,ENSG00000171863,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
rRNA modification in the nucleus and cytoso,R-HSA-6790901,https://reactome.org/PathwayBrowser/#/R-HSA-6790901,RPS7,ENSG00000171863,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
UCH proteinase,R-HSA-5689603,https://reactome.org/PathwayBrowser/#/R-HSA-5689603,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
UCH proteinase,R-HSA-5689603,https://reactome.org/PathwayBrowser/#/R-HSA-5689603,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
UCH proteinase,R-HSA-5689603,https://reactome.org/PathwayBrowser/#/R-HSA-5689603,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosi,R-HSA-9841922,https://reactome.org/PathwayBrowser/#/R-HSA-9841922,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL502835,NINTEDANIB,3.0,Completed,EFO_0000768,idiopathic pulmonary fibrosis,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL101253,VATALANIB,3.0,Completed,EFO_1000657,rectum cancer,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2109602,IMC-3C5,1.0,Completed,EFO_0000616,neoplasm,,
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,FLT4,ENSG00000037280,CHEMBL3109738,JNJ-26483327,1.0,Completed,MONDO_0004992,cancer,,COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
VEGF binds to VEGFR leading to receptor dimerizatio,R-HSA-195399,https://reactome.org/PathwayBrowser/#/R-HSA-195399,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL502835,NINTEDANIB,3.0,Completed,EFO_0000768,idiopathic pulmonary fibrosis,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL101253,VATALANIB,3.0,Completed,EFO_1000657,rectum cancer,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2109602,IMC-3C5,1.0,Completed,EFO_0000616,neoplasm,,
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
NOTCH4 Intracellular Domain Regulates Transcriptio,R-HSA-9013695,https://reactome.org/PathwayBrowser/#/R-HSA-9013695,FLT4,ENSG00000037280,CHEMBL3109738,JNJ-26483327,1.0,Completed,MONDO_0004992,cancer,,COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL535,SUNITINIB,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1336,SORAFENIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL502835,NINTEDANIB,3.0,Completed,EFO_0000768,idiopathic pulmonary fibrosis,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL101253,VATALANIB,3.0,Completed,EFO_1000657,rectum cancer,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2109602,IMC-3C5,1.0,Completed,EFO_0000616,neoplasm,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,FLT4,ENSG00000037280,CHEMBL3109738,JNJ-26483327,1.0,Completed,MONDO_0004992,cancer,,COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cell,R-HSA-9856530,https://reactome.org/PathwayBrowser/#/R-HSA-9856530,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCB,ENSG00000166501,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCB,ENSG00000166501,CHEMBL300138,ENZASTAURIN,3.0,Completed,EFO_0000403,diffuse large B-cell lymphoma,,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCB,ENSG00000166501,CHEMBL91829,RUBOXISTAURIN,3.0,Completed,EFO_0003770,diabetic retinopathy,,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCB,ENSG00000166501,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCB,ENSG00000166501,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCB,ENSG00000166501,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCG,ENSG00000126583,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCG,ENSG00000126583,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCG,ENSG00000126583,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Disinhibition of SNARE formatio,R-HSA-114516,https://reactome.org/PathwayBrowser/#/R-HSA-114516,PRKCG,ENSG00000126583,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Activation of NF-kappaB in B cell,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,PRKCB,ENSG00000166501,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Activation of NF-kappaB in B cell,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,PRKCB,ENSG00000166501,CHEMBL300138,ENZASTAURIN,3.0,Completed,EFO_0000403,diffuse large B-cell lymphoma,,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
Activation of NF-kappaB in B cell,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,PRKCB,ENSG00000166501,CHEMBL91829,RUBOXISTAURIN,3.0,Completed,EFO_0003770,diabetic retinopathy,,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
Activation of NF-kappaB in B cell,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,PRKCB,ENSG00000166501,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Activation of NF-kappaB in B cell,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,PRKCB,ENSG00000166501,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Activation of NF-kappaB in B cell,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,PRKCB,ENSG00000166501,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Activation of NF-kappaB in B cell,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Activation of NF-kappaB in B cell,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Activation of NF-kappaB in B cell,R-HSA-1169091,https://reactome.org/PathwayBrowser/#/R-HSA-1169091,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCB,ENSG00000166501,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCB,ENSG00000166501,CHEMBL300138,ENZASTAURIN,3.0,Completed,EFO_0000403,diffuse large B-cell lymphoma,,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCB,ENSG00000166501,CHEMBL91829,RUBOXISTAURIN,3.0,Completed,EFO_0003770,diabetic retinopathy,,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCB,ENSG00000166501,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCB,ENSG00000166501,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCB,ENSG00000166501,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCG,ENSG00000126583,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCG,ENSG00000126583,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCG,ENSG00000126583,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Trafficking of GluR2-containing AMPA receptor,R-HSA-416993,https://reactome.org/PathwayBrowser/#/R-HSA-416993,PRKCG,ENSG00000126583,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Depolymerization of the Nuclear Lamin,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Depolymerization of the Nuclear Lamin,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Depolymerization of the Nuclear Lamin,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Depolymerization of the Nuclear Lamin,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Depolymerization of the Nuclear Lamin,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Depolymerization of the Nuclear Lamin,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCB,ENSG00000166501,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Depolymerization of the Nuclear Lamin,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCB,ENSG00000166501,CHEMBL300138,ENZASTAURIN,3.0,Completed,EFO_0000403,diffuse large B-cell lymphoma,,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
Depolymerization of the Nuclear Lamin,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCB,ENSG00000166501,CHEMBL91829,RUBOXISTAURIN,3.0,Completed,EFO_0003770,diabetic retinopathy,,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
Depolymerization of the Nuclear Lamin,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCB,ENSG00000166501,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Depolymerization of the Nuclear Lamin,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCB,ENSG00000166501,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Depolymerization of the Nuclear Lamin,R-HSA-4419969,https://reactome.org/PathwayBrowser/#/R-HSA-4419969,PRKCB,ENSG00000166501,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCB,ENSG00000166501,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCB,ENSG00000166501,CHEMBL300138,ENZASTAURIN,3.0,Completed,EFO_0000403,diffuse large B-cell lymphoma,,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCB,ENSG00000166501,CHEMBL91829,RUBOXISTAURIN,3.0,Completed,EFO_0003770,diabetic retinopathy,,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCB,ENSG00000166501,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCB,ENSG00000166501,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCB,ENSG00000166501,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCG,ENSG00000126583,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCG,ENSG00000126583,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCG,ENSG00000126583,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
WNT5A-dependent internalization of FZD,R-HSA-5099900,https://reactome.org/PathwayBrowser/#/R-HSA-5099900,PRKCG,ENSG00000126583,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCB,ENSG00000166501,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCB,ENSG00000166501,CHEMBL300138,ENZASTAURIN,3.0,Completed,EFO_0000403,diffuse large B-cell lymphoma,,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCB,ENSG00000166501,CHEMBL91829,RUBOXISTAURIN,3.0,Completed,EFO_0003770,diabetic retinopathy,,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCB,ENSG00000166501,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCB,ENSG00000166501,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCB,ENSG00000166501,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCZ,ENSG00000067606,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCZ,ENSG00000067606,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCZ,ENSG00000067606,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
VEGFR2 mediated cell proliferatio,R-HSA-5218921,https://reactome.org/PathwayBrowser/#/R-HSA-5218921,PRKCZ,ENSG00000067606,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCB,ENSG00000166501,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCB,ENSG00000166501,CHEMBL300138,ENZASTAURIN,3.0,Completed,EFO_0000403,diffuse large B-cell lymphoma,,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCB,ENSG00000166501,CHEMBL91829,RUBOXISTAURIN,3.0,Completed,EFO_0003770,diabetic retinopathy,,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCB,ENSG00000166501,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCB,ENSG00000166501,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCB,ENSG00000166501,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCZ,ENSG00000067606,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCZ,ENSG00000067606,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCZ,ENSG00000067606,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RHO GTPases Activate NADPH Oxidase,R-HSA-5668599,https://reactome.org/PathwayBrowser/#/R-HSA-5668599,PRKCZ,ENSG00000067606,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCB,ENSG00000166501,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCB,ENSG00000166501,CHEMBL300138,ENZASTAURIN,3.0,Completed,EFO_0000403,diffuse large B-cell lymphoma,,Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCB,ENSG00000166501,CHEMBL91829,RUBOXISTAURIN,3.0,Completed,EFO_0003770,diabetic retinopathy,,CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCB,ENSG00000166501,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCB,ENSG00000166501,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCB,ENSG00000166501,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCG,ENSG00000126583,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCG,ENSG00000126583,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCG,ENSG00000126583,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Response to elevated platelet cytosolic Ca2,R-HSA-76005,https://reactome.org/PathwayBrowser/#/R-HSA-76005,PRKCG,ENSG00000126583,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Formation of the beta-catenin:TCF transactivating comple,R-HSA-201722,https://reactome.org/PathwayBrowser/#/R-HSA-201722,TERT,ENSG00000164362,CHEMBL2107856,IMETELSTAT,3.0,Recruiting,MONDO_0044903,myelofibrosis,,
Formation of the beta-catenin:TCF transactivating comple,R-HSA-201722,https://reactome.org/PathwayBrowser/#/R-HSA-201722,TERT,ENSG00000164362,CHEMBL2108702,IMETELSTAT SODIUM,2.0,Completed,MONDO_0007254,breast cancer,,
"Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescenc",R-HSA-9825895,https://reactome.org/PathwayBrowser/#/R-HSA-9825895,TERT,ENSG00000164362,CHEMBL2107856,IMETELSTAT,3.0,Recruiting,MONDO_0044903,myelofibrosis,,
"Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescenc",R-HSA-9825895,https://reactome.org/PathwayBrowser/#/R-HSA-9825895,TERT,ENSG00000164362,CHEMBL2108702,IMETELSTAT SODIUM,2.0,Completed,MONDO_0007254,breast cancer,,
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,AXL,ENSG00000167601,CHEMBL3301603,GILTERITINIB FUMARATE,4.0,,EFO_0000222,acute myeloid leukemia,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1.O=C(O)/C=C/C(=O)O
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,AXL,ENSG00000167601,CHEMBL3301622,GILTERITINIB,4.0,,EFO_0000616,neoplasm,,CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,AXL,ENSG00000167601,CHEMBL3809489,BEMCENTINIB,2.0,Completed,EFO_0000571,lung adenocarcinoma,,Nc1nc(Nc2ccc3c(c2)CC[C@@H](N2CCCC2)CC3)nn1-c1cc2c(nn1)-c1ccccc1CCC2
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,AXL,ENSG00000167601,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,AXL,ENSG00000167601,CHEMBL3545236,BPI-9016,1.0,Completed,EFO_0000616,neoplasm,,
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
VEGFA-VEGFR2 Pathwa,R-HSA-4420097,https://reactome.org/PathwayBrowser/#/R-HSA-4420097,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE,ENSG00000177084,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE,ENSG00000177084,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE,ENSG00000177084,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE,ENSG00000177084,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE,ENSG00000177084,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE,ENSG00000177084,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE,ENSG00000177084,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE2,ENSG00000100479,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE2,ENSG00000100479,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE2,ENSG00000100479,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE2,ENSG00000100479,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE2,ENSG00000100479,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE2,ENSG00000100479,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE2,ENSG00000100479,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE3,ENSG00000148229,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE3,ENSG00000148229,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE3,ENSG00000148229,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE3,ENSG00000148229,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE3,ENSG00000148229,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE3,ENSG00000148229,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,POLE3,ENSG00000148229,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Recognition of DNA damage by PCNA-containing replication comple,R-HSA-110314,https://reactome.org/PathwayBrowser/#/R-HSA-110314,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE,ENSG00000177084,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE,ENSG00000177084,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE,ENSG00000177084,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE,ENSG00000177084,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE,ENSG00000177084,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE,ENSG00000177084,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE,ENSG00000177084,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE2,ENSG00000100479,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE2,ENSG00000100479,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE2,ENSG00000100479,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE2,ENSG00000100479,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE2,ENSG00000100479,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE2,ENSG00000100479,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE2,ENSG00000100479,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE3,ENSG00000148229,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE3,ENSG00000148229,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE3,ENSG00000148229,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE3,ENSG00000148229,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE3,ENSG00000148229,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE3,ENSG00000148229,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
PCNA-Dependent Long Patch Base Excision Repai,R-HSA-5651801,https://reactome.org/PathwayBrowser/#/R-HSA-5651801,POLE3,ENSG00000148229,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE,ENSG00000177084,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE,ENSG00000177084,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE,ENSG00000177084,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE,ENSG00000177084,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE,ENSG00000177084,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE,ENSG00000177084,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE,ENSG00000177084,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE2,ENSG00000100479,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE2,ENSG00000100479,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE2,ENSG00000100479,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE2,ENSG00000100479,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE2,ENSG00000100479,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE2,ENSG00000100479,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE2,ENSG00000100479,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE3,ENSG00000148229,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE3,ENSG00000148229,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE3,ENSG00000148229,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE3,ENSG00000148229,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE3,ENSG00000148229,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE3,ENSG00000148229,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,POLE3,ENSG00000148229,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Termination of translesion DNA synthesi,R-HSA-5656169,https://reactome.org/PathwayBrowser/#/R-HSA-5656169,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE,ENSG00000177084,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE,ENSG00000177084,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE,ENSG00000177084,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE,ENSG00000177084,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE,ENSG00000177084,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE,ENSG00000177084,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE,ENSG00000177084,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE2,ENSG00000100479,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE2,ENSG00000100479,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE2,ENSG00000100479,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE2,ENSG00000100479,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE2,ENSG00000100479,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE2,ENSG00000100479,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE2,ENSG00000100479,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE3,ENSG00000148229,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE3,ENSG00000148229,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE3,ENSG00000148229,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE3,ENSG00000148229,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE3,ENSG00000148229,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE3,ENSG00000148229,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,POLE3,ENSG00000148229,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
HDR through Homologous Recombination (HRR,R-HSA-5685942,https://reactome.org/PathwayBrowser/#/R-HSA-5685942,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE,ENSG00000177084,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE,ENSG00000177084,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE,ENSG00000177084,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE,ENSG00000177084,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE,ENSG00000177084,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE,ENSG00000177084,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE,ENSG00000177084,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE2,ENSG00000100479,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE2,ENSG00000100479,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE2,ENSG00000100479,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE2,ENSG00000100479,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE2,ENSG00000100479,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE2,ENSG00000100479,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE2,ENSG00000100479,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE3,ENSG00000148229,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE3,ENSG00000148229,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE3,ENSG00000148229,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE3,ENSG00000148229,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE3,ENSG00000148229,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE3,ENSG00000148229,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,POLE3,ENSG00000148229,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in GG-NE,,,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Gap-filling DNA repair synthesis and ligation in GG-NE,,,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Gap-filling DNA repair synthesis and ligation in GG-NE,,,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE,ENSG00000177084,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE,ENSG00000177084,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE,ENSG00000177084,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE,ENSG00000177084,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE,ENSG00000177084,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE,ENSG00000177084,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE,ENSG00000177084,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE2,ENSG00000100479,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE2,ENSG00000100479,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE2,ENSG00000100479,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE2,ENSG00000100479,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE2,ENSG00000100479,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE2,ENSG00000100479,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE2,ENSG00000100479,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE3,ENSG00000148229,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE3,ENSG00000148229,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE3,ENSG00000148229,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE3,ENSG00000148229,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE3,ENSG00000148229,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE3,ENSG00000148229,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,POLE3,ENSG00000148229,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Dual Incision in GG-NE,R-HSA-5696400,https://reactome.org/PathwayBrowser/#/R-HSA-5696400,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE,ENSG00000177084,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE,ENSG00000177084,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE,ENSG00000177084,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE,ENSG00000177084,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE,ENSG00000177084,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE,ENSG00000177084,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE,ENSG00000177084,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE2,ENSG00000100479,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE2,ENSG00000100479,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE2,ENSG00000100479,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE2,ENSG00000100479,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE2,ENSG00000100479,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE2,ENSG00000100479,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE2,ENSG00000100479,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE3,ENSG00000148229,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE3,ENSG00000148229,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE3,ENSG00000148229,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE3,ENSG00000148229,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE3,ENSG00000148229,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE3,ENSG00000148229,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,POLE3,ENSG00000148229,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Dual incision in TC-NE,R-HSA-6782135,https://reactome.org/PathwayBrowser/#/R-HSA-6782135,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE,ENSG00000177084,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE,ENSG00000177084,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE,ENSG00000177084,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE,ENSG00000177084,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE,ENSG00000177084,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE,ENSG00000177084,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE,ENSG00000177084,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE2,ENSG00000100479,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE2,ENSG00000100479,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE2,ENSG00000100479,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE2,ENSG00000100479,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE2,ENSG00000100479,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE2,ENSG00000100479,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE2,ENSG00000100479,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE3,ENSG00000148229,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE3,ENSG00000148229,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE3,ENSG00000148229,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE3,ENSG00000148229,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE3,ENSG00000148229,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE3,ENSG00000148229,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,POLE3,ENSG00000148229,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Gap-filling DNA repair synthesis and ligation in TC-NE,R-HSA-6782210,https://reactome.org/PathwayBrowser/#/R-HSA-6782210,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
DNA replication initiatio,,,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
DNA replication initiatio,,,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
DNA replication initiatio,,,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
DNA replication initiatio,,,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
DNA replication initiatio,,,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
DNA replication initiatio,,,POLA2,ENSG00000014138,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
DNA replication initiatio,,,POLA2,ENSG00000014138,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
DNA replication initiatio,,,POLA2,ENSG00000014138,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
DNA replication initiatio,,,POLA2,ENSG00000014138,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,POLA2,ENSG00000014138,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,POLA2,ENSG00000014138,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
DNA replication initiatio,,,POLA2,ENSG00000014138,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
DNA replication initiatio,,,POLE,ENSG00000177084,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
DNA replication initiatio,,,POLE,ENSG00000177084,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
DNA replication initiatio,,,POLE,ENSG00000177084,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
DNA replication initiatio,,,POLE,ENSG00000177084,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,POLE,ENSG00000177084,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,POLE,ENSG00000177084,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
DNA replication initiatio,,,POLE,ENSG00000177084,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
DNA replication initiatio,,,POLE2,ENSG00000100479,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
DNA replication initiatio,,,POLE2,ENSG00000100479,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
DNA replication initiatio,,,POLE2,ENSG00000100479,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
DNA replication initiatio,,,POLE2,ENSG00000100479,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,POLE2,ENSG00000100479,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,POLE2,ENSG00000100479,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
DNA replication initiatio,,,POLE2,ENSG00000100479,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
DNA replication initiatio,,,POLE3,ENSG00000148229,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
DNA replication initiatio,,,POLE3,ENSG00000148229,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
DNA replication initiatio,,,POLE3,ENSG00000148229,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
DNA replication initiatio,,,POLE3,ENSG00000148229,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,POLE3,ENSG00000148229,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,POLE3,ENSG00000148229,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
DNA replication initiatio,,,POLE3,ENSG00000148229,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
DNA replication initiatio,,,PRIM1,ENSG00000198056,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
DNA replication initiatio,,,PRIM1,ENSG00000198056,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
DNA replication initiatio,,,PRIM1,ENSG00000198056,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
DNA replication initiatio,,,PRIM1,ENSG00000198056,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,PRIM1,ENSG00000198056,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,PRIM1,ENSG00000198056,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
DNA replication initiatio,,,PRIM1,ENSG00000198056,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
DNA replication initiatio,,,PRIM2,ENSG00000146143,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
DNA replication initiatio,,,PRIM2,ENSG00000146143,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
DNA replication initiatio,,,PRIM2,ENSG00000146143,CHEMBL803,CYTARABINE,4.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
DNA replication initiatio,,,PRIM2,ENSG00000146143,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,PRIM2,ENSG00000146143,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
DNA replication initiatio,,,PRIM2,ENSG00000146143,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
DNA replication initiatio,,,PRIM2,ENSG00000146143,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA2,ENSG00000014138,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA2,ENSG00000014138,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA2,ENSG00000014138,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA2,ENSG00000014138,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA2,ENSG00000014138,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA2,ENSG00000014138,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLA2,ENSG00000014138,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE,ENSG00000177084,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE,ENSG00000177084,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE,ENSG00000177084,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE,ENSG00000177084,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE,ENSG00000177084,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE,ENSG00000177084,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE,ENSG00000177084,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE2,ENSG00000100479,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE2,ENSG00000100479,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE2,ENSG00000100479,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE2,ENSG00000100479,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE2,ENSG00000100479,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE2,ENSG00000100479,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE2,ENSG00000100479,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE3,ENSG00000148229,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE3,ENSG00000148229,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE3,ENSG00000148229,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE3,ENSG00000148229,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE3,ENSG00000148229,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE3,ENSG00000148229,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,POLE3,ENSG00000148229,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM1,ENSG00000198056,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM1,ENSG00000198056,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM1,ENSG00000198056,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM1,ENSG00000198056,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM1,ENSG00000198056,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM1,ENSG00000198056,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM1,ENSG00000198056,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM2,ENSG00000146143,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM2,ENSG00000146143,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM2,ENSG00000146143,CHEMBL803,CYTARABINE,4.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM2,ENSG00000146143,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM2,ENSG00000146143,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM2,ENSG00000146143,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Activation of the pre-replicative comple,R-HSA-68962,https://reactome.org/PathwayBrowser/#/R-HSA-68962,PRIM2,ENSG00000146143,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
GPVI-mediated activation cascad,R-HSA-114604,https://reactome.org/PathwayBrowser/#/R-HSA-114604,PRKCZ,ENSG00000067606,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
GPVI-mediated activation cascad,R-HSA-114604,https://reactome.org/PathwayBrowser/#/R-HSA-114604,PRKCZ,ENSG00000067606,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
GPVI-mediated activation cascad,R-HSA-114604,https://reactome.org/PathwayBrowser/#/R-HSA-114604,PRKCZ,ENSG00000067606,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
GPVI-mediated activation cascad,R-HSA-114604,https://reactome.org/PathwayBrowser/#/R-HSA-114604,PRKCZ,ENSG00000067606,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
GPVI-mediated activation cascad,R-HSA-114604,https://reactome.org/PathwayBrowser/#/R-HSA-114604,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition,R-HSA-2173791,https://reactome.org/PathwayBrowser/#/R-HSA-2173791,PRKCZ,ENSG00000067606,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition,R-HSA-2173791,https://reactome.org/PathwayBrowser/#/R-HSA-2173791,PRKCZ,ENSG00000067606,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition,R-HSA-2173791,https://reactome.org/PathwayBrowser/#/R-HSA-2173791,PRKCZ,ENSG00000067606,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition,R-HSA-2173791,https://reactome.org/PathwayBrowser/#/R-HSA-2173791,PRKCZ,ENSG00000067606,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition,R-HSA-2173791,https://reactome.org/PathwayBrowser/#/R-HSA-2173791,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition,R-HSA-2173791,https://reactome.org/PathwayBrowser/#/R-HSA-2173791,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition,R-HSA-2173791,https://reactome.org/PathwayBrowser/#/R-HSA-2173791,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Estrogen-stimulated signaling through PRKC,R-HSA-9634635,https://reactome.org/PathwayBrowser/#/R-HSA-9634635,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Estrogen-stimulated signaling through PRKC,R-HSA-9634635,https://reactome.org/PathwayBrowser/#/R-HSA-9634635,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Estrogen-stimulated signaling through PRKC,R-HSA-9634635,https://reactome.org/PathwayBrowser/#/R-HSA-9634635,PRKCZ,ENSG00000067606,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Estrogen-stimulated signaling through PRKC,R-HSA-9634635,https://reactome.org/PathwayBrowser/#/R-HSA-9634635,PRKCZ,ENSG00000067606,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Estrogen-stimulated signaling through PRKC,R-HSA-9634635,https://reactome.org/PathwayBrowser/#/R-HSA-9634635,PRKCZ,ENSG00000067606,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Estrogen-stimulated signaling through PRKC,R-HSA-9634635,https://reactome.org/PathwayBrowser/#/R-HSA-9634635,PRKCZ,ENSG00000067606,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Regulation of RAS by GAP,R-HSA-5658442,https://reactome.org/PathwayBrowser/#/R-HSA-5658442,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Regulation of RAS by GAP,R-HSA-5658442,https://reactome.org/PathwayBrowser/#/R-HSA-5658442,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Regulation of RAS by GAP,R-HSA-5658442,https://reactome.org/PathwayBrowser/#/R-HSA-5658442,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of RAS by GAP,R-HSA-5658442,https://reactome.org/PathwayBrowser/#/R-HSA-5658442,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of RAS by GAP,R-HSA-5658442,https://reactome.org/PathwayBrowser/#/R-HSA-5658442,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
RAS signaling downstream of NF1 loss-of-function variant,R-HSA-6802953,https://reactome.org/PathwayBrowser/#/R-HSA-6802953,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
RAS signaling downstream of NF1 loss-of-function variant,R-HSA-6802953,https://reactome.org/PathwayBrowser/#/R-HSA-6802953,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
TP53 Regulates Transcription of DNA Repair Gene,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of DNA Repair Gene,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of DNA Repair Gene,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of DNA Repair Gene,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of DNA Repair Gene,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of DNA Repair Gene,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of DNA Repair Gene,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of DNA Repair Gene,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of DNA Repair Gene,R-HSA-6796648,https://reactome.org/PathwayBrowser/#/R-HSA-6796648,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Translesion synthesis by REV,R-HSA-5655862,https://reactome.org/PathwayBrowser/#/R-HSA-5655862,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translesion synthesis by REV,R-HSA-5655862,https://reactome.org/PathwayBrowser/#/R-HSA-5655862,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translesion synthesis by REV,R-HSA-5655862,https://reactome.org/PathwayBrowser/#/R-HSA-5655862,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Translesion synthesis by POL,R-HSA-5655862,https://reactome.org/PathwayBrowser/#/R-HSA-5655862,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Translesion synthesis by POL,R-HSA-5655862,https://reactome.org/PathwayBrowser/#/R-HSA-5655862,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Translesion synthesis by POL,R-HSA-5655862,https://reactome.org/PathwayBrowser/#/R-HSA-5655862,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Synthesis of active ubiquitin: roles of E1 and E2 enzyme,R-HSA-8866652,https://reactome.org/PathwayBrowser/#/R-HSA-8866652,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Synthesis of active ubiquitin: roles of E1 and E2 enzyme,R-HSA-8866652,https://reactome.org/PathwayBrowser/#/R-HSA-8866652,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Synthesis of active ubiquitin: roles of E1 and E2 enzyme,R-HSA-8866652,https://reactome.org/PathwayBrowser/#/R-HSA-8866652,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
"Interleukin-3, Interleukin-5 and GM-CSF signalin",R-HSA-512988,https://reactome.org/PathwayBrowser/#/R-HSA-512988,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Surfactant metabolis,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
Surfactant metabolis,R-HSA-5683826,https://reactome.org/PathwayBrowser/#/R-HSA-5683826,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Defective CSF2RB causes SMDP,R-HSA-5688849,https://reactome.org/PathwayBrowser/#/R-HSA-5688849,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
Defective CSF2RB causes SMDP,R-HSA-5688849,https://reactome.org/PathwayBrowser/#/R-HSA-5688849,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Defective CSF2RA causes SMDP,R-HSA-5688890,https://reactome.org/PathwayBrowser/#/R-HSA-5688890,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
Defective CSF2RA causes SMDP,R-HSA-5688890,https://reactome.org/PathwayBrowser/#/R-HSA-5688890,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,CSF2RA,ENSG00000198223,CHEMBL1201670,SARGRAMOSTIM,4.0,,EFO_0000222,acute myeloid leukemia,,
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,CSF2RA,ENSG00000198223,CHEMBL1743039,MAVRILIMUMAB,2.0,Terminated,EFO_0000685,rheumatoid arthritis,,
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin receptor SHC signalin,R-HSA-912526,https://reactome.org/PathwayBrowser/#/R-HSA-912526,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA2,ENSG00000014138,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA2,ENSG00000014138,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA2,ENSG00000014138,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA2,ENSG00000014138,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA2,ENSG00000014138,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA2,ENSG00000014138,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,POLA2,ENSG00000014138,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM1,ENSG00000198056,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM1,ENSG00000198056,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM1,ENSG00000198056,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM1,ENSG00000198056,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM1,ENSG00000198056,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM1,ENSG00000198056,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM1,ENSG00000198056,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM2,ENSG00000146143,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM2,ENSG00000146143,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM2,ENSG00000146143,CHEMBL803,CYTARABINE,4.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM2,ENSG00000146143,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM2,ENSG00000146143,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM2,ENSG00000146143,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Inhibition of replication initiation of damaged DNA by RB1/E2F,R-HSA-113501,https://reactome.org/PathwayBrowser/#/R-HSA-113501,PRIM2,ENSG00000146143,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA2,ENSG00000014138,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA2,ENSG00000014138,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA2,ENSG00000014138,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA2,ENSG00000014138,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA2,ENSG00000014138,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA2,ENSG00000014138,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLA2,ENSG00000014138,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM1,ENSG00000198056,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM1,ENSG00000198056,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM1,ENSG00000198056,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM1,ENSG00000198056,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM1,ENSG00000198056,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM1,ENSG00000198056,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM1,ENSG00000198056,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM2,ENSG00000146143,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM2,ENSG00000146143,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM2,ENSG00000146143,CHEMBL803,CYTARABINE,4.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM2,ENSG00000146143,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM2,ENSG00000146143,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM2,ENSG00000146143,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switching on the C-strand of the telomer,R-HSA-174411,https://reactome.org/PathwayBrowser/#/R-HSA-174411,PRIM2,ENSG00000146143,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA2,ENSG00000014138,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA2,ENSG00000014138,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA2,ENSG00000014138,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA2,ENSG00000014138,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA2,ENSG00000014138,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA2,ENSG00000014138,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,POLA2,ENSG00000014138,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM1,ENSG00000198056,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM1,ENSG00000198056,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM1,ENSG00000198056,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM1,ENSG00000198056,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM1,ENSG00000198056,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM1,ENSG00000198056,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM1,ENSG00000198056,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM2,ENSG00000146143,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM2,ENSG00000146143,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM2,ENSG00000146143,CHEMBL803,CYTARABINE,4.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM2,ENSG00000146143,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM2,ENSG00000146143,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM2,ENSG00000146143,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Telomere C-strand synthesis initiatio,R-HSA-174430,https://reactome.org/PathwayBrowser/#/R-HSA-174430,PRIM2,ENSG00000146143,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA2,ENSG00000014138,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA2,ENSG00000014138,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA2,ENSG00000014138,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA2,ENSG00000014138,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA2,ENSG00000014138,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA2,ENSG00000014138,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLA2,ENSG00000014138,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM1,ENSG00000198056,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM1,ENSG00000198056,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM1,ENSG00000198056,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM1,ENSG00000198056,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM1,ENSG00000198056,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM1,ENSG00000198056,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM1,ENSG00000198056,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM2,ENSG00000146143,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM2,ENSG00000146143,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM2,ENSG00000146143,CHEMBL803,CYTARABINE,4.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM2,ENSG00000146143,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM2,ENSG00000146143,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM2,ENSG00000146143,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Polymerase switchin,R-HSA-69091,https://reactome.org/PathwayBrowser/#/R-HSA-69091,PRIM2,ENSG00000146143,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA2,ENSG00000014138,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA2,ENSG00000014138,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA2,ENSG00000014138,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA2,ENSG00000014138,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA2,ENSG00000014138,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA2,ENSG00000014138,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLA2,ENSG00000014138,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM1,ENSG00000198056,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM1,ENSG00000198056,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM1,ENSG00000198056,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM1,ENSG00000198056,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM1,ENSG00000198056,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM1,ENSG00000198056,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM1,ENSG00000198056,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM2,ENSG00000146143,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM2,ENSG00000146143,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM2,ENSG00000146143,CHEMBL803,CYTARABINE,4.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM2,ENSG00000146143,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM2,ENSG00000146143,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM2,ENSG00000146143,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediat,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,PRIM2,ENSG00000146143,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA2,ENSG00000014138,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA2,ENSG00000014138,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA2,ENSG00000014138,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA2,ENSG00000014138,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA2,ENSG00000014138,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA2,ENSG00000014138,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLA2,ENSG00000014138,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM1,ENSG00000198056,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM1,ENSG00000198056,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM1,ENSG00000198056,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM1,ENSG00000198056,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM1,ENSG00000198056,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM1,ENSG00000198056,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM1,ENSG00000198056,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM2,ENSG00000146143,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM2,ENSG00000146143,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM2,ENSG00000146143,CHEMBL803,CYTARABINE,4.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM2,ENSG00000146143,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM2,ENSG00000146143,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM2,ENSG00000146143,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the lagging stran,R-HSA-69183,https://reactome.org/PathwayBrowser/#/R-HSA-69183,PRIM2,ENSG00000146143,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Stimuli-sensing channel,R-HSA-2672351,https://reactome.org/PathwayBrowser/#/R-HSA-2672351,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Rap1 signallin,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Rap1 signallin,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Rap1 signallin,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Rap1 signallin,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Rap1 signallin,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Rap1 signallin,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Rap1 signallin,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Rap1 signallin,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Rap1 signallin,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Rap1 signallin,R-HSA-392517,https://reactome.org/PathwayBrowser/#/R-HSA-392517,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
GP1b-IX-V activation signallin,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
GP1b-IX-V activation signallin,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
GP1b-IX-V activation signallin,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
GP1b-IX-V activation signallin,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
GP1b-IX-V activation signallin,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
GP1b-IX-V activation signallin,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
GP1b-IX-V activation signallin,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
GP1b-IX-V activation signallin,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
GP1b-IX-V activation signallin,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
GP1b-IX-V activation signallin,R-HSA-430116,https://reactome.org/PathwayBrowser/#/R-HSA-430116,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
CD209 (DC-SIGN) signalin,R-HSA-5621575,https://reactome.org/PathwayBrowser/#/R-HSA-5621575,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
RAF activatio,R-HSA-5673000,https://reactome.org/PathwayBrowser/#/R-HSA-5673000,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
MAP2K and MAPK activatio,R-HSA-5674135,https://reactome.org/PathwayBrowser/#/R-HSA-5674135,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Negative feedback regulation of MAPK pathwa,R-HSA-5674499,https://reactome.org/PathwayBrowser/#/R-HSA-5674499,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Negative regulation of MAPK pathwa,R-HSA-5675221,https://reactome.org/PathwayBrowser/#/R-HSA-5675221,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by moderate kinase activity BRAF mutant,R-HSA-6802946,https://reactome.org/PathwayBrowser/#/R-HSA-6802946,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by high-kinase activity BRAF mutant,R-HSA-6802948,https://reactome.org/PathwayBrowser/#/R-HSA-6802948,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by BRAF and RAF1 fusion,R-HSA-6802952,https://reactome.org/PathwayBrowser/#/R-HSA-6802952,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Paradoxical activation of RAF signaling by kinase inactive BRA,R-HSA-6802955,https://reactome.org/PathwayBrowser/#/R-HSA-6802955,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling downstream of RAS mutant,R-HSA-9649948,https://reactome.org/PathwayBrowser/#/R-HSA-9649948,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signaling by RAF1 mutant,R-HSA-9656223,https://reactome.org/PathwayBrowser/#/R-HSA-9656223,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
SHOC2 M1731 mutant abolishes MRAS complex functio,R-HSA-9726840,https://reactome.org/PathwayBrowser/#/R-HSA-9726840,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Gain-of-function MRAS complexes activate RAF signalin,R-HSA-9726842,https://reactome.org/PathwayBrowser/#/R-HSA-9726842,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
IFNG signaling activates MAPK,R-HSA-9732724,https://reactome.org/PathwayBrowser/#/R-HSA-9732724,RAF1,ENSG00000132155,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Separation of Sister Chromatid,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Separation of Sister Chromatid,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Separation of Sister Chromatid,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Separation of Sister Chromatid,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Separation of Sister Chromatid,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Separation of Sister Chromatid,R-HSA-2467813,https://reactome.org/PathwayBrowser/#/R-HSA-2467813,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Resolution of Sister Chromatid Cohesio,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Resolution of Sister Chromatid Cohesio,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Resolution of Sister Chromatid Cohesio,R-HSA-2500257,https://reactome.org/PathwayBrowser/#/R-HSA-2500257,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL1738797,ALECTINIB,4.0,,EFO_0000616,neoplasm,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL4559134,SELPERCATINIB,4.0,,EFO_0000616,neoplasm,,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL4582651,PRALSETINIB,4.0,,EFO_0000616,neoplasm,,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL3707320,ALECTINIB HYDROCHLORIDE,4.0,,EFO_0003060,non-small cell lung carcinoma,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL4650296,BOS-589,2.0,Completed,EFO_0000555,irritable bowel syndrome,,
RET signalin,R-HSA-8853659,https://reactome.org/PathwayBrowser/#/R-HSA-8853659,RET,ENSG00000165731,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL1738797,ALECTINIB,4.0,,EFO_0000616,neoplasm,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL4559134,SELPERCATINIB,4.0,,EFO_0000616,neoplasm,,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL4582651,PRALSETINIB,4.0,,EFO_0000616,neoplasm,,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL3707320,ALECTINIB HYDROCHLORIDE,4.0,,EFO_0003060,non-small cell lung carcinoma,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL4650296,BOS-589,2.0,Completed,EFO_0000555,irritable bowel syndrome,,
NPAS4 regulates expression of target gene,R-HSA-9768919,https://reactome.org/PathwayBrowser/#/R-HSA-9768919,RET,ENSG00000165731,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL1738797,ALECTINIB,4.0,,EFO_0000616,neoplasm,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL4559134,SELPERCATINIB,4.0,,EFO_0000616,neoplasm,,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL4582651,PRALSETINIB,4.0,,EFO_0000616,neoplasm,,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL3707320,ALECTINIB HYDROCHLORIDE,4.0,,EFO_0003060,non-small cell lung carcinoma,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL4650296,BOS-589,2.0,Completed,EFO_0000555,irritable bowel syndrome,,
Formation of the nephric duc,R-HSA-9830364,https://reactome.org/PathwayBrowser/#/R-HSA-9830364,RET,ENSG00000165731,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL1738797,ALECTINIB,4.0,,EFO_0000616,neoplasm,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL4559134,SELPERCATINIB,4.0,,EFO_0000616,neoplasm,,COc1ccc(CN2C3CC2CN(c2ccc(-c4cc(OCC(C)(C)O)cn5ncc(C#N)c45)cn2)C3)cn1
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL4582651,PRALSETINIB,4.0,,EFO_0000616,neoplasm,,CO[C@]1(C(=O)N[C@@H](C)c2ccc(-n3cc(F)cn3)nc2)CC[C@H](c2nc(C)cc(Nc3cc(C)[nH]n3)n2)CC1
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL3707320,ALECTINIB HYDROCHLORIDE,4.0,,EFO_0003060,non-small cell lung carcinoma,,CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O.Cl
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL4650296,BOS-589,2.0,Completed,EFO_0000555,irritable bowel syndrome,,
Formation of the ureteric bu,R-HSA-9830674,https://reactome.org/PathwayBrowser/#/R-HSA-9830674,RET,ENSG00000165731,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Apoptotic cleavage of cellular protein,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Apoptotic cleavage of cellular protein,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Apoptotic cleavage of cellular protein,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Apoptotic cleavage of cellular protein,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Apoptotic cleavage of cellular protein,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Apoptotic cleavage of cellular protein,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Apoptotic cleavage of cellular protein,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Apoptotic cleavage of cellular protein,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Apoptotic cleavage of cellular protein,R-HSA-111465,https://reactome.org/PathwayBrowser/#/R-HSA-111465,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCG,ENSG00000126583,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCG,ENSG00000126583,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCG,ENSG00000126583,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Calmodulin induced event,R-HSA-111933,https://reactome.org/PathwayBrowser/#/R-HSA-111933,PRKCG,ENSG00000126583,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCE,ENSG00000171132,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCE,ENSG00000171132,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCE,ENSG00000171132,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCE,ENSG00000171132,CHEMBL4297775,KAI-1678,2.0,Completed,HP_0012531,Pain,,
SHC1 events in ERBB2 signalin,R-HSA-1250196,https://reactome.org/PathwayBrowser/#/R-HSA-1250196,PRKCE,ENSG00000171132,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
DAG and IP3 signalin,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
DAG and IP3 signalin,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
DAG and IP3 signalin,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
DAG and IP3 signalin,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
DAG and IP3 signalin,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
DAG and IP3 signalin,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCE,ENSG00000171132,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
DAG and IP3 signalin,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCE,ENSG00000171132,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
DAG and IP3 signalin,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCE,ENSG00000171132,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
DAG and IP3 signalin,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCE,ENSG00000171132,CHEMBL4297775,KAI-1678,2.0,Completed,HP_0012531,Pain,,
DAG and IP3 signalin,R-HSA-1489509,https://reactome.org/PathwayBrowser/#/R-HSA-1489509,PRKCE,ENSG00000171132,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Role of phospholipids in phagocytosi,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Role of phospholipids in phagocytosi,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Role of phospholipids in phagocytosi,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Role of phospholipids in phagocytosi,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Role of phospholipids in phagocytosi,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Role of phospholipids in phagocytosi,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCE,ENSG00000171132,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Role of phospholipids in phagocytosi,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCE,ENSG00000171132,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Role of phospholipids in phagocytosi,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCE,ENSG00000171132,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Role of phospholipids in phagocytosi,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCE,ENSG00000171132,CHEMBL4297775,KAI-1678,2.0,Completed,HP_0012531,Pain,,
Role of phospholipids in phagocytosi,R-HSA-2029485,https://reactome.org/PathwayBrowser/#/R-HSA-2029485,PRKCE,ENSG00000171132,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
HuR (ELAVL1) binds and stabilizes mRN,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
HuR (ELAVL1) binds and stabilizes mRN,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
HuR (ELAVL1) binds and stabilizes mRN,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
HuR (ELAVL1) binds and stabilizes mRN,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
HuR (ELAVL1) binds and stabilizes mRN,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
HuR (ELAVL1) binds and stabilizes mRN,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
HuR (ELAVL1) binds and stabilizes mRN,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
HuR (ELAVL1) binds and stabilizes mRN,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
HuR (ELAVL1) binds and stabilizes mRN,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
HuR (ELAVL1) binds and stabilizes mRN,R-HSA-450520,https://reactome.org/PathwayBrowser/#/R-HSA-450520,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
CLEC7A (Dectin-1) signalin,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
CLEC7A (Dectin-1) signalin,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
CLEC7A (Dectin-1) signalin,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
CLEC7A (Dectin-1) signalin,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
CLEC7A (Dectin-1) signalin,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
CLEC7A (Dectin-1) signalin,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
CLEC7A (Dectin-1) signalin,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
CLEC7A (Dectin-1) signalin,R-HSA-5607764,https://reactome.org/PathwayBrowser/#/R-HSA-5607764,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Interferon gamma signalin,R-HSA-877300,https://reactome.org/PathwayBrowser/#/R-HSA-877300,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCD,ENSG00000163932,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCD,ENSG00000163932,CHEMBL2107872,DELCASERTIB,2.0,Completed,EFO_0000612,myocardial infarction,,
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCD,ENSG00000163932,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCD,ENSG00000163932,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCD,ENSG00000163932,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCI,ENSG00000163558,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCI,ENSG00000163558,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCI,ENSG00000163558,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,PRKCI,ENSG00000163558,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
KEAP1-NFE2L2 pathwa,R-HSA-9755511,https://reactome.org/PathwayBrowser/#/R-HSA-9755511,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
NoRC negatively regulates rRNA expressio,R-HSA-427413,https://reactome.org/PathwayBrowser/#/R-HSA-427413,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
NoRC negatively regulates rRNA expressio,R-HSA-427413,https://reactome.org/PathwayBrowser/#/R-HSA-427413,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
STAT3 nuclear events downstream of ALK signalin,R-HSA-9701898,https://reactome.org/PathwayBrowser/#/R-HSA-9701898,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
STAT3 nuclear events downstream of ALK signalin,R-HSA-9701898,https://reactome.org/PathwayBrowser/#/R-HSA-9701898,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Nuclear events stimulated by ALK signaling in cance,R-HSA-9725371,https://reactome.org/PathwayBrowser/#/R-HSA-9725371,DNMT1,ENSG00000130816,CHEMBL1201129,DECITABINE,4.0,Unknown status,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1
Nuclear events stimulated by ALK signaling in cance,R-HSA-9725371,https://reactome.org/PathwayBrowser/#/R-HSA-9725371,DNMT1,ENSG00000130816,CHEMBL1489,AZACITIDINE,4.0,,EFO_0000198,myelodysplastic syndrome,,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
Nuclear events stimulated by ALK signaling in cance,R-HSA-9725371,https://reactome.org/PathwayBrowser/#/R-HSA-9725371,NPM1,ENSG00000181163,CHEMBL601719,CRIZOTINIB,4.0,,EFO_0000616,neoplasm,,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
Nuclear events stimulated by ALK signaling in cance,R-HSA-9725371,https://reactome.org/PathwayBrowser/#/R-HSA-9725371,NPM1,ENSG00000181163,CHEMBL2403108,CERITINIB,4.0,,EFO_0000616,neoplasm,,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
Sphingolipid de novo biosynthesi,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD1,ENSG00000184304,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sphingolipid de novo biosynthesi,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD1,ENSG00000184304,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Sphingolipid de novo biosynthesi,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD1,ENSG00000184304,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Sphingolipid de novo biosynthesi,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD1,ENSG00000184304,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Sphingolipid de novo biosynthesi,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD3,ENSG00000115825,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sphingolipid de novo biosynthesi,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD3,ENSG00000115825,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Sphingolipid de novo biosynthesi,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD3,ENSG00000115825,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Sphingolipid de novo biosynthesi,R-HSA-1660661,https://reactome.org/PathwayBrowser/#/R-HSA-1660661,PRKD3,ENSG00000115825,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
ISG15 antiviral mechanis,R-HSA-1169408,https://reactome.org/PathwayBrowser/#/R-HSA-1169408,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
ISG15 antiviral mechanis,R-HSA-1169408,https://reactome.org/PathwayBrowser/#/R-HSA-1169408,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
ISG15 antiviral mechanis,R-HSA-1169408,https://reactome.org/PathwayBrowser/#/R-HSA-1169408,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Nuclear import of Rev protei,R-HSA-180746,https://reactome.org/PathwayBrowser/#/R-HSA-180746,NPM1,ENSG00000181163,CHEMBL601719,CRIZOTINIB,4.0,,EFO_0000616,neoplasm,,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
Nuclear import of Rev protei,R-HSA-180746,https://reactome.org/PathwayBrowser/#/R-HSA-180746,NPM1,ENSG00000181163,CHEMBL2403108,CERITINIB,4.0,,EFO_0000616,neoplasm,,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
HCMV Early Event,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,EZH2,ENSG00000106462,CHEMBL4594260,TAZEMETOSTAT HYDROBROMIDE,4.0,,EFO_0000691,sarcoma,,Br.CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
HCMV Early Event,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,EZH2,ENSG00000106462,CHEMBL3414621,TAZEMETOSTAT,4.0,,EFO_0000616,neoplasm,,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
HCMV Early Event,R-HSA-9609690,https://reactome.org/PathwayBrowser/#/R-HSA-9609690,EZH2,ENSG00000106462,CHEMBL3287735,GSK2816126,1.0,Terminated,EFO_0000616,neoplasm,,CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21
SARS-CoV-2 activates/modulates innate and adaptive immune response,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
SARS-CoV-2 activates/modulates innate and adaptive immune response,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SARS-CoV-2 activates/modulates innate and adaptive immune response,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SARS-CoV-2 activates/modulates innate and adaptive immune response,R-HSA-9705671,https://reactome.org/PathwayBrowser/#/R-HSA-9705671,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Collagen degradatio,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,ELANE,ENSG00000197561,CHEMBL4297879,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,4.0,,EFO_0000508,genetic disorder,,
Collagen degradatio,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,ELANE,ENSG00000197561,CHEMBL76688,SIVELESTAT,3.0,Not yet recruiting,EFO_0003777,heart disease,,CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1
Collagen degradatio,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,ELANE,ENSG00000197561,CHEMBL3617964,ALVELESTAT,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1
Degradation of the extracellular matri,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,ELANE,ENSG00000197561,CHEMBL4297879,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,4.0,,EFO_0000508,genetic disorder,,
Degradation of the extracellular matri,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,ELANE,ENSG00000197561,CHEMBL76688,SIVELESTAT,3.0,Not yet recruiting,EFO_0003777,heart disease,,CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1
Degradation of the extracellular matri,R-HSA-1474228,https://reactome.org/PathwayBrowser/#/R-HSA-1474228,ELANE,ENSG00000197561,CHEMBL3617964,ALVELESTAT,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1
Activation of Matrix Metalloproteinase,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,ELANE,ENSG00000197561,CHEMBL4297879,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,4.0,,EFO_0000508,genetic disorder,,
Activation of Matrix Metalloproteinase,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,ELANE,ENSG00000197561,CHEMBL76688,SIVELESTAT,3.0,Not yet recruiting,EFO_0003777,heart disease,,CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1
Activation of Matrix Metalloproteinase,R-HSA-1592389,https://reactome.org/PathwayBrowser/#/R-HSA-1592389,ELANE,ENSG00000197561,CHEMBL3617964,ALVELESTAT,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,ELANE,ENSG00000197561,CHEMBL4297879,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,4.0,,EFO_0000508,genetic disorder,,
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,ELANE,ENSG00000197561,CHEMBL76688,SIVELESTAT,3.0,Not yet recruiting,EFO_0003777,heart disease,,CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,ELANE,ENSG00000197561,CHEMBL3617964,ALVELESTAT,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Pyroptosi,R-HSA-5620971,https://reactome.org/PathwayBrowser/#/R-HSA-5620971,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Antimicrobial peptide,R-HSA-6803157,https://reactome.org/PathwayBrowser/#/R-HSA-6803157,ELANE,ENSG00000197561,CHEMBL4297879,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,4.0,,EFO_0000508,genetic disorder,,
Antimicrobial peptide,R-HSA-6803157,https://reactome.org/PathwayBrowser/#/R-HSA-6803157,ELANE,ENSG00000197561,CHEMBL76688,SIVELESTAT,3.0,Not yet recruiting,EFO_0003777,heart disease,,CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1
Antimicrobial peptide,R-HSA-6803157,https://reactome.org/PathwayBrowser/#/R-HSA-6803157,ELANE,ENSG00000197561,CHEMBL3617964,ALVELESTAT,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1
Regulation of Complement cascad,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,ELANE,ENSG00000197561,CHEMBL4297879,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,4.0,,EFO_0000508,genetic disorder,,
Regulation of Complement cascad,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,ELANE,ENSG00000197561,CHEMBL76688,SIVELESTAT,3.0,Not yet recruiting,EFO_0003777,heart disease,,CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1
Regulation of Complement cascad,R-HSA-977606,https://reactome.org/PathwayBrowser/#/R-HSA-977606,ELANE,ENSG00000197561,CHEMBL3617964,ALVELESTAT,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1
Expression of NOTCH2NL gene,R-HSA-9911233,https://reactome.org/PathwayBrowser/#/R-HSA-9911233,ELANE,ENSG00000197561,CHEMBL4297879,.ALPHA.1-PROTEINASE INHIBITOR HUMAN,4.0,,EFO_0000508,genetic disorder,,
Expression of NOTCH2NL gene,R-HSA-9911233,https://reactome.org/PathwayBrowser/#/R-HSA-9911233,ELANE,ENSG00000197561,CHEMBL76688,SIVELESTAT,3.0,Not yet recruiting,EFO_0003777,heart disease,,CC(C)(C)C(=O)Oc1ccc(S(=O)(=O)Nc2ccccc2C(=O)NCC(=O)O)cc1
Expression of NOTCH2NL gene,R-HSA-9911233,https://reactome.org/PathwayBrowser/#/R-HSA-9911233,ELANE,ENSG00000197561,CHEMBL3617964,ALVELESTAT,2.0,Completed,EFO_0000341,chronic obstructive pulmonary disease,,Cc1c(-c2ccnn2C)cc(C(=O)NCc2ccc(S(C)(=O)=O)cn2)c(=O)n1-c1cccc(C(F)(F)F)c1
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signa,R-HSA-141444,https://reactome.org/PathwayBrowser/#/R-HSA-141444,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signa,R-HSA-141444,https://reactome.org/PathwayBrowser/#/R-HSA-141444,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signa,R-HSA-141444,https://reactome.org/PathwayBrowser/#/R-HSA-141444,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
RHO GTPases Activate Formin,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
RHO GTPases Activate Formin,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
RHO GTPases Activate Formin,R-HSA-5663220,https://reactome.org/PathwayBrowser/#/R-HSA-5663220,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Mitotic Prometaphas,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Mitotic Prometaphas,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Mitotic Prometaphas,R-HSA-68877,https://reactome.org/PathwayBrowser/#/R-HSA-68877,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
EML4 and NUDC in mitotic spindle formatio,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,RPS27,ENSG00000177954,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
EML4 and NUDC in mitotic spindle formatio,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,RPS27,ENSG00000177954,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
EML4 and NUDC in mitotic spindle formatio,R-HSA-9648025,https://reactome.org/PathwayBrowser/#/R-HSA-9648025,RPS27,ENSG00000177954,CHEMBL4297744,ELX-02,2.0,Recruiting,MONDO_0018965,Alport syndrome,,
Association of TriC/CCT with target proteins during biosynthesi,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Association of TriC/CCT with target proteins during biosynthesi,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Association of TriC/CCT with target proteins during biosynthesi,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Association of TriC/CCT with target proteins during biosynthesi,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Association of TriC/CCT with target proteins during biosynthesi,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Association of TriC/CCT with target proteins during biosynthesi,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Association of TriC/CCT with target proteins during biosynthesi,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Association of TriC/CCT with target proteins during biosynthesi,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Association of TriC/CCT with target proteins during biosynthesi,R-HSA-390471,https://reactome.org/PathwayBrowser/#/R-HSA-390471,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-6 signalin,R-HSA-1059683,https://reactome.org/PathwayBrowser/#/R-HSA-1059683,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variant,R-HSA-1236382,https://reactome.org/PathwayBrowser/#/R-HSA-1236382,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variant,R-HSA-1236382,https://reactome.org/PathwayBrowser/#/R-HSA-1236382,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variant,R-HSA-1236382,https://reactome.org/PathwayBrowser/#/R-HSA-1236382,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variant,R-HSA-1236382,https://reactome.org/PathwayBrowser/#/R-HSA-1236382,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variant,R-HSA-1236382,https://reactome.org/PathwayBrowser/#/R-HSA-1236382,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Spry regulation of FGF signalin,R-HSA-1295596,https://reactome.org/PathwayBrowser/#/R-HSA-1295596,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Regulation of KIT signalin,R-HSA-1433559,https://reactome.org/PathwayBrowser/#/R-HSA-1433559,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
EGFR downregulatio,R-HSA-182971,https://reactome.org/PathwayBrowser/#/R-HSA-182971,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
EGFR downregulatio,R-HSA-182971,https://reactome.org/PathwayBrowser/#/R-HSA-182971,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
EGFR downregulatio,R-HSA-182971,https://reactome.org/PathwayBrowser/#/R-HSA-182971,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Constitutive Signaling by EGFRvII,R-HSA-5637810,https://reactome.org/PathwayBrowser/#/R-HSA-5637810,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Constitutive Signaling by EGFRvII,R-HSA-5637810,https://reactome.org/PathwayBrowser/#/R-HSA-5637810,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Negative regulation of FGFR1 signalin,R-HSA-5654726,https://reactome.org/PathwayBrowser/#/R-HSA-5654726,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Negative regulation of FGFR1 signalin,R-HSA-5654726,https://reactome.org/PathwayBrowser/#/R-HSA-5654726,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Negative regulation of FGFR1 signalin,R-HSA-5654726,https://reactome.org/PathwayBrowser/#/R-HSA-5654726,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Negative regulation of FGFR1 signalin,R-HSA-5654726,https://reactome.org/PathwayBrowser/#/R-HSA-5654726,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Negative regulation of FGFR2 signalin,R-HSA-5654727,https://reactome.org/PathwayBrowser/#/R-HSA-5654727,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Negative regulation of FGFR2 signalin,R-HSA-5654727,https://reactome.org/PathwayBrowser/#/R-HSA-5654727,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Negative regulation of FGFR2 signalin,R-HSA-5654727,https://reactome.org/PathwayBrowser/#/R-HSA-5654727,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Negative regulation of FGFR2 signalin,R-HSA-5654727,https://reactome.org/PathwayBrowser/#/R-HSA-5654727,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Negative regulation of FGFR3 signalin,R-HSA-5654732,https://reactome.org/PathwayBrowser/#/R-HSA-5654732,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Negative regulation of FGFR3 signalin,R-HSA-5654732,https://reactome.org/PathwayBrowser/#/R-HSA-5654732,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Negative regulation of FGFR3 signalin,R-HSA-5654732,https://reactome.org/PathwayBrowser/#/R-HSA-5654732,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Negative regulation of FGFR3 signalin,R-HSA-5654732,https://reactome.org/PathwayBrowser/#/R-HSA-5654732,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Negative regulation of FGFR4 signalin,R-HSA-5654733,https://reactome.org/PathwayBrowser/#/R-HSA-5654733,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Negative regulation of FGFR4 signalin,R-HSA-5654733,https://reactome.org/PathwayBrowser/#/R-HSA-5654733,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Negative regulation of FGFR4 signalin,R-HSA-5654733,https://reactome.org/PathwayBrowser/#/R-HSA-5654733,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Negative regulation of FGFR4 signalin,R-HSA-5654733,https://reactome.org/PathwayBrowser/#/R-HSA-5654733,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Negative regulation of MET activit,R-HSA-6807004,https://reactome.org/PathwayBrowser/#/R-HSA-6807004,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Negative regulation of MET activit,R-HSA-6807004,https://reactome.org/PathwayBrowser/#/R-HSA-6807004,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Negative regulation of MET activit,R-HSA-6807004,https://reactome.org/PathwayBrowser/#/R-HSA-6807004,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK,R-HSA-8849469,https://reactome.org/PathwayBrowser/#/R-HSA-8849469,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK,R-HSA-8849469,https://reactome.org/PathwayBrowser/#/R-HSA-8849469,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK,R-HSA-8849469,https://reactome.org/PathwayBrowser/#/R-HSA-8849469,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Cargo recognition for clathrin-mediated endocytosi,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Cargo recognition for clathrin-mediated endocytosi,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Cargo recognition for clathrin-mediated endocytosi,R-HSA-8856825,https://reactome.org/PathwayBrowser/#/R-HSA-8856825,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Clathrin-mediated endocytosi,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Clathrin-mediated endocytosi,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Clathrin-mediated endocytosi,R-HSA-8856828,https://reactome.org/PathwayBrowser/#/R-HSA-8856828,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
InlB-mediated entry of Listeria monocytogenes into host cel,R-HSA-8875360,https://reactome.org/PathwayBrowser/#/R-HSA-8875360,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
InlB-mediated entry of Listeria monocytogenes into host cel,R-HSA-8875360,https://reactome.org/PathwayBrowser/#/R-HSA-8875360,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
InlB-mediated entry of Listeria monocytogenes into host cel,R-HSA-8875360,https://reactome.org/PathwayBrowser/#/R-HSA-8875360,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of signaling by CB,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of signaling by CB,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of signaling by CB,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Signaling by CSF1 (M-CSF) in myeloid cell,R-HSA-9680350,https://reactome.org/PathwayBrowser/#/R-HSA-9680350,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by CSF1 (M-CSF) in myeloid cell,R-HSA-9680350,https://reactome.org/PathwayBrowser/#/R-HSA-9680350,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by CSF1 (M-CSF) in myeloid cell,R-HSA-9680350,https://reactome.org/PathwayBrowser/#/R-HSA-9680350,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Signaling by CSF1 (M-CSF) in myeloid cell,R-HSA-9680350,https://reactome.org/PathwayBrowser/#/R-HSA-9680350,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Signaling by CSF1 (M-CSF) in myeloid cell,R-HSA-9680350,https://reactome.org/PathwayBrowser/#/R-HSA-9680350,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Signaling by CSF1 (M-CSF) in myeloid cell,R-HSA-9680350,https://reactome.org/PathwayBrowser/#/R-HSA-9680350,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Downstream TCR signalin,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Downstream TCR signalin,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Downstream TCR signalin,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Downstream TCR signalin,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Downstream TCR signalin,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Downstream TCR signalin,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Downstream TCR signalin,R-HSA-202424,https://reactome.org/PathwayBrowser/#/R-HSA-202424,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
"Inactivation, recovery and regulation of the phototransduction cascad",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"Inactivation, recovery and regulation of the phototransduction cascad",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
"Inactivation, recovery and regulation of the phototransduction cascad",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
"Inactivation, recovery and regulation of the phototransduction cascad",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
"Inactivation, recovery and regulation of the phototransduction cascad",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
"Inactivation, recovery and regulation of the phototransduction cascad",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"Inactivation, recovery and regulation of the phototransduction cascad",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
"Inactivation, recovery and regulation of the phototransduction cascad",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
"Inactivation, recovery and regulation of the phototransduction cascad",R-HSA-2514859,https://reactome.org/PathwayBrowser/#/R-HSA-2514859,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
FCERI mediated NF-kB activatio,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
FCERI mediated NF-kB activatio,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
FCERI mediated NF-kB activatio,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
FCERI mediated NF-kB activatio,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
FCERI mediated NF-kB activatio,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
FCERI mediated NF-kB activatio,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
FCERI mediated NF-kB activatio,R-HSA-2871837,https://reactome.org/PathwayBrowser/#/R-HSA-2871837,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Netrin-1 signalin,R-HSA-373752,https://reactome.org/PathwayBrowser/#/R-HSA-373752,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Netrin-1 signalin,R-HSA-373752,https://reactome.org/PathwayBrowser/#/R-HSA-373752,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Netrin-1 signalin,R-HSA-373752,https://reactome.org/PathwayBrowser/#/R-HSA-373752,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Netrin-1 signalin,R-HSA-373752,https://reactome.org/PathwayBrowser/#/R-HSA-373752,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RAS processin,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
RAS processin,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
RAS processin,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,PRKCQ,ENSG00000065675,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
RAS processin,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,PRKCQ,ENSG00000065675,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
RAS processin,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,PRKCQ,ENSG00000065675,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
RAS processin,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,PRKCQ,ENSG00000065675,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
RAS processin,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
RAS processin,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
RAS processin,R-HSA-9648002,https://reactome.org/PathwayBrowser/#/R-HSA-9648002,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Other interleukin signalin,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL1201567,FILGRASTIM,4.0,,EFO_0000544,infection,,
Other interleukin signalin,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL1201568,PEGFILGRASTIM,4.0,,EFO_0000544,infection,,
Other interleukin signalin,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL2109128,LENOGRASTIM,4.0,,EFO_0000616,neoplasm,,
Other interleukin signalin,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL3833384,EFLAPEGRASTIM,4.0,,EFO_0000616,neoplasm,,
Other interleukin signalin,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL4297950,EFBEMALENOGRASTIM ALFA,4.0,,EFO_0000616,neoplasm,,
Other interleukin signalin,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL4594230,LIPEGFILGRASTIM,4.0,,EFO_0000616,neoplasm,,
Other interleukin signalin,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL2107881,REGRAMOSTIM,3.0,Completed,EFO_0000756,melanoma,,
Other interleukin signalin,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL4297800,PEGTEOGRASTIM,2.0,,EFO_0000616,neoplasm,,
Other interleukin signalin,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL2108572,BALUGRASTIM,2.0,,EFO_0000616,neoplasm,,
Other interleukin signalin,R-HSA-449836,https://reactome.org/PathwayBrowser/#/R-HSA-449836,CSF3R,ENSG00000119535,CHEMBL4650461,ANUMIGILIMAB,2.0,Withdrawn,MONDO_0100096,COVID-19,,
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL1201567,FILGRASTIM,4.0,,EFO_0000544,infection,,
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL1201568,PEGFILGRASTIM,4.0,,EFO_0000544,infection,,
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL2109128,LENOGRASTIM,4.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL3833384,EFLAPEGRASTIM,4.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL4297950,EFBEMALENOGRASTIM ALFA,4.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL4594230,LIPEGFILGRASTIM,4.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL2107881,REGRAMOSTIM,3.0,Completed,EFO_0000756,melanoma,,
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL4297800,PEGTEOGRASTIM,2.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL2108572,BALUGRASTIM,2.0,,EFO_0000616,neoplasm,,
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,CSF3R,ENSG00000119535,CHEMBL4650461,ANUMIGILIMAB,2.0,Withdrawn,MONDO_0100096,COVID-19,,
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by CSF3 (G-CSF,R-HSA-9674555,https://reactome.org/PathwayBrowser/#/R-HSA-9674555,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL1201567,FILGRASTIM,4.0,,EFO_0000544,infection,,
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL1201568,PEGFILGRASTIM,4.0,,EFO_0000544,infection,,
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL2109128,LENOGRASTIM,4.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL3833384,EFLAPEGRASTIM,4.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL4297950,EFBEMALENOGRASTIM ALFA,4.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL4594230,LIPEGFILGRASTIM,4.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL2107881,REGRAMOSTIM,3.0,Completed,EFO_0000756,melanoma,,
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL4297800,PEGTEOGRASTIM,2.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL2108572,BALUGRASTIM,2.0,,EFO_0000616,neoplasm,,
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,CSF3R,ENSG00000119535,CHEMBL4650461,ANUMIGILIMAB,2.0,Withdrawn,MONDO_0100096,COVID-19,,
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Inactivation of CSF3 (G-CSF) signalin,R-HSA-9705462,https://reactome.org/PathwayBrowser/#/R-HSA-9705462,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Processive synthesis on the C-strand of the telomer,R-HSA-174414,https://reactome.org/PathwayBrowser/#/R-HSA-174414,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Telomere C-strand (Lagging Strand) Synthesi,R-HSA-174417,https://reactome.org/PathwayBrowser/#/R-HSA-174417,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Removal of the Flap Intermediate from the C-stran,R-HSA-69166,https://reactome.org/PathwayBrowser/#/R-HSA-69166,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
DNA Damage/Telomere Stress Induced Senescenc,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
DNA Damage/Telomere Stress Induced Senescenc,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
DNA Damage/Telomere Stress Induced Senescenc,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
DNA Damage/Telomere Stress Induced Senescenc,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
DNA Damage/Telomere Stress Induced Senescenc,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
DNA Damage/Telomere Stress Induced Senescenc,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
DNA Damage/Telomere Stress Induced Senescenc,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
DNA Damage/Telomere Stress Induced Senescenc,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
DNA Damage/Telomere Stress Induced Senescenc,R-HSA-2559586,https://reactome.org/PathwayBrowser/#/R-HSA-2559586,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
p75NTR recruits signalling complexe,R-HSA-209543,https://reactome.org/PathwayBrowser/#/R-HSA-209543,PRKCI,ENSG00000163558,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
p75NTR recruits signalling complexe,R-HSA-209543,https://reactome.org/PathwayBrowser/#/R-HSA-209543,PRKCI,ENSG00000163558,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
p75NTR recruits signalling complexe,R-HSA-209543,https://reactome.org/PathwayBrowser/#/R-HSA-209543,PRKCI,ENSG00000163558,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
p75NTR recruits signalling complexe,R-HSA-209543,https://reactome.org/PathwayBrowser/#/R-HSA-209543,PRKCI,ENSG00000163558,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
p75NTR recruits signalling complexe,R-HSA-209543,https://reactome.org/PathwayBrowser/#/R-HSA-209543,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
p75NTR recruits signalling complexe,R-HSA-209543,https://reactome.org/PathwayBrowser/#/R-HSA-209543,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
p75NTR recruits signalling complexe,R-HSA-209543,https://reactome.org/PathwayBrowser/#/R-HSA-209543,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Tight junction interaction,R-HSA-420029,https://reactome.org/PathwayBrowser/#/R-HSA-420029,PRKCI,ENSG00000163558,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Tight junction interaction,R-HSA-420029,https://reactome.org/PathwayBrowser/#/R-HSA-420029,PRKCI,ENSG00000163558,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Tight junction interaction,R-HSA-420029,https://reactome.org/PathwayBrowser/#/R-HSA-420029,PRKCI,ENSG00000163558,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000676,psoriasis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Tight junction interaction,R-HSA-420029,https://reactome.org/PathwayBrowser/#/R-HSA-420029,PRKCI,ENSG00000163558,CHEMBL494089,GSK-690693,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Regulation of actin dynamics for phagocytic cup formatio,R-HSA-2029482,https://reactome.org/PathwayBrowser/#/R-HSA-2029482,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Role of ABL in ROBO-SLIT signalin,R-HSA-428890,https://reactome.org/PathwayBrowser/#/R-HSA-428890,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Myogenesi,R-HSA-525793,https://reactome.org/PathwayBrowser/#/R-HSA-525793,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
RHO GTPases Activate WASPs and WAVE,R-HSA-5663213,https://reactome.org/PathwayBrowser/#/R-HSA-5663213,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
HDR through Single Strand Annealing (SSA,R-HSA-5685938,https://reactome.org/PathwayBrowser/#/R-HSA-5685938,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand break,R-HSA-5693565,https://reactome.org/PathwayBrowser/#/R-HSA-5693565,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Cyclin D associated events in G,R-HSA-69231,https://reactome.org/PathwayBrowser/#/R-HSA-69231,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
RUNX2 regulates osteoblast differentiatio,R-HSA-8940973,https://reactome.org/PathwayBrowser/#/R-HSA-8940973,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
FCGR3A-mediated phagocytosi,R-HSA-9664422,https://reactome.org/PathwayBrowser/#/R-HSA-9664422,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Factors involved in megakaryocyte development and platelet productio,R-HSA-983231,https://reactome.org/PathwayBrowser/#/R-HSA-983231,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3948730,UMBRALISIB,4.0,,EFO_0000616,neoplasm,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3989869,UMBRALISIB TOSYLATE,4.0,,EFO_1000630,marginal zone B-cell lymphoma,,CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F.Cc1ccc(S(=O)(=O)O)cc1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1171837,PONATINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3545413,FLUMATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ncc(NC(=O)c2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cccnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3678958,RUSERONTINIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL255863,NILOTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL288441,BOSUTINIB,3.0,Not yet recruiting,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4297524,RADOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL206834,BAFETINIB,2.0,Completed,EFO_0000095,chronic lymphocytic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL217092,SARACATINIB,2.0,Terminated,EFO_0000365,colorectal adenocarcinoma,,CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL4130229,VODOBATINIB,2.0,"Active, not recruiting",MONDO_0005180,Parkinson disease,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL3545085,XL-228,1.0,Terminated,EFO_0000220,acute lymphoblastic leukemia,,CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1908397,KW-2449,1.0,Terminated,EFO_0000222,acute myeloid leukemia,,O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL1738757,REBASTINIB,1.0,Terminated,EFO_0000304,breast adenocarcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1
"Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cell",R-HSA-9860927,https://reactome.org/PathwayBrowser/#/R-HSA-9860927,ABL1,ENSG00000097007,CHEMBL5314408,AZD-0424,1.0,Terminated,EFO_0000616,neoplasm,,CC(=O)N1CCN(CCOc2cc(OC(C)C)c3c(Nc4c(Cl)cnc5c4OCO5)ncnc3c2)CC1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha,R-HSA-5358565,https://reactome.org/PathwayBrowser/#/R-HSA-5358565,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD2,ENSG00000106628,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD2,ENSG00000106628,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD2,ENSG00000106628,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD2,ENSG00000106628,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD2,ENSG00000106628,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD2,ENSG00000106628,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD2,ENSG00000106628,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD3,ENSG00000077514,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD3,ENSG00000077514,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD3,ENSG00000077514,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD3,ENSG00000077514,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD3,ENSG00000077514,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD3,ENSG00000077514,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD3,ENSG00000077514,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD4,ENSG00000175482,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD4,ENSG00000175482,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD4,ENSG00000175482,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD4,ENSG00000175482,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD4,ENSG00000175482,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD4,ENSG00000175482,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta,R-HSA-5358606,https://reactome.org/PathwayBrowser/#/R-HSA-5358606,POLD4,ENSG00000175482,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Downstream signal transductio,R-HSA-186763,https://reactome.org/PathwayBrowser/#/R-HSA-186763,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL535,SUNITINIB,4.0,Terminated,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1567,SUNITINIB MALATE,4.0,Completed,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL576982,QUIZARTINIB,3.0,Withdrawn,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL491473,CEDIRANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL3545316,RINUCUMAB,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Signaling by PDG,R-HSA-2028269,https://reactome.org/PathwayBrowser/#/R-HSA-2028269,PDGFRB,ENSG00000113721,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Platelet Aggregation (Plug Formation,R-HSA-76009,https://reactome.org/PathwayBrowser/#/R-HSA-76009,MPL,ENSG00000117400,CHEMBL2105758,AVATROMBOPAG MALEATE,4.0,,EFO_0001421,liver disease,,O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1.O=C(O)/C=C\C(=O)O
Platelet Aggregation (Plug Formation,R-HSA-76009,https://reactome.org/PathwayBrowser/#/R-HSA-76009,MPL,ENSG00000117400,CHEMBL3989691,ELTROMBOPAG OLAMINE,4.0,,EFO_0004220,chronic hepatitis C virus infection,,CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O.NCCO.NCCO
Platelet Aggregation (Plug Formation,R-HSA-76009,https://reactome.org/PathwayBrowser/#/R-HSA-76009,MPL,ENSG00000117400,CHEMBL1201832,ROMIPLOSTIM,4.0,Completed,EFO_0007160,autoimmune thrombocytopenic purpura,,
Platelet Aggregation (Plug Formation,R-HSA-76009,https://reactome.org/PathwayBrowser/#/R-HSA-76009,MPL,ENSG00000117400,CHEMBL2107831,LUSUTROMBOPAG,4.0,,HP_0001873,Thrombocytopenia,,CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC
Platelet Aggregation (Plug Formation,R-HSA-76009,https://reactome.org/PathwayBrowser/#/R-HSA-76009,MPL,ENSG00000117400,CHEMBL2103883,AVATROMBOPAG,4.0,,MP_0001914,hemorrhage,,O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1
Platelet Aggregation (Plug Formation,R-HSA-76009,https://reactome.org/PathwayBrowser/#/R-HSA-76009,MPL,ENSG00000117400,CHEMBL461101,ELTROMBOPAG,3.0,Unknown status,EFO_0000616,neoplasm,,CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O
Platelet Aggregation (Plug Formation,R-HSA-76009,https://reactome.org/PathwayBrowser/#/R-HSA-76009,MPL,ENSG00000117400,CHEMBL4297764,HETROMBOPAG OLAMINE,3.0,Completed,EFO_0007160,autoimmune thrombocytopenic purpura,,
Platelet Aggregation (Plug Formation,R-HSA-76009,https://reactome.org/PathwayBrowser/#/R-HSA-76009,MPL,ENSG00000117400,CHEMBL4594401,RAFUTROMBOPAG,3.0,Not yet recruiting,HP_0001873,Thrombocytopenia,,CC1=NN(c2ccc3c(c2)CCCC3)C(=O)/C1=N\Nc1cccc(-c2ccc(C(=O)O)o2)c1O
Class B/2 (Secretin family receptors,R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL4297534,GLASDEGIB MALEATE,4.0,,EFO_0000222,acute myeloid leukemia,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O
Class B/2 (Secretin family receptors,R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL2043437,GLASDEGIB,4.0,,EFO_0000616,neoplasm,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
Class B/2 (Secretin family receptors,R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL2105737,SONIDEGIB,4.0,,EFO_0000616,neoplasm,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
Class B/2 (Secretin family receptors,R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL473417,VISMODEGIB,4.0,,EFO_0000616,neoplasm,,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
Class B/2 (Secretin family receptors,R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL3137317,SONIDEGIB PHOSPHATE,4.0,,EFO_0004193,basal cell carcinoma,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O
Class B/2 (Secretin family receptors,R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL538867,PATIDEGIB,3.0,Terminated,MONDO_0007187,nevoid basal cell carcinoma syndrome,,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
Class B/2 (Secretin family receptors,R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL3545403,BMS-833923,2.0,Terminated,EFO_0000565,leukemia,,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1
Class B/2 (Secretin family receptors,R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL2142592,TALADEGIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1
Class B/2 (Secretin family receptors,R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL2205230,TAK-441,1.0,Completed,EFO_0004193,basal cell carcinoma,,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1
Class B/2 (Secretin family receptors,R-HSA-373080,https://reactome.org/PathwayBrowser/#/R-HSA-373080,SMO,ENSG00000128602,CHEMBL3133037,LEQ506,1.0,Completed,EFO_0002939,medulloblastoma,,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C
Hedgehog 'off' stat,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL4297534,GLASDEGIB MALEATE,4.0,,EFO_0000222,acute myeloid leukemia,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O
Hedgehog 'off' stat,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL2043437,GLASDEGIB,4.0,,EFO_0000616,neoplasm,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
Hedgehog 'off' stat,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL2105737,SONIDEGIB,4.0,,EFO_0000616,neoplasm,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
Hedgehog 'off' stat,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL473417,VISMODEGIB,4.0,,EFO_0000616,neoplasm,,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
Hedgehog 'off' stat,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL3137317,SONIDEGIB PHOSPHATE,4.0,,EFO_0004193,basal cell carcinoma,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O
Hedgehog 'off' stat,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL538867,PATIDEGIB,3.0,Terminated,MONDO_0007187,nevoid basal cell carcinoma syndrome,,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
Hedgehog 'off' stat,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL3545403,BMS-833923,2.0,Terminated,EFO_0000565,leukemia,,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1
Hedgehog 'off' stat,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL2142592,TALADEGIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1
Hedgehog 'off' stat,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL2205230,TAK-441,1.0,Completed,EFO_0004193,basal cell carcinoma,,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1
Hedgehog 'off' stat,R-HSA-5610787,https://reactome.org/PathwayBrowser/#/R-HSA-5610787,SMO,ENSG00000128602,CHEMBL3133037,LEQ506,1.0,Completed,EFO_0002939,medulloblastoma,,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C
BBSome-mediated cargo-targeting to ciliu,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL4297534,GLASDEGIB MALEATE,4.0,,EFO_0000222,acute myeloid leukemia,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O
BBSome-mediated cargo-targeting to ciliu,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL2043437,GLASDEGIB,4.0,,EFO_0000616,neoplasm,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
BBSome-mediated cargo-targeting to ciliu,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL2105737,SONIDEGIB,4.0,,EFO_0000616,neoplasm,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
BBSome-mediated cargo-targeting to ciliu,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL473417,VISMODEGIB,4.0,,EFO_0000616,neoplasm,,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
BBSome-mediated cargo-targeting to ciliu,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL3137317,SONIDEGIB PHOSPHATE,4.0,,EFO_0004193,basal cell carcinoma,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O
BBSome-mediated cargo-targeting to ciliu,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL538867,PATIDEGIB,3.0,Terminated,MONDO_0007187,nevoid basal cell carcinoma syndrome,,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
BBSome-mediated cargo-targeting to ciliu,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL3545403,BMS-833923,2.0,Terminated,EFO_0000565,leukemia,,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1
BBSome-mediated cargo-targeting to ciliu,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL2142592,TALADEGIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1
BBSome-mediated cargo-targeting to ciliu,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL2205230,TAK-441,1.0,Completed,EFO_0004193,basal cell carcinoma,,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1
BBSome-mediated cargo-targeting to ciliu,R-HSA-5620922,https://reactome.org/PathwayBrowser/#/R-HSA-5620922,SMO,ENSG00000128602,CHEMBL3133037,LEQ506,1.0,Completed,EFO_0002939,medulloblastoma,,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL4297534,GLASDEGIB MALEATE,4.0,,EFO_0000222,acute myeloid leukemia,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL2043437,GLASDEGIB,4.0,,EFO_0000616,neoplasm,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL2105737,SONIDEGIB,4.0,,EFO_0000616,neoplasm,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL473417,VISMODEGIB,4.0,,EFO_0000616,neoplasm,,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL3137317,SONIDEGIB PHOSPHATE,4.0,,EFO_0004193,basal cell carcinoma,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL538867,PATIDEGIB,3.0,Terminated,MONDO_0007187,nevoid basal cell carcinoma syndrome,,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL3545403,BMS-833923,2.0,Terminated,EFO_0000565,leukemia,,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL2142592,TALADEGIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL2205230,TAK-441,1.0,Completed,EFO_0004193,basal cell carcinoma,,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1
Hedgehog 'on' stat,R-HSA-5632684,https://reactome.org/PathwayBrowser/#/R-HSA-5632684,SMO,ENSG00000128602,CHEMBL3133037,LEQ506,1.0,Completed,EFO_0002939,medulloblastoma,,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C
Activation of SM,R-HSA-165158,https://reactome.org/PathwayBrowser/#/R-HSA-165158,SMO,ENSG00000128602,CHEMBL4297534,GLASDEGIB MALEATE,4.0,,EFO_0000222,acute myeloid leukemia,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1.O=C(O)/C=C\C(=O)O
Activation of SM,R-HSA-165158,https://reactome.org/PathwayBrowser/#/R-HSA-165158,SMO,ENSG00000128602,CHEMBL2043437,GLASDEGIB,4.0,,EFO_0000616,neoplasm,,CN1CC[C@@H](NC(=O)Nc2ccc(C#N)cc2)C[C@@H]1c1nc2ccccc2[nH]1
Activation of SM,R-HSA-165158,https://reactome.org/PathwayBrowser/#/R-HSA-165158,SMO,ENSG00000128602,CHEMBL2105737,SONIDEGIB,4.0,,EFO_0000616,neoplasm,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1
Activation of SM,R-HSA-165158,https://reactome.org/PathwayBrowser/#/R-HSA-165158,SMO,ENSG00000128602,CHEMBL473417,VISMODEGIB,4.0,,EFO_0000616,neoplasm,,CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1
Activation of SM,R-HSA-165158,https://reactome.org/PathwayBrowser/#/R-HSA-165158,SMO,ENSG00000128602,CHEMBL3137317,SONIDEGIB PHOSPHATE,4.0,,EFO_0004193,basal cell carcinoma,,Cc1c(C(=O)Nc2ccc(N3C[C@@H](C)O[C@@H](C)C3)nc2)cccc1-c1ccc(OC(F)(F)F)cc1.O=P(O)(O)O.O=P(O)(O)O
Activation of SM,R-HSA-165158,https://reactome.org/PathwayBrowser/#/R-HSA-165158,SMO,ENSG00000128602,CHEMBL538867,PATIDEGIB,3.0,Terminated,MONDO_0007187,nevoid basal cell carcinoma syndrome,,CC1=C2C[C@H]3[C@@H](CC[C@@H]4C[C@H](NS(C)(=O)=O)CC[C@@]43C)[C@@H]2CC[C@@]2(C1)O[C@@H]1C[C@H](C)CN[C@H]1[C@H]2C
Activation of SM,R-HSA-165158,https://reactome.org/PathwayBrowser/#/R-HSA-165158,SMO,ENSG00000128602,CHEMBL3545403,BMS-833923,2.0,Terminated,EFO_0000565,leukemia,,CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1
Activation of SM,R-HSA-165158,https://reactome.org/PathwayBrowser/#/R-HSA-165158,SMO,ENSG00000128602,CHEMBL2142592,TALADEGIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,CN(C(=O)c1ccc(F)cc1C(F)(F)F)C1CCN(c2nnc(-c3ccnn3C)c3ccccc23)CC1
Activation of SM,R-HSA-165158,https://reactome.org/PathwayBrowser/#/R-HSA-165158,SMO,ENSG00000128602,CHEMBL2205230,TAK-441,1.0,Completed,EFO_0004193,basal cell carcinoma,,CCc1cc2c(c(OCC(F)(F)F)c(C(=O)NC3CCN(C(=O)CO)CC3)n2C)c(=O)n1CC(=O)c1ccccc1
Activation of SM,R-HSA-165158,https://reactome.org/PathwayBrowser/#/R-HSA-165158,SMO,ENSG00000128602,CHEMBL3133037,LEQ506,1.0,Completed,EFO_0002939,medulloblastoma,,Cc1c(Cc2ccccc2)nnc(N2CCN(c3cnc(C(C)(C)O)cn3)[C@H](C)C2)c1C
PKMTs methylate histone lysine,R-HSA-3214841,https://reactome.org/PathwayBrowser/#/R-HSA-3214841,EZH2,ENSG00000106462,CHEMBL4594260,TAZEMETOSTAT HYDROBROMIDE,4.0,,EFO_0000691,sarcoma,,Br.CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
PKMTs methylate histone lysine,R-HSA-3214841,https://reactome.org/PathwayBrowser/#/R-HSA-3214841,EZH2,ENSG00000106462,CHEMBL3414621,TAZEMETOSTAT,4.0,,EFO_0000616,neoplasm,,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
PKMTs methylate histone lysine,R-HSA-3214841,https://reactome.org/PathwayBrowser/#/R-HSA-3214841,EZH2,ENSG00000106462,CHEMBL3287735,GSK2816126,1.0,Terminated,EFO_0000616,neoplasm,,CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21
PKMTs methylate histone lysine,R-HSA-3214841,https://reactome.org/PathwayBrowser/#/R-HSA-3214841,KMT2A,ENSG00000118058,CHEMBL4650827,REVUMENIB,2.0,Not yet recruiting,EFO_0000222,acute myeloid leukemia,,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C
PKMTs methylate histone lysine,R-HSA-3214841,https://reactome.org/PathwayBrowser/#/R-HSA-3214841,KMT2A,ENSG00000118058,CHEMBL4650278,REVUMENIB SESQUIFUMARATE,1.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O
SUMOylation of transcription cofactor,R-HSA-3899300,https://reactome.org/PathwayBrowser/#/R-HSA-3899300,NPM1,ENSG00000181163,CHEMBL601719,CRIZOTINIB,4.0,,EFO_0000616,neoplasm,,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
SUMOylation of transcription cofactor,R-HSA-3899300,https://reactome.org/PathwayBrowser/#/R-HSA-3899300,NPM1,ENSG00000181163,CHEMBL2403108,CERITINIB,4.0,,EFO_0000616,neoplasm,,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
Deposition of new CENPA-containing nucleosomes at the centromer,R-HSA-606279,https://reactome.org/PathwayBrowser/#/R-HSA-606279,NPM1,ENSG00000181163,CHEMBL601719,CRIZOTINIB,4.0,,EFO_0000616,neoplasm,,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
Deposition of new CENPA-containing nucleosomes at the centromer,R-HSA-606279,https://reactome.org/PathwayBrowser/#/R-HSA-606279,NPM1,ENSG00000181163,CHEMBL2403108,CERITINIB,4.0,,EFO_0000616,neoplasm,,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,NPM1,ENSG00000181163,CHEMBL601719,CRIZOTINIB,4.0,,EFO_0000616,neoplasm,,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,NPM1,ENSG00000181163,CHEMBL2403108,CERITINIB,4.0,,EFO_0000616,neoplasm,,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertai,R-HSA-6804115,https://reactome.org/PathwayBrowser/#/R-HSA-6804115,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiatio,R-HSA-8869496,https://reactome.org/PathwayBrowser/#/R-HSA-8869496,NPM1,ENSG00000181163,CHEMBL601719,CRIZOTINIB,4.0,,EFO_0000616,neoplasm,,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiatio,R-HSA-8869496,https://reactome.org/PathwayBrowser/#/R-HSA-8869496,NPM1,ENSG00000181163,CHEMBL2403108,CERITINIB,4.0,,EFO_0000616,neoplasm,,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
SARS-CoV-1-host interaction,R-HSA-9692914,https://reactome.org/PathwayBrowser/#/R-HSA-9692914,NPM1,ENSG00000181163,CHEMBL601719,CRIZOTINIB,4.0,,EFO_0000616,neoplasm,,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
SARS-CoV-1-host interaction,R-HSA-9692914,https://reactome.org/PathwayBrowser/#/R-HSA-9692914,NPM1,ENSG00000181163,CHEMBL2403108,CERITINIB,4.0,,EFO_0000616,neoplasm,,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
ALK mutants bind TKI,R-HSA-9700645,https://reactome.org/PathwayBrowser/#/R-HSA-9700645,NPM1,ENSG00000181163,CHEMBL601719,CRIZOTINIB,4.0,,EFO_0000616,neoplasm,,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
ALK mutants bind TKI,R-HSA-9700645,https://reactome.org/PathwayBrowser/#/R-HSA-9700645,NPM1,ENSG00000181163,CHEMBL2403108,CERITINIB,4.0,,EFO_0000616,neoplasm,,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,NPM1,ENSG00000181163,CHEMBL601719,CRIZOTINIB,4.0,,EFO_0000616,neoplasm,,C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,NPM1,ENSG00000181163,CHEMBL2403108,CERITINIB,4.0,,EFO_0000616,neoplasm,,Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Signaling by ALK fusions and activated point mutant,R-HSA-9725370,https://reactome.org/PathwayBrowser/#/R-HSA-9725370,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Formation of WDR5-containing histone-modifying complexe,R-HSA-9772755,https://reactome.org/PathwayBrowser/#/R-HSA-9772755,KMT2A,ENSG00000118058,CHEMBL4650827,REVUMENIB,2.0,Not yet recruiting,EFO_0000222,acute myeloid leukemia,,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C
Formation of WDR5-containing histone-modifying complexe,R-HSA-9772755,https://reactome.org/PathwayBrowser/#/R-HSA-9772755,KMT2A,ENSG00000118058,CHEMBL4650278,REVUMENIB SESQUIFUMARATE,1.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(C[C@H]3CC[C@H](NS(=O)(=O)CC)CC3)CC2)C1)C(C)C.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O
Formation of Incision Complex in GG-NE,R-HSA-5696395,https://reactome.org/PathwayBrowser/#/R-HSA-5696395,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of Incision Complex in GG-NE,R-HSA-5696395,https://reactome.org/PathwayBrowser/#/R-HSA-5696395,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of Incision Complex in GG-NE,R-HSA-5696395,https://reactome.org/PathwayBrowser/#/R-HSA-5696395,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Signaling by SCF-KI,R-HSA-1433557,https://reactome.org/PathwayBrowser/#/R-HSA-1433557,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
TFAP2 (AP-2) family regulates transcription of growth factors and their receptor,R-HSA-8866910,https://reactome.org/PathwayBrowser/#/R-HSA-8866910,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Dasatinib-resistant KIT mutant,R-HSA-9669914,https://reactome.org/PathwayBrowser/#/R-HSA-9669914,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Imatinib-resistant KIT mutant,R-HSA-9669917,https://reactome.org/PathwayBrowser/#/R-HSA-9669917,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
KIT mutants bind TKI,R-HSA-9669921,https://reactome.org/PathwayBrowser/#/R-HSA-9669921,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Masitinib-resistant KIT mutant,R-HSA-9669924,https://reactome.org/PathwayBrowser/#/R-HSA-9669924,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Nilotinib-resistant KIT mutant,R-HSA-9669926,https://reactome.org/PathwayBrowser/#/R-HSA-9669926,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Regorafenib-resistant KIT mutant,R-HSA-9669929,https://reactome.org/PathwayBrowser/#/R-HSA-9669929,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by kinase domain mutants of KI,R-HSA-9669933,https://reactome.org/PathwayBrowser/#/R-HSA-9669933,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Sunitinib-resistant KIT mutant,R-HSA-9669934,https://reactome.org/PathwayBrowser/#/R-HSA-9669934,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by juxtamembrane domain KIT mutant,R-HSA-9669935,https://reactome.org/PathwayBrowser/#/R-HSA-9669935,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Sorafenib-resistant KIT mutant,R-HSA-9669936,https://reactome.org/PathwayBrowser/#/R-HSA-9669936,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutant",R-HSA-9670439,https://reactome.org/PathwayBrowser/#/R-HSA-9670439,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by extracellular domain mutants of KI,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1421,DASATINIB ANHYDROUS,4.0,Unknown status,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1642,IMATINIB MESYLATE,4.0,Completed,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0000681,renal cell carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3813873,PEXIDARTINIB,4.0,,EFO_0000616,neoplasm,,FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3989973,PEXIDARTINIB HYDROCHLORIDE,4.0,,EFO_1000562,Tenosynovial Giant Cell Tumor,,Cl.FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4303201,CATEQUENTINIB,3.0,Not yet recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1289494,TIVOZANIB,3.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL4650333,SERALUTINIB,3.0,Recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL124660,TANDUTINIB,2.0,Completed,EFO_0000349,clear cell renal carcinoma,,COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Transcriptional and post-translational regulation of MITF-M expression and activit,R-HSA-9856649,https://reactome.org/PathwayBrowser/#/R-HSA-9856649,KIT,ENSG00000157404,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
EGFR Transactivation by Gastri,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
EGFR Transactivation by Gastri,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
EGFR Transactivation by Gastri,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
EGFR Transactivation by Gastri,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
EGFR Transactivation by Gastri,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
EGFR Transactivation by Gastri,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
EGFR Transactivation by Gastri,R-HSA-2179392,https://reactome.org/PathwayBrowser/#/R-HSA-2179392,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Syndecan interaction,R-HSA-3000170,https://reactome.org/PathwayBrowser/#/R-HSA-3000170,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Syndecan interaction,R-HSA-3000170,https://reactome.org/PathwayBrowser/#/R-HSA-3000170,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Syndecan interaction,R-HSA-3000170,https://reactome.org/PathwayBrowser/#/R-HSA-3000170,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Syndecan interaction,R-HSA-3000170,https://reactome.org/PathwayBrowser/#/R-HSA-3000170,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Syndecan interaction,R-HSA-3000170,https://reactome.org/PathwayBrowser/#/R-HSA-3000170,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Acetylcholine regulates insulin secretio,R-HSA-399997,https://reactome.org/PathwayBrowser/#/R-HSA-399997,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Acetylcholine regulates insulin secretio,R-HSA-399997,https://reactome.org/PathwayBrowser/#/R-HSA-399997,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Acetylcholine regulates insulin secretio,R-HSA-399997,https://reactome.org/PathwayBrowser/#/R-HSA-399997,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Acetylcholine regulates insulin secretio,R-HSA-399997,https://reactome.org/PathwayBrowser/#/R-HSA-399997,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Acetylcholine regulates insulin secretio,R-HSA-399997,https://reactome.org/PathwayBrowser/#/R-HSA-399997,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Ca2+ pathwa,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Ca2+ pathwa,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
Ca2+ pathwa,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
Ca2+ pathwa,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
Ca2+ pathwa,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
ROBO receptors bind AKAP,R-HSA-9010642,https://reactome.org/PathwayBrowser/#/R-HSA-9010642,PRKCA,ENSG00000154229,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
ROBO receptors bind AKAP,R-HSA-9010642,https://reactome.org/PathwayBrowser/#/R-HSA-9010642,PRKCA,ENSG00000154229,CHEMBL2108287,APRINOCARSEN,3.0,Completed,EFO_0003060,non-small cell lung carcinoma,,
ROBO receptors bind AKAP,R-HSA-9010642,https://reactome.org/PathwayBrowser/#/R-HSA-9010642,PRKCA,ENSG00000154229,CHEMBL574737,UCN-01,2.0,Terminated,EFO_0000574,lymphoma,,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O
ROBO receptors bind AKAP,R-HSA-9010642,https://reactome.org/PathwayBrowser/#/R-HSA-9010642,PRKCA,ENSG00000154229,CHEMBL565612,SOTRASTAURIN,2.0,Completed,EFO_0000729,ulcerative colitis,,CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1
ROBO receptors bind AKAP,R-HSA-9010642,https://reactome.org/PathwayBrowser/#/R-HSA-9010642,PRKCA,ENSG00000154229,CHEMBL494089,GSK-690693,1.0,Withdrawn,MONDO_0004992,cancer,,CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Frs2-mediated activatio,R-HSA-170968,https://reactome.org/PathwayBrowser/#/R-HSA-170968,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
ARMS-mediated activatio,R-HSA-170984,https://reactome.org/PathwayBrowser/#/R-HSA-170984,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL3301612,ENCORAFENIB,4.0,,EFO_0000616,neoplasm,,COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL1229517,VEMURAFENIB,4.0,Completed,EFO_0000616,neoplasm,,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL2105729,DABRAFENIB MESYLATE,4.0,,EFO_0000756,melanoma,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1.CS(=O)(=O)O
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL2028663,DABRAFENIB,4.0,,EFO_0000616,neoplasm,,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL4583691,NAPORAFENIB,3.0,Recruiting,EFO_0000756,melanoma,,Cc1ccc(NC(=O)c2ccnc(C(F)(F)F)c2)cc1-c1cc(OCCO)nc(N2CCOCC2)c1
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL3348923,TOVORAFENIB,3.0,Recruiting,MONDO_0021637,low grade glioma,,C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL3977543,BELVARAFENIB,2.0,Recruiting,EFO_0000616,neoplasm,,Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL4303729,PLIXORAFENIB,2.0,Recruiting,MONDO_0004992,cancer,,O=C(c1c(F)ccc(NS(=O)(=O)N2CC[C@@H](F)C2)c1F)c1c[nH]c2ncc(-c3cnc(C4CC4)nc3)cc12
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL4209157,LIFIRAFENIB,1.0,Recruiting,EFO_0000616,neoplasm,,O=C1CCc2c(Oc3ccc4c(c3)[C@@H]3[C@H](O4)[C@H]3c3nc4cc(C(F)(F)F)ccc4[nH]3)ccnc2N1
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL5314407,ARQ-736,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)([O-])[O-])c5)nc5occn45)n3)C2)n1.[Na+].[Na+]
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL5316167,ARQ-736 FREE ACID,1.0,Completed,EFO_0000616,neoplasm,,Cn1ccc(S(=O)(=O)N2CCC[C@@H](Nc3nccc(-c4c(-c5cccc(OCOP(=O)(O)O)c5)nc5occn45)n3)C2)n1
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL2029988,CEP-32496,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL3545027,XL-281,1.0,Completed,EFO_0000641,papillary thyroid carcinoma,,COC(=O)Nc1nc2cc(C3(O)c4ccccc4C(=O)N3c3cc(Cl)ccc3C)ccc2[nH]1
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL3577124,LY-3009120,1.0,Terminated,EFO_0000756,melanoma,,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1
Signalling to p38 via RIT and RI,R-HSA-187706,https://reactome.org/PathwayBrowser/#/R-HSA-187706,BRAF,ENSG00000157764,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Transcriptional regulation of testis differentiatio,R-HSA-9690406,https://reactome.org/PathwayBrowser/#/R-HSA-9690406,WT1,ENSG00000184937,CHEMBL3833386,GALINPEPIMUT-S,3.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,
Transcriptional regulation of testis differentiatio,R-HSA-9690406,https://reactome.org/PathwayBrowser/#/R-HSA-9690406,WT1,ENSG00000184937,CHEMBL4297235,OMBIPEPIMUT-S,3.0,Completed,EFO_0000519,glioblastoma multiforme,,
Nephron developmen,R-HSA-9831926,https://reactome.org/PathwayBrowser/#/R-HSA-9831926,WT1,ENSG00000184937,CHEMBL3833386,GALINPEPIMUT-S,3.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,
Nephron developmen,R-HSA-9831926,https://reactome.org/PathwayBrowser/#/R-HSA-9831926,WT1,ENSG00000184937,CHEMBL4297235,OMBIPEPIMUT-S,3.0,Completed,EFO_0000519,glioblastoma multiforme,,
Regulation of TP53 Activity through Acetylatio,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Activity through Acetylatio,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Activity through Acetylatio,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Activity through Acetylatio,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Activity through Acetylatio,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Activity through Acetylatio,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Activity through Acetylatio,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Activity through Acetylatio,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Activity through Acetylatio,R-HSA-6804758,https://reactome.org/PathwayBrowser/#/R-HSA-6804758,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of PTEN localizatio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of PTEN localizatio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of PTEN localizatio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
Neurophilin interactions with VEGF and VEGF,R-HSA-194306,https://reactome.org/PathwayBrowser/#/R-HSA-194306,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
Integrin cell surface interaction,R-HSA-216083,https://reactome.org/PathwayBrowser/#/R-HSA-216083,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2103868,CABOZANTINIB S-MALATE,4.0,,EFO_0000182,hepatocellular carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL24828,VANDETANIB,4.0,,EFO_0000616,neoplasm,,COc1cc2/c(=N/c3ccc(Br)cc3F)nc[nH]c2cc1OCC1CCN(C)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2105717,CABOZANTINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000717,systemic scleroderma,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1743062,RAMUCIRUMAB,4.0,,EFO_0000616,neoplasm,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1289601,LENVATINIB,4.0,,EFO_0000616,neoplasm,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1289926,AXITINIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1200485,SORAFENIB TOSYLATE,4.0,,EFO_0002892,thyroid carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2105704,LENVATINIB MESYLATE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2105756,TIVOZANIB HYDROCHLORIDE,4.0,,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL4303214,FRUQUINTINIB,4.0,,EFO_0004142,colorectal neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1336,SORAFENIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3186534,RIVOCERANIB,3.0,"Active, not recruiting",EFO_0000182,hepatocellular carcinoma,,N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL4303201,CATEQUENTINIB,3.0,Recruiting,EFO_0000182,hepatocellular carcinoma,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545414,RIVOCERANIB MESYLATE,3.0,Recruiting,EFO_0000178,gastric carcinoma,,CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL377300,BRIVANIB,3.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL4297190,SURUFATINIB,3.0,,EFO_0000616,neoplasm,,Cc1cc2cc(Oc3ccnc(Nc4cccc(CS(=O)(=O)NCCN(C)C)c4)n3)ccc2[nH]1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1289494,TIVOZANIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545427,CM-082,3.0,Unknown status,EFO_0000681,renal cell carcinoma,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL5095033,IBCASERTIB,3.0,Recruiting,EFO_0000702,small cell lung carcinoma,,COc1ccc2c(Oc3ccc4c(C(=O)Nc5ccccc5N)cccc4c3)ccnc2c1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL270995,BRIVANIB ALANINATE,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL276711,SEMAXANIB,3.0,Completed,MONDO_0005575,colorectal cancer,,Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL482968,ENMD-2076,2.0,Completed,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2010872,CEP-11981,2.0,Recruiting,EFO_0000196,metastatic prostate cancer,,CC(C)Cn1c2ccc(Nc3ncccn3)cc2c2c3c(c4c(c21)CCc1nn(C)cc1-4)C(=O)NC3
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2108356,PEGDINETANIB,2.0,Completed,EFO_0000365,colorectal adenocarcinoma,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL4298119,OLINVACIMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3989914,GLESATINIB,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545401,X-82,2.0,Terminated,EFO_0003839,retinopathy,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2220486,LUCITANIB,2.0,Terminated,EFO_0000702,small cell lung carcinoma,,CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2108557,TELBERMIN,2.0,Completed,EFO_0001645,coronary artery disease,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL403989,TG100-801,2.0,Terminated,EFO_0009606,macular degeneration,,Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545396,BMS-690514,2.0,Completed,EFO_0003060,non-small cell lung carcinoma,,COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3984441,NINGETINIB,2.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL4080062,BFH-772,2.0,Completed,EFO_1000760,rosacea,,O=C(Nc1cccc(C(F)(F)F)c1)c1cccc2cc(Oc3cc(CO)ncn3)ccc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL253969,OSI-632,2.0,Completed,MONDO_0002158,fallopian tube cancer,,NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2079588,TELATINIB,2.0,Completed,MONDO_0001056,gastric cancer,,CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL5314406,4SC-203,1.0,Completed,EFO_0000222,acute myeloid leukemia,,COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL587723,AEE-788,1.0,Completed,EFO_0000519,glioblastoma multiforme,,CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545050,BMS-817378,1.0,Withdrawn,EFO_0000616,neoplasm,,
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1980391,RG-1530,1.0,Completed,EFO_0000616,neoplasm,,COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL558752,RAF-265,1.0,Completed,EFO_0000616,neoplasm,,Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1738697,PF-00337210,1.0,Completed,EFO_0000616,neoplasm,,CNC(=O)c1c(C)oc2cc(Oc3ccnc4cc(OCCN5CCOCC5)ccc34)ccc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3039525,GOLVATINIB,1.0,Completed,EFO_0000616,neoplasm,,CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL482967,CYC-116,1.0,Terminated,EFO_0000616,neoplasm,,Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1614710,OSI-930,1.0,Completed,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545155,JI-101,1.0,Completed,EFO_0000616,neoplasm,,COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(N)c1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL3545365,ALTIRATINIB,1.0,Terminated,EFO_0000616,neoplasm,,O=C(Nc1cc(Oc2cc(F)c(NC(=O)C3(C(=O)Nc4ccc(F)cc4)CC3)cc2F)ccn1)C1CC1
Signaling by membrane-tethered fusions of PDGFRA or PDGFR,R-HSA-9673768,https://reactome.org/PathwayBrowser/#/R-HSA-9673768,KDR,ENSG00000128052,CHEMBL1277072,HENATINIB,1.0,Terminated,MONDO_0004992,cancer,,Cc1c(/C=C2\C(=O)Nc3ccc(F)cc32)[nH]c2c1C(=O)N(C[C@H](O)CN1CCOCC1)CCC2
Activation of NOXA and translocation to mitochondri,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Activation of NOXA and translocation to mitochondri,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Activation of NOXA and translocation to mitochondri,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Activation of NOXA and translocation to mitochondri,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Activation of NOXA and translocation to mitochondri,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Activation of NOXA and translocation to mitochondri,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Activation of NOXA and translocation to mitochondri,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Activation of NOXA and translocation to mitochondri,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Activation of NOXA and translocation to mitochondri,R-HSA-111448,https://reactome.org/PathwayBrowser/#/R-HSA-111448,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Activation of PUMA and translocation to mitochondri,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Activation of PUMA and translocation to mitochondri,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Activation of PUMA and translocation to mitochondri,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Activation of PUMA and translocation to mitochondri,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Activation of PUMA and translocation to mitochondri,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Activation of PUMA and translocation to mitochondri,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Activation of PUMA and translocation to mitochondri,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Activation of PUMA and translocation to mitochondri,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Activation of PUMA and translocation to mitochondri,R-HSA-139915,https://reactome.org/PathwayBrowser/#/R-HSA-139915,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,EZH2,ENSG00000106462,CHEMBL4594260,TAZEMETOSTAT HYDROBROMIDE,4.0,,EFO_0000691,sarcoma,,Br.CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,EZH2,ENSG00000106462,CHEMBL3414621,TAZEMETOSTAT,4.0,,EFO_0000616,neoplasm,,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,EZH2,ENSG00000106462,CHEMBL3287735,GSK2816126,1.0,Terminated,EFO_0000616,neoplasm,,CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Oxidative Stress Induced Senescenc,R-HSA-2559580,https://reactome.org/PathwayBrowser/#/R-HSA-2559580,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Formation of Senescence-Associated Heterochromatin Foci (SAHF,R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Formation of Senescence-Associated Heterochromatin Foci (SAHF,R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Formation of Senescence-Associated Heterochromatin Foci (SAHF,R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Formation of Senescence-Associated Heterochromatin Foci (SAHF,R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Formation of Senescence-Associated Heterochromatin Foci (SAHF,R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Formation of Senescence-Associated Heterochromatin Foci (SAHF,R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Formation of Senescence-Associated Heterochromatin Foci (SAHF,R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Formation of Senescence-Associated Heterochromatin Foci (SAHF,R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Formation of Senescence-Associated Heterochromatin Foci (SAHF,R-HSA-2559584,https://reactome.org/PathwayBrowser/#/R-HSA-2559584,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Oncogene Induced Senescenc,R-HSA-2559585,https://reactome.org/PathwayBrowser/#/R-HSA-2559585,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
SUMOylation of transcription factor,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
SUMOylation of transcription factor,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
SUMOylation of transcription factor,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
SUMOylation of transcription factor,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
SUMOylation of transcription factor,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
SUMOylation of transcription factor,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
SUMOylation of transcription factor,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
SUMOylation of transcription factor,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
SUMOylation of transcription factor,R-HSA-3232118,https://reactome.org/PathwayBrowser/#/R-HSA-3232118,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Autodegradation of the E3 ubiquitin ligase COP,R-HSA-349425,https://reactome.org/PathwayBrowser/#/R-HSA-349425,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Metabolic Gene,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Metabolic Gene,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Metabolic Gene,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Metabolic Gene,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Metabolic Gene,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Metabolic Gene,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Metabolic Gene,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Metabolic Gene,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Metabolic Gene,R-HSA-5628897,https://reactome.org/PathwayBrowser/#/R-HSA-5628897,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Ub-specific processing protease,R-HSA-5689880,https://reactome.org/PathwayBrowser/#/R-HSA-5689880,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Ovarian tumor domain protease,R-HSA-5689896,https://reactome.org/PathwayBrowser/#/R-HSA-5689896,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Transcription of Genes Involved in Cytochrome C Releas,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of Genes Involved in Cytochrome C Releas,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of Genes Involved in Cytochrome C Releas,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of Genes Involved in Cytochrome C Releas,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of Genes Involved in Cytochrome C Releas,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of Genes Involved in Cytochrome C Releas,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of Genes Involved in Cytochrome C Releas,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of Genes Involved in Cytochrome C Releas,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of Genes Involved in Cytochrome C Releas,R-HSA-6803204,https://reactome.org/PathwayBrowser/#/R-HSA-6803204,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertai,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertai,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertai,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertai,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertai,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertai,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertai,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertai,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertai,R-HSA-6803205,https://reactome.org/PathwayBrowser/#/R-HSA-6803205,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Transcription of Caspase Activators and Caspase,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of Caspase Activators and Caspase,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of Caspase Activators and Caspase,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of Caspase Activators and Caspase,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of Caspase Activators and Caspase,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of Caspase Activators and Caspase,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of Caspase Activators and Caspase,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of Caspase Activators and Caspase,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of Caspase Activators and Caspase,R-HSA-6803207,https://reactome.org/PathwayBrowser/#/R-HSA-6803207,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Transcription of Death Receptors and Ligand,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of Death Receptors and Ligand,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of Death Receptors and Ligand,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of Death Receptors and Ligand,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of Death Receptors and Ligand,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of Death Receptors and Ligand,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of Death Receptors and Ligand,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of Death Receptors and Ligand,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of Death Receptors and Ligand,R-HSA-6803211,https://reactome.org/PathwayBrowser/#/R-HSA-6803211,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arres,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arres,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arres,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arres,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arres,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arres,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arres,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arres,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arres,R-HSA-6804114,https://reactome.org/PathwayBrowser/#/R-HSA-6804114,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arres,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arres,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arres,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arres,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arres,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arres,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arres,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arres,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arres,R-HSA-6804116,https://reactome.org/PathwayBrowser/#/R-HSA-6804116,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of TP53 Expressio,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Expressio,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Expressio,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Expressio,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Expressio,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Expressio,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Expressio,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Expressio,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Expressio,R-HSA-6804754,https://reactome.org/PathwayBrowser/#/R-HSA-6804754,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Activity through Phosphorylatio,R-HSA-6804756,https://reactome.org/PathwayBrowser/#/R-HSA-6804756,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Degradatio,R-HSA-6804757,https://reactome.org/PathwayBrowser/#/R-HSA-6804757,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of TP53 Activity through Association with Co-factor,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Activity through Association with Co-factor,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Activity through Association with Co-factor,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Activity through Association with Co-factor,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Activity through Association with Co-factor,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Activity through Association with Co-factor,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Activity through Association with Co-factor,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Activity through Association with Co-factor,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Activity through Association with Co-factor,R-HSA-6804759,https://reactome.org/PathwayBrowser/#/R-HSA-6804759,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of TP53 Activity through Methylatio,R-HSA-6804760,https://reactome.org/PathwayBrowser/#/R-HSA-6804760,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
PI5P Regulates TP53 Acetylatio,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
PI5P Regulates TP53 Acetylatio,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
PI5P Regulates TP53 Acetylatio,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
PI5P Regulates TP53 Acetylatio,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
PI5P Regulates TP53 Acetylatio,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
PI5P Regulates TP53 Acetylatio,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
PI5P Regulates TP53 Acetylatio,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
PI5P Regulates TP53 Acetylatio,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
PI5P Regulates TP53 Acetylatio,R-HSA-6811555,https://reactome.org/PathwayBrowser/#/R-HSA-6811555,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
G2/M DNA damage checkpoin,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
G2/M DNA damage checkpoin,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
G2/M DNA damage checkpoin,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
G2/M DNA damage checkpoin,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
G2/M DNA damage checkpoin,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
G2/M DNA damage checkpoin,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
G2/M DNA damage checkpoin,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
G2/M DNA damage checkpoin,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
G2/M DNA damage checkpoin,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
G2/M Checkpoint,R-HSA-69473,https://reactome.org/PathwayBrowser/#/R-HSA-69473,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Stabilization of p5,R-HSA-69541,https://reactome.org/PathwayBrowser/#/R-HSA-69541,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Transcriptional activation of cell cycle inhibitor p2,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Transcriptional activation of cell cycle inhibitor p2,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Transcriptional activation of cell cycle inhibitor p2,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Transcriptional activation of cell cycle inhibitor p2,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Transcriptional activation of cell cycle inhibitor p2,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Transcriptional activation of cell cycle inhibitor p2,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Transcriptional activation of cell cycle inhibitor p2,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Transcriptional activation of cell cycle inhibitor p2,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Transcriptional activation of cell cycle inhibitor p2,R-HSA-69895,https://reactome.org/PathwayBrowser/#/R-HSA-69895,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
The role of GTSE1 in G2/M progression after G2 checkpoin,R-HSA-8852276,https://reactome.org/PathwayBrowser/#/R-HSA-8852276,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Transcriptional Regulation by VENT,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Transcriptional Regulation by VENT,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Transcriptional Regulation by VENT,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Transcriptional Regulation by VENT,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Transcriptional Regulation by VENT,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Transcriptional Regulation by VENT,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Transcriptional Regulation by VENT,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Transcriptional Regulation by VENT,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Transcriptional Regulation by VENT,R-HSA-8853884,https://reactome.org/PathwayBrowser/#/R-HSA-8853884,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
RUNX3 regulates CDKN1A transcriptio,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
RUNX3 regulates CDKN1A transcriptio,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
RUNX3 regulates CDKN1A transcriptio,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
RUNX3 regulates CDKN1A transcriptio,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
RUNX3 regulates CDKN1A transcriptio,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
RUNX3 regulates CDKN1A transcriptio,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
RUNX3 regulates CDKN1A transcriptio,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
RUNX3 regulates CDKN1A transcriptio,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
RUNX3 regulates CDKN1A transcriptio,R-HSA-8941855,https://reactome.org/PathwayBrowser/#/R-HSA-8941855,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,EZH2,ENSG00000106462,CHEMBL4594260,TAZEMETOSTAT HYDROBROMIDE,4.0,,EFO_0000691,sarcoma,,Br.CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,EZH2,ENSG00000106462,CHEMBL3414621,TAZEMETOSTAT,4.0,,EFO_0000616,neoplasm,,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,EZH2,ENSG00000106462,CHEMBL3287735,GSK2816126,1.0,Terminated,EFO_0000616,neoplasm,,CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of PTEN gene transcriptio,R-HSA-6807070,https://reactome.org/PathwayBrowser/#/R-HSA-6807070,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Loss of function of TP53 in cancer due to loss of tetramerization abilit,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Loss of function of TP53 in cancer due to loss of tetramerization abilit,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Loss of function of TP53 in cancer due to loss of tetramerization abilit,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Loss of function of TP53 in cancer due to loss of tetramerization abilit,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Loss of function of TP53 in cancer due to loss of tetramerization abilit,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Loss of function of TP53 in cancer due to loss of tetramerization abilit,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Loss of function of TP53 in cancer due to loss of tetramerization abilit,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Loss of function of TP53 in cancer due to loss of tetramerization abilit,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Loss of function of TP53 in cancer due to loss of tetramerization abilit,R-HSA-9723905,https://reactome.org/PathwayBrowser/#/R-HSA-9723905,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Regulation of NF-kappa B signalin,R-HSA-9758274,https://reactome.org/PathwayBrowser/#/R-HSA-9758274,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Zygotic genome activation (ZGA,R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL3186011,EPRENETAPOPT,3.0,Completed,EFO_0000198,myelodysplastic syndrome,,COCC1(CO)C(=O)C2CCN1CC2
Zygotic genome activation (ZGA,R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL2402737,IDASANUTLIN,3.0,Terminated,EFO_0000222,acute myeloid leukemia,,COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F
Zygotic genome activation (ZGA,R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL2219776,CENERSEN SODIUM,2.0,Terminated,EFO_0000095,chronic lymphocytic leukemia,,
Zygotic genome activation (ZGA,R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL2108280,CENERSEN,2.0,Completed,EFO_0000222,acute myeloid leukemia,,
Zygotic genome activation (ZGA,R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL3125702,NAVTEMADLIN,2.0,Recruiting,EFO_0000479,essential thrombocythemia,,CC(C)[C@@H](CS(=O)(=O)C(C)C)N1C(=O)[C@@](C)(CC(=O)O)C[C@H](c2cccc(Cl)c2)[C@H]1c1ccc(Cl)cc1
Zygotic genome activation (ZGA,R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL3653256,SIREMADLIN,2.0,Recruiting,EFO_0000616,neoplasm,,COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
Zygotic genome activation (ZGA,R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL2108585,CONTUSUGENE LADENOVEC,2.0,Unknown status,EFO_0003060,non-small cell lung carcinoma,,
Zygotic genome activation (ZGA,R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL4091801,ALRIZOMADLIN,2.0,Recruiting,EFO_0004289,lymphoid leukemia,,CCN1[C@@H](C(=O)NC23CCC(C(=O)O)(CC2)CC3)[C@H](c2cccc(Cl)c2F)[C@]2(C(=O)Nc3cc(Cl)ccc32)C12CCCCC2
Zygotic genome activation (ZGA,R-HSA-9819196,https://reactome.org/PathwayBrowser/#/R-HSA-9819196,TP53,ENSG00000141510,CHEMBL4297574,TEPRASIRAN,2.0,Completed,HP_0001919,Acute kidney injury,,
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alph,R-HSA-1234176,https://reactome.org/PathwayBrowser/#/R-HSA-1234176,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alph,R-HSA-1234176,https://reactome.org/PathwayBrowser/#/R-HSA-1234176,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alph,R-HSA-1234176,https://reactome.org/PathwayBrowser/#/R-HSA-1234176,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
ER-Phagosome pathwa,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
ER-Phagosome pathwa,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
ER-Phagosome pathwa,R-HSA-1236974,https://reactome.org/PathwayBrowser/#/R-HSA-1236974,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Downregulation of ERBB4 signalin,R-HSA-1253288,https://reactome.org/PathwayBrowser/#/R-HSA-1253288,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Downregulation of ERBB4 signalin,R-HSA-1253288,https://reactome.org/PathwayBrowser/#/R-HSA-1253288,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Downregulation of ERBB4 signalin,R-HSA-1253288,https://reactome.org/PathwayBrowser/#/R-HSA-1253288,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Downregulation of ERBB2:ERBB3 signalin,R-HSA-1358803,https://reactome.org/PathwayBrowser/#/R-HSA-1358803,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Downregulation of ERBB2:ERBB3 signalin,R-HSA-1358803,https://reactome.org/PathwayBrowser/#/R-HSA-1358803,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Downregulation of ERBB2:ERBB3 signalin,R-HSA-1358803,https://reactome.org/PathwayBrowser/#/R-HSA-1358803,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Budding and maturation of HIV virio,R-HSA-162588,https://reactome.org/PathwayBrowser/#/R-HSA-162588,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Budding and maturation of HIV virio,R-HSA-162588,https://reactome.org/PathwayBrowser/#/R-HSA-162588,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Budding and maturation of HIV virio,R-HSA-162588,https://reactome.org/PathwayBrowser/#/R-HSA-162588,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
NOD1/2 Signaling Pathwa,R-HSA-168638,https://reactome.org/PathwayBrowser/#/R-HSA-168638,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
NOD1/2 Signaling Pathwa,R-HSA-168638,https://reactome.org/PathwayBrowser/#/R-HSA-168638,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
NOD1/2 Signaling Pathwa,R-HSA-168638,https://reactome.org/PathwayBrowser/#/R-HSA-168638,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
"TICAM1, RIP1-mediated IKK complex recruitmen",R-HSA-168927,https://reactome.org/PathwayBrowser/#/R-HSA-168927,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"TICAM1, RIP1-mediated IKK complex recruitmen",R-HSA-168927,https://reactome.org/PathwayBrowser/#/R-HSA-168927,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"TICAM1, RIP1-mediated IKK complex recruitmen",R-HSA-168927,https://reactome.org/PathwayBrowser/#/R-HSA-168927,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
DDX58/IFIH1-mediated induction of interferon-alpha/bet,R-HSA-168928,https://reactome.org/PathwayBrowser/#/R-HSA-168928,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
DDX58/IFIH1-mediated induction of interferon-alpha/bet,R-HSA-168928,https://reactome.org/PathwayBrowser/#/R-HSA-168928,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
DDX58/IFIH1-mediated induction of interferon-alpha/bet,R-HSA-168928,https://reactome.org/PathwayBrowser/#/R-HSA-168928,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
APC/C:Cdc20 mediated degradation of Cyclin,R-HSA-174048,https://reactome.org/PathwayBrowser/#/R-HSA-174048,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
APC/C:Cdc20 mediated degradation of Cyclin,R-HSA-174048,https://reactome.org/PathwayBrowser/#/R-HSA-174048,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
APC/C:Cdc20 mediated degradation of Cyclin,R-HSA-174048,https://reactome.org/PathwayBrowser/#/R-HSA-174048,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Autodegradation of Cdh1 by Cdh1:APC/,,,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Autodegradation of Cdh1 by Cdh1:APC/,,,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Autodegradation of Cdh1 by Cdh1:APC/,,,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SCF-beta-TrCP mediated degradation of Emi,R-HSA-174113,https://reactome.org/PathwayBrowser/#/R-HSA-174113,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SCF-beta-TrCP mediated degradation of Emi,R-HSA-174113,https://reactome.org/PathwayBrowser/#/R-HSA-174113,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SCF-beta-TrCP mediated degradation of Emi,R-HSA-174113,https://reactome.org/PathwayBrowser/#/R-HSA-174113,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
APC/C:Cdc20 mediated degradation of Securi,R-HSA-174154,https://reactome.org/PathwayBrowser/#/R-HSA-174154,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
APC/C:Cdc20 mediated degradation of Securi,R-HSA-174154,https://reactome.org/PathwayBrowser/#/R-HSA-174154,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
APC/C:Cdc20 mediated degradation of Securi,R-HSA-174154,https://reactome.org/PathwayBrowser/#/R-HSA-174154,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G,R-HSA-174178,https://reactome.org/PathwayBrowser/#/R-HSA-174178,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G,R-HSA-174178,https://reactome.org/PathwayBrowser/#/R-HSA-174178,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G,R-HSA-174178,https://reactome.org/PathwayBrowser/#/R-HSA-174178,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Cdc20:Phospho-APC/C mediated degradation of Cyclin,R-HSA-174184,https://reactome.org/PathwayBrowser/#/R-HSA-174184,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Cdc20:Phospho-APC/C mediated degradation of Cyclin,R-HSA-174184,https://reactome.org/PathwayBrowser/#/R-HSA-174184,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Cdc20:Phospho-APC/C mediated degradation of Cyclin,R-HSA-174184,https://reactome.org/PathwayBrowser/#/R-HSA-174184,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Membrane binding and targetting of GAG protein,R-HSA-174490,https://reactome.org/PathwayBrowser/#/R-HSA-174490,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Membrane binding and targetting of GAG protein,R-HSA-174490,https://reactome.org/PathwayBrowser/#/R-HSA-174490,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Membrane binding and targetting of GAG protein,R-HSA-174490,https://reactome.org/PathwayBrowser/#/R-HSA-174490,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Assembly Of The HIV Virio,R-HSA-175474,https://reactome.org/PathwayBrowser/#/R-HSA-175474,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Assembly Of The HIV Virio,R-HSA-175474,https://reactome.org/PathwayBrowser/#/R-HSA-175474,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Assembly Of The HIV Virio,R-HSA-175474,https://reactome.org/PathwayBrowser/#/R-HSA-175474,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
APC-Cdc20 mediated degradation of Nek2,R-HSA-179409,https://reactome.org/PathwayBrowser/#/R-HSA-179409,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
APC-Cdc20 mediated degradation of Nek2,R-HSA-179409,https://reactome.org/PathwayBrowser/#/R-HSA-179409,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
APC-Cdc20 mediated degradation of Nek2,R-HSA-179409,https://reactome.org/PathwayBrowser/#/R-HSA-179409,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Vpu mediated degradation of CD,R-HSA-180534,https://reactome.org/PathwayBrowser/#/R-HSA-180534,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Vpu mediated degradation of CD,R-HSA-180534,https://reactome.org/PathwayBrowser/#/R-HSA-180534,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Vpu mediated degradation of CD,R-HSA-180534,https://reactome.org/PathwayBrowser/#/R-HSA-180534,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Vif-mediated degradation of APOBEC3,R-HSA-180585,https://reactome.org/PathwayBrowser/#/R-HSA-180585,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Vif-mediated degradation of APOBEC3,R-HSA-180585,https://reactome.org/PathwayBrowser/#/R-HSA-180585,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Vif-mediated degradation of APOBEC3,R-HSA-180585,https://reactome.org/PathwayBrowser/#/R-HSA-180585,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SCF(Skp2)-mediated degradation of p27/p2,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SCF(Skp2)-mediated degradation of p27/p2,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SCF(Skp2)-mediated degradation of p27/p2,R-HSA-1442490,https://reactome.org/PathwayBrowser/#/R-HSA-1442490,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Degradation of beta-catenin by the destruction comple,R-HSA-195253,https://reactome.org/PathwayBrowser/#/R-HSA-195253,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Degradation of beta-catenin by the destruction comple,R-HSA-195253,https://reactome.org/PathwayBrowser/#/R-HSA-195253,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Degradation of beta-catenin by the destruction comple,R-HSA-195253,https://reactome.org/PathwayBrowser/#/R-HSA-195253,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
TCF dependent signaling in response to WN,R-HSA-201681,https://reactome.org/PathwayBrowser/#/R-HSA-201681,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
TCF dependent signaling in response to WN,R-HSA-201681,https://reactome.org/PathwayBrowser/#/R-HSA-201681,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
TCF dependent signaling in response to WN,R-HSA-201681,https://reactome.org/PathwayBrowser/#/R-HSA-201681,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
NRIF signals cell death from the nucleu,R-HSA-205043,https://reactome.org/PathwayBrowser/#/R-HSA-205043,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
NRIF signals cell death from the nucleu,R-HSA-205043,https://reactome.org/PathwayBrowser/#/R-HSA-205043,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
NRIF signals cell death from the nucleu,R-HSA-205043,https://reactome.org/PathwayBrowser/#/R-HSA-205043,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
NF-kB is activated and signals surviva,R-HSA-209560,https://reactome.org/PathwayBrowser/#/R-HSA-209560,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
NF-kB is activated and signals surviva,R-HSA-209560,https://reactome.org/PathwayBrowser/#/R-HSA-209560,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
NF-kB is activated and signals surviva,R-HSA-209560,https://reactome.org/PathwayBrowser/#/R-HSA-209560,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of activated PAK-2p34 by proteasome mediated degradatio,R-HSA-211733,https://reactome.org/PathwayBrowser/#/R-HSA-211733,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of activated PAK-2p34 by proteasome mediated degradatio,R-HSA-211733,https://reactome.org/PathwayBrowser/#/R-HSA-211733,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of activated PAK-2p34 by proteasome mediated degradatio,R-HSA-211733,https://reactome.org/PathwayBrowser/#/R-HSA-211733,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
NOTCH1 Intracellular Domain Regulates Transcriptio,R-HSA-2122947,https://reactome.org/PathwayBrowser/#/R-HSA-2122947,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
NOTCH1 Intracellular Domain Regulates Transcriptio,R-HSA-2122947,https://reactome.org/PathwayBrowser/#/R-HSA-2122947,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
NOTCH1 Intracellular Domain Regulates Transcriptio,R-HSA-2122947,https://reactome.org/PathwayBrowser/#/R-HSA-2122947,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Activated NOTCH1 Transmits Signal to the Nucleu,R-HSA-2122948,https://reactome.org/PathwayBrowser/#/R-HSA-2122948,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Activated NOTCH1 Transmits Signal to the Nucleu,R-HSA-2122948,https://reactome.org/PathwayBrowser/#/R-HSA-2122948,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Activated NOTCH1 Transmits Signal to the Nucleu,R-HSA-2122948,https://reactome.org/PathwayBrowser/#/R-HSA-2122948,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Downregulation of TGF-beta receptor signalin,R-HSA-2173788,https://reactome.org/PathwayBrowser/#/R-HSA-2173788,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Downregulation of TGF-beta receptor signalin,R-HSA-2173788,https://reactome.org/PathwayBrowser/#/R-HSA-2173788,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Downregulation of TGF-beta receptor signalin,R-HSA-2173788,https://reactome.org/PathwayBrowser/#/R-HSA-2173788,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Downregulation of SMAD2/3:SMAD4 transcriptional activit,R-HSA-2173795,https://reactome.org/PathwayBrowser/#/R-HSA-2173795,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Downregulation of SMAD2/3:SMAD4 transcriptional activit,R-HSA-2173795,https://reactome.org/PathwayBrowser/#/R-HSA-2173795,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Downregulation of SMAD2/3:SMAD4 transcriptional activit,R-HSA-2173795,https://reactome.org/PathwayBrowser/#/R-HSA-2173795,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptio,R-HSA-2173796,https://reactome.org/PathwayBrowser/#/R-HSA-2173796,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptio,R-HSA-2173796,https://reactome.org/PathwayBrowser/#/R-HSA-2173796,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcriptio,R-HSA-2173796,https://reactome.org/PathwayBrowser/#/R-HSA-2173796,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Senescence-Associated Secretory Phenotype (SASP,R-HSA-2559582,https://reactome.org/PathwayBrowser/#/R-HSA-2559582,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Senescence-Associated Secretory Phenotype (SASP,R-HSA-2559582,https://reactome.org/PathwayBrowser/#/R-HSA-2559582,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Senescence-Associated Secretory Phenotype (SASP,R-HSA-2559582,https://reactome.org/PathwayBrowser/#/R-HSA-2559582,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of PLK1 Activity at G2/M Transitio,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of PLK1 Activity at G2/M Transitio,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of PLK1 Activity at G2/M Transitio,R-HSA-2565942,https://reactome.org/PathwayBrowser/#/R-HSA-2565942,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Constitutive Signaling by NOTCH1 PEST Domain Mutant,R-HSA-2644606,https://reactome.org/PathwayBrowser/#/R-HSA-2644606,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Constitutive Signaling by NOTCH1 PEST Domain Mutant,R-HSA-2644606,https://reactome.org/PathwayBrowser/#/R-HSA-2644606,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Constitutive Signaling by NOTCH1 PEST Domain Mutant,R-HSA-2644606,https://reactome.org/PathwayBrowser/#/R-HSA-2644606,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Constitutive Signaling by NOTCH1 HD Domain Mutant,R-HSA-2691232,https://reactome.org/PathwayBrowser/#/R-HSA-2691232,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Constitutive Signaling by NOTCH1 HD Domain Mutant,R-HSA-2691232,https://reactome.org/PathwayBrowser/#/R-HSA-2691232,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Constitutive Signaling by NOTCH1 HD Domain Mutant,R-HSA-2691232,https://reactome.org/PathwayBrowser/#/R-HSA-2691232,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutant,R-HSA-2894862,https://reactome.org/PathwayBrowser/#/R-HSA-2894862,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutant,R-HSA-2894862,https://reactome.org/PathwayBrowser/#/R-HSA-2894862,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutant,R-HSA-2894862,https://reactome.org/PathwayBrowser/#/R-HSA-2894862,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
NOTCH2 Activation and Transmission of Signal to the Nucleu,R-HSA-2979096,https://reactome.org/PathwayBrowser/#/R-HSA-2979096,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
NOTCH2 Activation and Transmission of Signal to the Nucleu,R-HSA-2979096,https://reactome.org/PathwayBrowser/#/R-HSA-2979096,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
NOTCH2 Activation and Transmission of Signal to the Nucleu,R-HSA-2979096,https://reactome.org/PathwayBrowser/#/R-HSA-2979096,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of innate immune responses to cytosolic DN,R-HSA-3134975,https://reactome.org/PathwayBrowser/#/R-HSA-3134975,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of innate immune responses to cytosolic DN,R-HSA-3134975,https://reactome.org/PathwayBrowser/#/R-HSA-3134975,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of innate immune responses to cytosolic DN,R-HSA-3134975,https://reactome.org/PathwayBrowser/#/R-HSA-3134975,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Glycogen synthesi,R-HSA-3322077,https://reactome.org/PathwayBrowser/#/R-HSA-3322077,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Glycogen synthesi,R-HSA-3322077,https://reactome.org/PathwayBrowser/#/R-HSA-3322077,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Glycogen synthesi,R-HSA-3322077,https://reactome.org/PathwayBrowser/#/R-HSA-3322077,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Deactivation of the beta-catenin transactivating comple,R-HSA-3769402,https://reactome.org/PathwayBrowser/#/R-HSA-3769402,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Deactivation of the beta-catenin transactivating comple,R-HSA-3769402,https://reactome.org/PathwayBrowser/#/R-HSA-3769402,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Deactivation of the beta-catenin transactivating comple,R-HSA-3769402,https://reactome.org/PathwayBrowser/#/R-HSA-3769402,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Myoclonic epilepsy of Lafor,R-HSA-3785653,https://reactome.org/PathwayBrowser/#/R-HSA-3785653,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Myoclonic epilepsy of Lafor,R-HSA-3785653,https://reactome.org/PathwayBrowser/#/R-HSA-3785653,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Myoclonic epilepsy of Lafor,R-HSA-3785653,https://reactome.org/PathwayBrowser/#/R-HSA-3785653,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
ABC-family proteins mediated transpor,R-HSA-382556,https://reactome.org/PathwayBrowser/#/R-HSA-382556,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
ABC-family proteins mediated transpor,R-HSA-382556,https://reactome.org/PathwayBrowser/#/R-HSA-382556,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
ABC-family proteins mediated transpor,R-HSA-382556,https://reactome.org/PathwayBrowser/#/R-HSA-382556,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Circadian Cloc,,,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Circadian Cloc,,,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Circadian Cloc,,,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
TAK1-dependent IKK and NF-kappa-B activatio,R-HSA-445989,https://reactome.org/PathwayBrowser/#/R-HSA-445989,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
TAK1-dependent IKK and NF-kappa-B activatio,R-HSA-445989,https://reactome.org/PathwayBrowser/#/R-HSA-445989,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
TAK1-dependent IKK and NF-kappa-B activatio,R-HSA-445989,https://reactome.org/PathwayBrowser/#/R-HSA-445989,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
activated TAK1 mediates p38 MAPK activatio,R-HSA-450302,https://reactome.org/PathwayBrowser/#/R-HSA-450302,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
activated TAK1 mediates p38 MAPK activatio,R-HSA-450302,https://reactome.org/PathwayBrowser/#/R-HSA-450302,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
activated TAK1 mediates p38 MAPK activatio,R-HSA-450302,https://reactome.org/PathwayBrowser/#/R-HSA-450302,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK,R-HSA-450321,https://reactome.org/PathwayBrowser/#/R-HSA-450321,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK,R-HSA-450321,https://reactome.org/PathwayBrowser/#/R-HSA-450321,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK,R-HSA-450321,https://reactome.org/PathwayBrowser/#/R-HSA-450321,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
AUF1 (hnRNP D0) binds and destabilizes mRN,R-HSA-450408,https://reactome.org/PathwayBrowser/#/R-HSA-450408,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
AUF1 (hnRNP D0) binds and destabilizes mRN,R-HSA-450408,https://reactome.org/PathwayBrowser/#/R-HSA-450408,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
AUF1 (hnRNP D0) binds and destabilizes mRN,R-HSA-450408,https://reactome.org/PathwayBrowser/#/R-HSA-450408,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Asymmetric localization of PCP protein,R-HSA-4608870,https://reactome.org/PathwayBrowser/#/R-HSA-4608870,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Asymmetric localization of PCP protein,R-HSA-4608870,https://reactome.org/PathwayBrowser/#/R-HSA-4608870,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Asymmetric localization of PCP protein,R-HSA-4608870,https://reactome.org/PathwayBrowser/#/R-HSA-4608870,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Degradation of AXI,R-HSA-4641257,https://reactome.org/PathwayBrowser/#/R-HSA-4641257,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Degradation of AXI,R-HSA-4641257,https://reactome.org/PathwayBrowser/#/R-HSA-4641257,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Degradation of AXI,R-HSA-4641257,https://reactome.org/PathwayBrowser/#/R-HSA-4641257,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Degradation of DV,R-HSA-9766229,https://reactome.org/PathwayBrowser/#/R-HSA-9766229,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Degradation of DV,R-HSA-9766229,https://reactome.org/PathwayBrowser/#/R-HSA-9766229,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Degradation of DV,R-HSA-9766229,https://reactome.org/PathwayBrowser/#/R-HSA-9766229,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of FZD by ubiquitinatio,R-HSA-4641263,https://reactome.org/PathwayBrowser/#/R-HSA-4641263,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of FZD by ubiquitinatio,R-HSA-4641263,https://reactome.org/PathwayBrowser/#/R-HSA-4641263,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of FZD by ubiquitinatio,R-HSA-4641263,https://reactome.org/PathwayBrowser/#/R-HSA-4641263,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
PINK1-PRKN Mediated Mitophag,R-HSA-5205685,https://reactome.org/PathwayBrowser/#/R-HSA-5205685,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
PINK1-PRKN Mediated Mitophag,R-HSA-5205685,https://reactome.org/PathwayBrowser/#/R-HSA-5205685,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
PINK1-PRKN Mediated Mitophag,R-HSA-5205685,https://reactome.org/PathwayBrowser/#/R-HSA-5205685,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
N-glycan trimming in the ER and Calnexin/Calreticulin cycl,R-HSA-532668,https://reactome.org/PathwayBrowser/#/R-HSA-532668,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
N-glycan trimming in the ER and Calnexin/Calreticulin cycl,R-HSA-532668,https://reactome.org/PathwayBrowser/#/R-HSA-532668,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
N-glycan trimming in the ER and Calnexin/Calreticulin cycl,R-HSA-532668,https://reactome.org/PathwayBrowser/#/R-HSA-532668,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of TNFR1 signalin,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of TNFR1 signalin,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of TNFR1 signalin,R-HSA-5357905,https://reactome.org/PathwayBrowser/#/R-HSA-5357905,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
TNFR1-induced NF-kappa-B signaling pathwa,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
TNFR1-induced NF-kappa-B signaling pathwa,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
TNFR1-induced NF-kappa-B signaling pathwa,R-HSA-5357956,https://reactome.org/PathwayBrowser/#/R-HSA-5357956,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Hedgehog ligand biogenesi,R-HSA-5358346,https://reactome.org/PathwayBrowser/#/R-HSA-5358346,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Hedgehog ligand biogenesi,R-HSA-5358346,https://reactome.org/PathwayBrowser/#/R-HSA-5358346,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Hedgehog ligand biogenesi,R-HSA-5358346,https://reactome.org/PathwayBrowser/#/R-HSA-5358346,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Hh mutants are degraded by ERA,R-HSA-5362768,https://reactome.org/PathwayBrowser/#/R-HSA-5362768,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Hh mutants are degraded by ERA,R-HSA-5362768,https://reactome.org/PathwayBrowser/#/R-HSA-5362768,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Hh mutants are degraded by ERA,R-HSA-5362768,https://reactome.org/PathwayBrowser/#/R-HSA-5362768,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Dectin-1 mediated noncanonical NF-kB signalin,R-HSA-5607761,https://reactome.org/PathwayBrowser/#/R-HSA-5607761,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Dectin-1 mediated noncanonical NF-kB signalin,R-HSA-5607761,https://reactome.org/PathwayBrowser/#/R-HSA-5607761,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Dectin-1 mediated noncanonical NF-kB signalin,R-HSA-5607761,https://reactome.org/PathwayBrowser/#/R-HSA-5607761,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Degradation of GLI1 by the proteasom,R-HSA-5610780,https://reactome.org/PathwayBrowser/#/R-HSA-5610780,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Degradation of GLI1 by the proteasom,R-HSA-5610780,https://reactome.org/PathwayBrowser/#/R-HSA-5610780,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Degradation of GLI1 by the proteasom,R-HSA-5610780,https://reactome.org/PathwayBrowser/#/R-HSA-5610780,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Degradation of GLI2 by the proteasom,R-HSA-5610783,https://reactome.org/PathwayBrowser/#/R-HSA-5610783,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Degradation of GLI2 by the proteasom,R-HSA-5610783,https://reactome.org/PathwayBrowser/#/R-HSA-5610783,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Degradation of GLI2 by the proteasom,R-HSA-5610783,https://reactome.org/PathwayBrowser/#/R-HSA-5610783,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
GLI3 is processed to GLI3R by the proteasom,R-HSA-5610785,https://reactome.org/PathwayBrowser/#/R-HSA-5610785,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GLI3 is processed to GLI3R by the proteasom,R-HSA-5610785,https://reactome.org/PathwayBrowser/#/R-HSA-5610785,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GLI3 is processed to GLI3R by the proteasom,R-HSA-5610785,https://reactome.org/PathwayBrowser/#/R-HSA-5610785,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
TNFR2 non-canonical NF-kB pathwa,R-HSA-5668541,https://reactome.org/PathwayBrowser/#/R-HSA-5668541,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
TNFR2 non-canonical NF-kB pathwa,R-HSA-5668541,https://reactome.org/PathwayBrowser/#/R-HSA-5668541,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
TNFR2 non-canonical NF-kB pathwa,R-HSA-5668541,https://reactome.org/PathwayBrowser/#/R-HSA-5668541,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of necroptotic cell deat,R-HSA-5675482,https://reactome.org/PathwayBrowser/#/R-HSA-5675482,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of necroptotic cell deat,R-HSA-5675482,https://reactome.org/PathwayBrowser/#/R-HSA-5675482,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of necroptotic cell deat,R-HSA-5675482,https://reactome.org/PathwayBrowser/#/R-HSA-5675482,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
NIK-->noncanonical NF-kB signalin,R-HSA-5676590,https://reactome.org/PathwayBrowser/#/R-HSA-5676590,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
NIK-->noncanonical NF-kB signalin,R-HSA-5676590,https://reactome.org/PathwayBrowser/#/R-HSA-5676590,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
NIK-->noncanonical NF-kB signalin,R-HSA-5676590,https://reactome.org/PathwayBrowser/#/R-HSA-5676590,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Defective CFTR causes cystic fibrosi,R-HSA-5678895,https://reactome.org/PathwayBrowser/#/R-HSA-5678895,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Defective CFTR causes cystic fibrosi,R-HSA-5678895,https://reactome.org/PathwayBrowser/#/R-HSA-5678895,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Defective CFTR causes cystic fibrosi,R-HSA-5678895,https://reactome.org/PathwayBrowser/#/R-HSA-5678895,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
MAP3K8 (TPL2)-dependent MAPK1/3 activatio,R-HSA-112409,https://reactome.org/PathwayBrowser/#/R-HSA-112409,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
MAP3K8 (TPL2)-dependent MAPK1/3 activatio,R-HSA-112409,https://reactome.org/PathwayBrowser/#/R-HSA-112409,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
MAP3K8 (TPL2)-dependent MAPK1/3 activatio,R-HSA-112409,https://reactome.org/PathwayBrowser/#/R-HSA-112409,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
MAPK6/MAPK4 signalin,R-HSA-5687128,https://reactome.org/PathwayBrowser/#/R-HSA-5687128,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
MAPK6/MAPK4 signalin,R-HSA-5687128,https://reactome.org/PathwayBrowser/#/R-HSA-5687128,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
MAPK6/MAPK4 signalin,R-HSA-5687128,https://reactome.org/PathwayBrowser/#/R-HSA-5687128,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Josephin domain DUB,R-HSA-5689877,https://reactome.org/PathwayBrowser/#/R-HSA-5689877,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Josephin domain DUB,R-HSA-5689877,https://reactome.org/PathwayBrowser/#/R-HSA-5689877,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Josephin domain DUB,R-HSA-5689877,https://reactome.org/PathwayBrowser/#/R-HSA-5689877,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Metalloprotease DUB,R-HSA-5689901,https://reactome.org/PathwayBrowser/#/R-HSA-5689901,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Metalloprotease DUB,R-HSA-5689901,https://reactome.org/PathwayBrowser/#/R-HSA-5689901,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Metalloprotease DUB,R-HSA-5689901,https://reactome.org/PathwayBrowser/#/R-HSA-5689901,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Processing of DNA double-strand break end,R-HSA-5693607,https://reactome.org/PathwayBrowser/#/R-HSA-5693607,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Processing of DNA double-strand break end,R-HSA-5693607,https://reactome.org/PathwayBrowser/#/R-HSA-5693607,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Processing of DNA double-strand break end,R-HSA-5693607,https://reactome.org/PathwayBrowser/#/R-HSA-5693607,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
DNA Damage Recognition in GG-NE,R-HSA-5696394,https://reactome.org/PathwayBrowser/#/R-HSA-5696394,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
DNA Damage Recognition in GG-NE,R-HSA-5696394,https://reactome.org/PathwayBrowser/#/R-HSA-5696394,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
DNA Damage Recognition in GG-NE,R-HSA-5696394,https://reactome.org/PathwayBrowser/#/R-HSA-5696394,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Formation of TC-NER Pre-Incision Comple,R-HSA-6781823,https://reactome.org/PathwayBrowser/#/R-HSA-6781823,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Formation of TC-NER Pre-Incision Comple,R-HSA-6781823,https://reactome.org/PathwayBrowser/#/R-HSA-6781823,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Formation of TC-NER Pre-Incision Comple,R-HSA-6781823,https://reactome.org/PathwayBrowser/#/R-HSA-6781823,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Transcription-Coupled Nucleotide Excision Repair (TC-NER,R-HSA-6781827,https://reactome.org/PathwayBrowser/#/R-HSA-6781827,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Transcription-Coupled Nucleotide Excision Repair (TC-NER,R-HSA-6781827,https://reactome.org/PathwayBrowser/#/R-HSA-6781827,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Transcription-Coupled Nucleotide Excision Repair (TC-NER,R-HSA-6781827,https://reactome.org/PathwayBrowser/#/R-HSA-6781827,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Assembly of the pre-replicative comple,R-HSA-68867,https://reactome.org/PathwayBrowser/#/R-HSA-68867,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Assembly of the pre-replicative comple,R-HSA-68867,https://reactome.org/PathwayBrowser/#/R-HSA-68867,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Assembly of the pre-replicative comple,R-HSA-68867,https://reactome.org/PathwayBrowser/#/R-HSA-68867,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Orc1 removal from chromati,R-HSA-68949,https://reactome.org/PathwayBrowser/#/R-HSA-68949,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Orc1 removal from chromati,R-HSA-68949,https://reactome.org/PathwayBrowser/#/R-HSA-68949,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Orc1 removal from chromati,R-HSA-68949,https://reactome.org/PathwayBrowser/#/R-HSA-68949,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
CDK-mediated phosphorylation and removal of Cdc,R-HSA-69017,https://reactome.org/PathwayBrowser/#/R-HSA-69017,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
CDK-mediated phosphorylation and removal of Cdc,R-HSA-69017,https://reactome.org/PathwayBrowser/#/R-HSA-69017,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
CDK-mediated phosphorylation and removal of Cdc,R-HSA-69017,https://reactome.org/PathwayBrowser/#/R-HSA-69017,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Ubiquitin Mediated Degradation of Phosphorylated Cdc25,R-HSA-180534,https://reactome.org/PathwayBrowser/#/R-HSA-180534,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ubiquitin Mediated Degradation of Phosphorylated Cdc25,R-HSA-180534,https://reactome.org/PathwayBrowser/#/R-HSA-180534,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ubiquitin Mediated Degradation of Phosphorylated Cdc25,R-HSA-180534,https://reactome.org/PathwayBrowser/#/R-HSA-180534,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Ubiquitin-dependent degradation of Cyclin,R-HSA-75815,https://reactome.org/PathwayBrowser/#/R-HSA-75815,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Ubiquitin-dependent degradation of Cyclin,R-HSA-75815,https://reactome.org/PathwayBrowser/#/R-HSA-75815,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Ubiquitin-dependent degradation of Cyclin,R-HSA-75815,https://reactome.org/PathwayBrowser/#/R-HSA-75815,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
FBXL7 down-regulates AURKA during mitotic entry and in early mitosi,R-HSA-8854050,https://reactome.org/PathwayBrowser/#/R-HSA-8854050,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
FBXL7 down-regulates AURKA during mitotic entry and in early mitosi,R-HSA-8854050,https://reactome.org/PathwayBrowser/#/R-HSA-8854050,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
FBXL7 down-regulates AURKA during mitotic entry and in early mitosi,R-HSA-8854050,https://reactome.org/PathwayBrowser/#/R-HSA-8854050,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Downregulation of ERBB2 signalin,R-HSA-8863795,https://reactome.org/PathwayBrowser/#/R-HSA-8863795,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Downregulation of ERBB2 signalin,R-HSA-8863795,https://reactome.org/PathwayBrowser/#/R-HSA-8863795,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Downregulation of ERBB2 signalin,R-HSA-8863795,https://reactome.org/PathwayBrowser/#/R-HSA-8863795,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
VLDLR internalisation and degradatio,R-HSA-8866427,https://reactome.org/PathwayBrowser/#/R-HSA-8866427,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
VLDLR internalisation and degradatio,R-HSA-8866427,https://reactome.org/PathwayBrowser/#/R-HSA-8866427,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
VLDLR internalisation and degradatio,R-HSA-8866427,https://reactome.org/PathwayBrowser/#/R-HSA-8866427,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
E3 ubiquitin ligases ubiquitinate target protein,R-HSA-8866654,https://reactome.org/PathwayBrowser/#/R-HSA-8866654,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
E3 ubiquitin ligases ubiquitinate target protein,R-HSA-8866654,https://reactome.org/PathwayBrowser/#/R-HSA-8866654,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
E3 ubiquitin ligases ubiquitinate target protein,R-HSA-8866654,https://reactome.org/PathwayBrowser/#/R-HSA-8866654,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
InlA-mediated entry of Listeria monocytogenes into host cell,R-HSA-8876493,https://reactome.org/PathwayBrowser/#/R-HSA-8876493,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
InlA-mediated entry of Listeria monocytogenes into host cell,R-HSA-8876493,https://reactome.org/PathwayBrowser/#/R-HSA-8876493,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
InlA-mediated entry of Listeria monocytogenes into host cell,R-HSA-8876493,https://reactome.org/PathwayBrowser/#/R-HSA-8876493,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of RUNX2 expression and activit,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of RUNX2 expression and activit,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of RUNX2 expression and activit,R-HSA-8939902,https://reactome.org/PathwayBrowser/#/R-HSA-8939902,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of RUNX3 expression and activit,R-HSA-8941858,https://reactome.org/PathwayBrowser/#/R-HSA-8941858,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of RUNX3 expression and activit,R-HSA-8941858,https://reactome.org/PathwayBrowser/#/R-HSA-8941858,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of RUNX3 expression and activit,R-HSA-8941858,https://reactome.org/PathwayBrowser/#/R-HSA-8941858,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of PTEN stability and activit,R-HSA-8948751,https://reactome.org/PathwayBrowser/#/R-HSA-8948751,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of PTEN stability and activit,R-HSA-8948751,https://reactome.org/PathwayBrowser/#/R-HSA-8948751,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of PTEN stability and activit,R-HSA-8948751,https://reactome.org/PathwayBrowser/#/R-HSA-8948751,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Neddylatio,R-HSA-8951664,https://reactome.org/PathwayBrowser/#/R-HSA-8951664,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Neddylatio,R-HSA-8951664,https://reactome.org/PathwayBrowser/#/R-HSA-8951664,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Neddylatio,R-HSA-8951664,https://reactome.org/PathwayBrowser/#/R-HSA-8951664,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
ER Quality Control Compartment (ERQC,R-HSA-901032,https://reactome.org/PathwayBrowser/#/R-HSA-901032,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
ER Quality Control Compartment (ERQC,R-HSA-901032,https://reactome.org/PathwayBrowser/#/R-HSA-901032,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
ER Quality Control Compartment (ERQC,R-HSA-901032,https://reactome.org/PathwayBrowser/#/R-HSA-901032,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
NOTCH3 Activation and Transmission of Signal to the Nucleu,R-HSA-9013507,https://reactome.org/PathwayBrowser/#/R-HSA-9013507,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
NOTCH3 Activation and Transmission of Signal to the Nucleu,R-HSA-9013507,https://reactome.org/PathwayBrowser/#/R-HSA-9013507,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
NOTCH3 Activation and Transmission of Signal to the Nucleu,R-HSA-9013507,https://reactome.org/PathwayBrowser/#/R-HSA-9013507,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
TICAM1-dependent activation of IRF3/IRF,R-HSA-9013973,https://reactome.org/PathwayBrowser/#/R-HSA-9013973,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
TICAM1-dependent activation of IRF3/IRF,R-HSA-9013973,https://reactome.org/PathwayBrowser/#/R-HSA-9013973,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
TICAM1-dependent activation of IRF3/IRF,R-HSA-9013973,https://reactome.org/PathwayBrowser/#/R-HSA-9013973,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
"TICAM1,TRAF6-dependent induction of TAK1 comple",R-HSA-9014325,https://reactome.org/PathwayBrowser/#/R-HSA-9014325,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"TICAM1,TRAF6-dependent induction of TAK1 comple",R-HSA-9014325,https://reactome.org/PathwayBrowser/#/R-HSA-9014325,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"TICAM1,TRAF6-dependent induction of TAK1 comple",R-HSA-9014325,https://reactome.org/PathwayBrowser/#/R-HSA-9014325,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Interleukin-1 signalin,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Interleukin-1 signalin,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Interleukin-1 signalin,R-HSA-9020702,https://reactome.org/PathwayBrowser/#/R-HSA-9020702,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Interferon alpha/beta signalin,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Interferon alpha/beta signalin,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Interferon alpha/beta signalin,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Interferon alpha/beta signalin,R-HSA-909733,https://reactome.org/PathwayBrowser/#/R-HSA-909733,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Endosomal Sorting Complex Required For Transport (ESCRT,R-HSA-917729,https://reactome.org/PathwayBrowser/#/R-HSA-917729,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Endosomal Sorting Complex Required For Transport (ESCRT,R-HSA-917729,https://reactome.org/PathwayBrowser/#/R-HSA-917729,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Endosomal Sorting Complex Required For Transport (ESCRT,R-HSA-917729,https://reactome.org/PathwayBrowser/#/R-HSA-917729,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Iron uptake and transpor,R-HSA-917937,https://reactome.org/PathwayBrowser/#/R-HSA-917937,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Iron uptake and transpor,R-HSA-917937,https://reactome.org/PathwayBrowser/#/R-HSA-917937,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Iron uptake and transpor,R-HSA-917937,https://reactome.org/PathwayBrowser/#/R-HSA-917937,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Negative regulators of DDX58/IFIH1 signalin,R-HSA-936440,https://reactome.org/PathwayBrowser/#/R-HSA-936440,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Negative regulators of DDX58/IFIH1 signalin,R-HSA-936440,https://reactome.org/PathwayBrowser/#/R-HSA-936440,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Negative regulators of DDX58/IFIH1 signalin,R-HSA-936440,https://reactome.org/PathwayBrowser/#/R-HSA-936440,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
"Activation of IRF3, IRF7 mediated by TBK1, IKKEpsilon (IKBKE",R-HSA-936964,https://reactome.org/PathwayBrowser/#/R-HSA-936964,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
"Activation of IRF3, IRF7 mediated by TBK1, IKKEpsilon (IKBKE",R-HSA-936964,https://reactome.org/PathwayBrowser/#/R-HSA-936964,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Activation of IRF3, IRF7 mediated by TBK1, IKKEpsilon (IKBKE",R-HSA-936964,https://reactome.org/PathwayBrowser/#/R-HSA-936964,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Activation of IRF3, IRF7 mediated by TBK1, IKKEpsilon (IKBKE",R-HSA-936964,https://reactome.org/PathwayBrowser/#/R-HSA-936964,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
IRAK1 recruits IKK comple,R-HSA-937039,https://reactome.org/PathwayBrowser/#/R-HSA-937039,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
IRAK1 recruits IKK comple,R-HSA-937039,https://reactome.org/PathwayBrowser/#/R-HSA-937039,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
IRAK1 recruits IKK comple,R-HSA-937039,https://reactome.org/PathwayBrowser/#/R-HSA-937039,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
IKK complex recruitment mediated by RIP,R-HSA-937041,https://reactome.org/PathwayBrowser/#/R-HSA-937041,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
IKK complex recruitment mediated by RIP,R-HSA-937041,https://reactome.org/PathwayBrowser/#/R-HSA-937041,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
IKK complex recruitment mediated by RIP,R-HSA-937041,https://reactome.org/PathwayBrowser/#/R-HSA-937041,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
IRAK2 mediated activation of TAK1 comple,R-HSA-937042,https://reactome.org/PathwayBrowser/#/R-HSA-937042,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
IRAK2 mediated activation of TAK1 comple,R-HSA-937042,https://reactome.org/PathwayBrowser/#/R-HSA-937042,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
IRAK2 mediated activation of TAK1 comple,R-HSA-937042,https://reactome.org/PathwayBrowser/#/R-HSA-937042,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
TRAF6-mediated induction of TAK1 complex within TLR4 comple,R-HSA-937072,https://reactome.org/PathwayBrowser/#/R-HSA-937072,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
TRAF6-mediated induction of TAK1 complex within TLR4 comple,R-HSA-937072,https://reactome.org/PathwayBrowser/#/R-HSA-937072,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
TRAF6-mediated induction of TAK1 complex within TLR4 comple,R-HSA-937072,https://reactome.org/PathwayBrowser/#/R-HSA-937072,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Negative regulation of NOTCH4 signalin,R-HSA-9604323,https://reactome.org/PathwayBrowser/#/R-HSA-9604323,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Negative regulation of NOTCH4 signalin,R-HSA-9604323,https://reactome.org/PathwayBrowser/#/R-HSA-9604323,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Negative regulation of NOTCH4 signalin,R-HSA-9604323,https://reactome.org/PathwayBrowser/#/R-HSA-9604323,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Chaperone Mediated Autophag,R-HSA-9613829,https://reactome.org/PathwayBrowser/#/R-HSA-9613829,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Chaperone Mediated Autophag,R-HSA-9613829,https://reactome.org/PathwayBrowser/#/R-HSA-9613829,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Chaperone Mediated Autophag,R-HSA-9613829,https://reactome.org/PathwayBrowser/#/R-HSA-9613829,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Late endosomal microautophag,R-HSA-9615710,https://reactome.org/PathwayBrowser/#/R-HSA-9615710,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Late endosomal microautophag,R-HSA-9615710,https://reactome.org/PathwayBrowser/#/R-HSA-9615710,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Late endosomal microautophag,R-HSA-9615710,https://reactome.org/PathwayBrowser/#/R-HSA-9615710,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Prevention of phagosomal-lysosomal fusio,R-HSA-9636383,https://reactome.org/PathwayBrowser/#/R-HSA-9636383,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Prevention of phagosomal-lysosomal fusio,R-HSA-9636383,https://reactome.org/PathwayBrowser/#/R-HSA-9636383,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Prevention of phagosomal-lysosomal fusio,R-HSA-9636383,https://reactome.org/PathwayBrowser/#/R-HSA-9636383,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Modulation by Mtb of host immune syste,R-HSA-9637628,https://reactome.org/PathwayBrowser/#/R-HSA-9637628,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Modulation by Mtb of host immune syste,R-HSA-9637628,https://reactome.org/PathwayBrowser/#/R-HSA-9637628,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Modulation by Mtb of host immune syste,R-HSA-9637628,https://reactome.org/PathwayBrowser/#/R-HSA-9637628,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Alpha-protein kinase 1 signaling pathwa,R-HSA-9645460,https://reactome.org/PathwayBrowser/#/R-HSA-9645460,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Alpha-protein kinase 1 signaling pathwa,R-HSA-9645460,https://reactome.org/PathwayBrowser/#/R-HSA-9645460,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Alpha-protein kinase 1 signaling pathwa,R-HSA-9645460,https://reactome.org/PathwayBrowser/#/R-HSA-9645460,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Aggrephag,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Aggrephag,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Aggrephag,R-HSA-9646399,https://reactome.org/PathwayBrowser/#/R-HSA-9646399,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Pexophag,R-HSA-9664873,https://reactome.org/PathwayBrowser/#/R-HSA-9664873,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Pexophag,R-HSA-9664873,https://reactome.org/PathwayBrowser/#/R-HSA-9664873,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Pexophag,R-HSA-9664873,https://reactome.org/PathwayBrowser/#/R-HSA-9664873,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Maturation of protein,R-HSA-9683612,https://reactome.org/PathwayBrowser/#/R-HSA-9683612,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Maturation of protein,R-HSA-9683612,https://reactome.org/PathwayBrowser/#/R-HSA-9683612,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Maturation of protein,R-HSA-9683612,https://reactome.org/PathwayBrowser/#/R-HSA-9683612,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of BACH1 activit,R-HSA-9708530,https://reactome.org/PathwayBrowser/#/R-HSA-9708530,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of BACH1 activit,R-HSA-9708530,https://reactome.org/PathwayBrowser/#/R-HSA-9708530,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of BACH1 activit,R-HSA-9708530,https://reactome.org/PathwayBrowser/#/R-HSA-9708530,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signalin,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signalin,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signalin,R-HSA-975110,https://reactome.org/PathwayBrowser/#/R-HSA-975110,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulatio,R-HSA-975144,https://reactome.org/PathwayBrowser/#/R-HSA-975144,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulatio,R-HSA-975144,https://reactome.org/PathwayBrowser/#/R-HSA-975144,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulatio,R-HSA-975144,https://reactome.org/PathwayBrowser/#/R-HSA-975144,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulatio,R-HSA-975163,https://reactome.org/PathwayBrowser/#/R-HSA-975163,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulatio,R-HSA-975163,https://reactome.org/PathwayBrowser/#/R-HSA-975163,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulatio,R-HSA-975163,https://reactome.org/PathwayBrowser/#/R-HSA-975163,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L,R-HSA-9762114,https://reactome.org/PathwayBrowser/#/R-HSA-9762114,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L,R-HSA-9762114,https://reactome.org/PathwayBrowser/#/R-HSA-9762114,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L,R-HSA-9762114,https://reactome.org/PathwayBrowser/#/R-HSA-9762114,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Amyloid fiber formatio,R-HSA-977225,https://reactome.org/PathwayBrowser/#/R-HSA-977225,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Amyloid fiber formatio,R-HSA-977225,https://reactome.org/PathwayBrowser/#/R-HSA-977225,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Amyloid fiber formatio,R-HSA-977225,https://reactome.org/PathwayBrowser/#/R-HSA-977225,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
"Regulation of TBK1, IKKEpsilon (IKBKE)-mediated activation of IRF3, IRF",R-HSA-918233,https://reactome.org/PathwayBrowser/#/R-HSA-918233,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Regulation of TBK1, IKKEpsilon (IKBKE)-mediated activation of IRF3, IRF",R-HSA-918233,https://reactome.org/PathwayBrowser/#/R-HSA-918233,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Regulation of TBK1, IKKEpsilon (IKBKE)-mediated activation of IRF3, IRF",R-HSA-918233,https://reactome.org/PathwayBrowser/#/R-HSA-918233,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
"Regulation of TBK1, IKKEpsilon-mediated activation of IRF3, IRF7 upon TLR3 ligatio",R-HSA-9828211,https://reactome.org/PathwayBrowser/#/R-HSA-9828211,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
"Regulation of TBK1, IKKEpsilon-mediated activation of IRF3, IRF7 upon TLR3 ligatio",R-HSA-9828211,https://reactome.org/PathwayBrowser/#/R-HSA-9828211,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
"Regulation of TBK1, IKKEpsilon-mediated activation of IRF3, IRF7 upon TLR3 ligatio",R-HSA-9828211,https://reactome.org/PathwayBrowser/#/R-HSA-9828211,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Antigen processing: Ubiquitination & Proteasome degradatio,R-HSA-983168,https://reactome.org/PathwayBrowser/#/R-HSA-983168,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Antigen processing: Ubiquitination & Proteasome degradatio,R-HSA-983168,https://reactome.org/PathwayBrowser/#/R-HSA-983168,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Antigen processing: Ubiquitination & Proteasome degradatio,R-HSA-983168,https://reactome.org/PathwayBrowser/#/R-HSA-983168,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Evasion by RSV of host interferon response,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Evasion by RSV of host interferon response,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Evasion by RSV of host interferon response,R-HSA-9833109,https://reactome.org/PathwayBrowser/#/R-HSA-9833109,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Regulation of pyruvate metabolis,R-HSA-9861718,https://reactome.org/PathwayBrowser/#/R-HSA-9861718,RPS27A,ENSG00000143947,CHEMBL256997,ATALUREN,4.0,,MONDO_0010679,Duchenne muscular dystrophy,,O=C(O)c1cccc(-c2noc(-c3ccccc3F)n2)c1
Regulation of pyruvate metabolis,R-HSA-9861718,https://reactome.org/PathwayBrowser/#/R-HSA-9861718,RPS27A,ENSG00000143947,CHEMBL4297789,MT-3724,2.0,Terminated,EFO_0000403,diffuse large B-cell lymphoma,,
Regulation of pyruvate metabolis,R-HSA-9861718,https://reactome.org/PathwayBrowser/#/R-HSA-9861718,RPS27A,ENSG00000143947,CHEMBL4297744,ELX-02,2.0,Terminated,MONDO_0016239,cystinosis,,
Cytosolic iron-sulfur cluster assembl,R-HSA-2564830,https://reactome.org/PathwayBrowser/#/R-HSA-2564830,POLD1,ENSG00000062822,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
Cytosolic iron-sulfur cluster assembl,R-HSA-2564830,https://reactome.org/PathwayBrowser/#/R-HSA-2564830,POLD1,ENSG00000062822,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
Cytosolic iron-sulfur cluster assembl,R-HSA-2564830,https://reactome.org/PathwayBrowser/#/R-HSA-2564830,POLD1,ENSG00000062822,CHEMBL803,CYTARABINE,4.0,"Active, not recruiting",EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
Cytosolic iron-sulfur cluster assembl,R-HSA-2564830,https://reactome.org/PathwayBrowser/#/R-HSA-2564830,POLD1,ENSG00000062822,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Cytosolic iron-sulfur cluster assembl,R-HSA-2564830,https://reactome.org/PathwayBrowser/#/R-HSA-2564830,POLD1,ENSG00000062822,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
Cytosolic iron-sulfur cluster assembl,R-HSA-2564830,https://reactome.org/PathwayBrowser/#/R-HSA-2564830,POLD1,ENSG00000062822,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
Cytosolic iron-sulfur cluster assembl,R-HSA-2564830,https://reactome.org/PathwayBrowser/#/R-HSA-2564830,POLD1,ENSG00000062822,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Transcriptional activation of mitochondrial biogenesi,R-HSA-2151201,https://reactome.org/PathwayBrowser/#/R-HSA-2151201,IDH2,ENSG00000182054,CHEMBL3989931,ENASIDENIB MESYLATE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O
Transcriptional activation of mitochondrial biogenesi,R-HSA-2151201,https://reactome.org/PathwayBrowser/#/R-HSA-2151201,IDH2,ENSG00000182054,CHEMBL3989908,ENASIDENIB,3.0,Completed,EFO_0000565,leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1
Transcriptional activation of mitochondrial biogenesi,R-HSA-2151201,https://reactome.org/PathwayBrowser/#/R-HSA-2151201,IDH2,ENSG00000182054,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Citric acid cycle (TCA cycle,R-HSA-71403,https://reactome.org/PathwayBrowser/#/R-HSA-71403,IDH2,ENSG00000182054,CHEMBL3989931,ENASIDENIB MESYLATE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O
Citric acid cycle (TCA cycle,R-HSA-71403,https://reactome.org/PathwayBrowser/#/R-HSA-71403,IDH2,ENSG00000182054,CHEMBL3989908,ENASIDENIB,3.0,Completed,EFO_0000565,leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1
Citric acid cycle (TCA cycle,R-HSA-71403,https://reactome.org/PathwayBrowser/#/R-HSA-71403,IDH2,ENSG00000182054,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Mitochondrial protein degradatio,R-HSA-1268020,https://reactome.org/PathwayBrowser/#/R-HSA-1268020,IDH2,ENSG00000182054,CHEMBL3989931,ENASIDENIB MESYLATE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O
Mitochondrial protein degradatio,R-HSA-1268020,https://reactome.org/PathwayBrowser/#/R-HSA-1268020,IDH2,ENSG00000182054,CHEMBL3989908,ENASIDENIB,3.0,Completed,EFO_0000565,leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1
Mitochondrial protein degradatio,R-HSA-1268020,https://reactome.org/PathwayBrowser/#/R-HSA-1268020,IDH2,ENSG00000182054,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
Maturation of TCA enzymes and regulation of TCA cycl,R-HSA-9854311,https://reactome.org/PathwayBrowser/#/R-HSA-9854311,IDH2,ENSG00000182054,CHEMBL3989931,ENASIDENIB MESYLATE,4.0,,EFO_0000222,acute myeloid leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1.CS(=O)(=O)O
Maturation of TCA enzymes and regulation of TCA cycl,R-HSA-9854311,https://reactome.org/PathwayBrowser/#/R-HSA-9854311,IDH2,ENSG00000182054,CHEMBL3989908,ENASIDENIB,3.0,Completed,EFO_0000565,leukemia,,CC(C)(O)CNc1nc(Nc2ccnc(C(F)(F)F)c2)nc(-c2cccc(C(F)(F)F)n2)n1
Maturation of TCA enzymes and regulation of TCA cycl,R-HSA-9854311,https://reactome.org/PathwayBrowser/#/R-HSA-9854311,IDH2,ENSG00000182054,CHEMBL4279047,VORASIDENIB,3.0,"Active, not recruiting",EFO_1000453,Paraganglioma,,C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(-c2cccc(Cl)n2)n1)C(F)(F)F
G1/S-Specific Transcriptio,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL1096882,FLUDARABINE PHOSPHATE,4.0,,EFO_0000095,chronic lymphocytic leukemia,,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O
G1/S-Specific Transcriptio,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL1750,CLOFARABINE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F
G1/S-Specific Transcriptio,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL803,CYTARABINE,4.0,,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
G1/S-Specific Transcriptio,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL1637,GEMCITABINE HYDROCHLORIDE,4.0,,EFO_0000305,breast carcinoma,,Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
G1/S-Specific Transcriptio,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL888,GEMCITABINE,4.0,,EFO_0000616,neoplasm,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
G1/S-Specific Transcriptio,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL359164,TROXACITABINE,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1
G1/S-Specific Transcriptio,R-HSA-69205,https://reactome.org/PathwayBrowser/#/R-HSA-69205,POLA1,ENSG00000101868,CHEMBL4297599,ASPACYTARABINE,2.0,Completed,EFO_0000222,acute myeloid leukemia,,N[C@@H](CC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1)C(=O)O
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Prolactin receptor signalin,R-HSA-1170546,https://reactome.org/PathwayBrowser/#/R-HSA-1170546,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL1171837,PONATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL255863,NILOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL288441,BOSUTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL4297524,RADOTINIB,3.0,Recruiting,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Signaling by cytosolic FGFR1 fusion mutant,R-HSA-1839117,https://reactome.org/PathwayBrowser/#/R-HSA-1839117,BCR,ENSG00000186716,CHEMBL4130229,VODOBATINIB,2.0,Recruiting,HP_0000726,Dementia,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by Lepti,R-HSA-2586552,https://reactome.org/PathwayBrowser/#/R-HSA-2586552,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-20 family signalin,R-HSA-8854691,https://reactome.org/PathwayBrowser/#/R-HSA-8854691,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Erythropoietin activates STAT,R-HSA-9027283,https://reactome.org/PathwayBrowser/#/R-HSA-9027283,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by FLT3 fusion protein,R-HSA-9703465,https://reactome.org/PathwayBrowser/#/R-HSA-9703465,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by FLT3 fusion protein,R-HSA-9703465,https://reactome.org/PathwayBrowser/#/R-HSA-9703465,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Growth hormone receptor signalin,R-HSA-982772,https://reactome.org/PathwayBrowser/#/R-HSA-982772,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
SOS-mediated signallin,R-HSA-112412,https://reactome.org/PathwayBrowser/#/R-HSA-112412,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
SOS-mediated signallin,R-HSA-112412,https://reactome.org/PathwayBrowser/#/R-HSA-112412,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Activation of RAS in B cell,R-HSA-1169092,https://reactome.org/PathwayBrowser/#/R-HSA-1169092,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Activation of RAS in B cell,R-HSA-1169092,https://reactome.org/PathwayBrowser/#/R-HSA-1169092,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
SHC1 events in ERBB4 signalin,R-HSA-1250347,https://reactome.org/PathwayBrowser/#/R-HSA-1250347,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
SHC1 events in ERBB4 signalin,R-HSA-1250347,https://reactome.org/PathwayBrowser/#/R-HSA-1250347,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signalling to RA,R-HSA-5365859,https://reactome.org/PathwayBrowser/#/R-HSA-5365859,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signalling to RA,R-HSA-5365859,https://reactome.org/PathwayBrowser/#/R-HSA-5365859,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
p38MAPK event,R-HSA-171007,https://reactome.org/PathwayBrowser/#/R-HSA-171007,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
p38MAPK event,R-HSA-171007,https://reactome.org/PathwayBrowser/#/R-HSA-171007,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
GRB2 events in EGFR signalin,R-HSA-179812,https://reactome.org/PathwayBrowser/#/R-HSA-179812,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
GRB2 events in EGFR signalin,R-HSA-179812,https://reactome.org/PathwayBrowser/#/R-HSA-179812,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
SHC1 events in EGFR signalin,R-HSA-180336,https://reactome.org/PathwayBrowser/#/R-HSA-180336,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
SHC1 events in EGFR signalin,R-HSA-180336,https://reactome.org/PathwayBrowser/#/R-HSA-180336,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
GRB2 events in ERBB2 signalin,R-HSA-1963640,https://reactome.org/PathwayBrowser/#/R-HSA-1963640,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
GRB2 events in ERBB2 signalin,R-HSA-1963640,https://reactome.org/PathwayBrowser/#/R-HSA-1963640,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Tie2 Signalin,R-HSA-210993,https://reactome.org/PathwayBrowser/#/R-HSA-210993,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Tie2 Signalin,R-HSA-210993,https://reactome.org/PathwayBrowser/#/R-HSA-210993,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Tie2 Signalin,R-HSA-210993,https://reactome.org/PathwayBrowser/#/R-HSA-210993,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
DAP12 signalin,R-HSA-2424491,https://reactome.org/PathwayBrowser/#/R-HSA-2424491,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
DAP12 signalin,R-HSA-2424491,https://reactome.org/PathwayBrowser/#/R-HSA-2424491,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
SHC-related events triggered by IGF1,R-HSA-2428933,https://reactome.org/PathwayBrowser/#/R-HSA-2428933,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
SHC-related events triggered by IGF1,R-HSA-2428933,https://reactome.org/PathwayBrowser/#/R-HSA-2428933,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
FCERI mediated MAPK activatio,R-HSA-2871796,https://reactome.org/PathwayBrowser/#/R-HSA-2871796,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
FCERI mediated MAPK activatio,R-HSA-2871796,https://reactome.org/PathwayBrowser/#/R-HSA-2871796,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
NCAM signaling for neurite out-growt,R-HSA-375165,https://reactome.org/PathwayBrowser/#/R-HSA-375165,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
NCAM signaling for neurite out-growt,R-HSA-375165,https://reactome.org/PathwayBrowser/#/R-HSA-375165,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Ca2+ pathway. [P01116-,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Ca2+ pathway. [P01116-,R-HSA-4086398,https://reactome.org/PathwayBrowser/#/R-HSA-4086398,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Ras activation upon Ca2+ influx through NMDA recepto,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Ras activation upon Ca2+ influx through NMDA recepto,R-HSA-442982,https://reactome.org/PathwayBrowser/#/R-HSA-442982,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
SHC-mediated cascade:FGFR,R-HSA-5654699,https://reactome.org/PathwayBrowser/#/R-HSA-5654699,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
SHC-mediated cascade:FGFR,R-HSA-5654699,https://reactome.org/PathwayBrowser/#/R-HSA-5654699,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
FRS-mediated FGFR1 signalin,R-HSA-5654693,https://reactome.org/PathwayBrowser/#/R-HSA-5654693,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
FRS-mediated FGFR1 signalin,R-HSA-5654693,https://reactome.org/PathwayBrowser/#/R-HSA-5654693,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
FRS-mediated FGFR1 signalin,R-HSA-5654693,https://reactome.org/PathwayBrowser/#/R-HSA-5654693,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
FRS-mediated FGFR2 signalin,R-HSA-5654700,https://reactome.org/PathwayBrowser/#/R-HSA-5654700,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
FRS-mediated FGFR2 signalin,R-HSA-5654700,https://reactome.org/PathwayBrowser/#/R-HSA-5654700,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
FRS-mediated FGFR2 signalin,R-HSA-5654700,https://reactome.org/PathwayBrowser/#/R-HSA-5654700,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
FRS-mediated FGFR3 signalin,R-HSA-5654706,https://reactome.org/PathwayBrowser/#/R-HSA-5654706,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
FRS-mediated FGFR3 signalin,R-HSA-5654706,https://reactome.org/PathwayBrowser/#/R-HSA-5654706,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
FRS-mediated FGFR3 signalin,R-HSA-5654706,https://reactome.org/PathwayBrowser/#/R-HSA-5654706,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
FRS-mediated FGFR4 signalin,R-HSA-5654712,https://reactome.org/PathwayBrowser/#/R-HSA-5654712,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
FRS-mediated FGFR4 signalin,R-HSA-5654712,https://reactome.org/PathwayBrowser/#/R-HSA-5654712,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
FRS-mediated FGFR4 signalin,R-HSA-5654712,https://reactome.org/PathwayBrowser/#/R-HSA-5654712,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Signaling by FGFR2 in diseas,R-HSA-5654738,https://reactome.org/PathwayBrowser/#/R-HSA-5654738,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by FGFR2 in diseas,R-HSA-5654738,https://reactome.org/PathwayBrowser/#/R-HSA-5654738,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by FGFR4 in diseas,R-HSA-5654743,https://reactome.org/PathwayBrowser/#/R-HSA-5654743,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by FGFR4 in diseas,R-HSA-5654743,https://reactome.org/PathwayBrowser/#/R-HSA-5654743,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL1171837,PONATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL255863,NILOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL288441,BOSUTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL4297524,RADOTINIB,3.0,Recruiting,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,BCR,ENSG00000186716,CHEMBL4130229,VODOBATINIB,2.0,Recruiting,HP_0000726,Dementia,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by FGFR1 in diseas,R-HSA-5654736,https://reactome.org/PathwayBrowser/#/R-HSA-5654736,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by FGFR3 in diseas,R-HSA-5654741,https://reactome.org/PathwayBrowser/#/R-HSA-5654741,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by FGFR3 in diseas,R-HSA-5654741,https://reactome.org/PathwayBrowser/#/R-HSA-5654741,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Insulin receptor signalling cascad,R-HSA-74751,https://reactome.org/PathwayBrowser/#/R-HSA-74751,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Insulin receptor signalling cascad,R-HSA-74751,https://reactome.org/PathwayBrowser/#/R-HSA-74751,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinase",R-HSA-8849471,https://reactome.org/PathwayBrowser/#/R-HSA-8849471,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinase",R-HSA-8849471,https://reactome.org/PathwayBrowser/#/R-HSA-8849471,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
MET activates RAS signalin,R-HSA-8851805,https://reactome.org/PathwayBrowser/#/R-HSA-8851805,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
MET activates RAS signalin,R-HSA-8851805,https://reactome.org/PathwayBrowser/#/R-HSA-8851805,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Activated NTRK2 signals through RA,R-HSA-9032500,https://reactome.org/PathwayBrowser/#/R-HSA-9032500,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Activated NTRK2 signals through RA,R-HSA-9032500,https://reactome.org/PathwayBrowser/#/R-HSA-9032500,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Erythropoietin activates RA,R-HSA-9027284,https://reactome.org/PathwayBrowser/#/R-HSA-9027284,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Activated NTRK2 signals through FRS2 and FRS,R-HSA-9028731,https://reactome.org/PathwayBrowser/#/R-HSA-9028731,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Activated NTRK2 signals through FRS2 and FRS,R-HSA-9028731,https://reactome.org/PathwayBrowser/#/R-HSA-9028731,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Activated NTRK2 signals through FRS2 and FRS,R-HSA-9028731,https://reactome.org/PathwayBrowser/#/R-HSA-9028731,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Activated NTRK3 signals through RA,R-HSA-9603381,https://reactome.org/PathwayBrowser/#/R-HSA-9603381,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Activated NTRK3 signals through RA,R-HSA-9603381,https://reactome.org/PathwayBrowser/#/R-HSA-9603381,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Constitutive Signaling by Overexpressed ERBB,R-HSA-9634285,https://reactome.org/PathwayBrowser/#/R-HSA-9634285,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Constitutive Signaling by Overexpressed ERBB,R-HSA-9634285,https://reactome.org/PathwayBrowser/#/R-HSA-9634285,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by ERBB2 KD Mutant,R-HSA-9664565,https://reactome.org/PathwayBrowser/#/R-HSA-9664565,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by ERBB2 KD Mutant,R-HSA-9664565,https://reactome.org/PathwayBrowser/#/R-HSA-9664565,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by ERBB2 ECD mutant,R-HSA-9665348,https://reactome.org/PathwayBrowser/#/R-HSA-9665348,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by ERBB2 ECD mutant,R-HSA-9665348,https://reactome.org/PathwayBrowser/#/R-HSA-9665348,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by ERBB2 TMD/JMD mutant,R-HSA-9665686,https://reactome.org/PathwayBrowser/#/R-HSA-9665686,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by ERBB2 TMD/JMD mutant,R-HSA-9665686,https://reactome.org/PathwayBrowser/#/R-HSA-9665686,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutant",R-HSA-9673767,https://reactome.org/PathwayBrowser/#/R-HSA-9673767,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Signaling by PDGFRA extracellular domain mutant,R-HSA-9673770,https://reactome.org/PathwayBrowser/#/R-HSA-9673770,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Signaling by RAS GAP mutant,R-HSA-9753510,https://reactome.org/PathwayBrowser/#/R-HSA-9753510,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by RAS GAP mutant,R-HSA-9753510,https://reactome.org/PathwayBrowser/#/R-HSA-9753510,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Signaling by RAS GTPase mutant,R-HSA-9753512,https://reactome.org/PathwayBrowser/#/R-HSA-9753512,KRAS,ENSG00000133703,CHEMBL4535757,SOTORASIB,4.0,,EFO_0000616,neoplasm,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1
Signaling by RAS GTPase mutant,R-HSA-9753512,https://reactome.org/PathwayBrowser/#/R-HSA-9753512,KRAS,ENSG00000133703,CHEMBL4594350,ADAGRASIB,4.0,,EFO_0000616,neoplasm,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cel,R-HSA-198933,https://reactome.org/PathwayBrowser/#/R-HSA-198933,CD33,ENSG00000105383,CHEMBL1201506,GEMTUZUMAB OZOGAMICIN,4.0,,EFO_0000222,acute myeloid leukemia,,
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cel,R-HSA-198933,https://reactome.org/PathwayBrowser/#/R-HSA-198933,CD33,ENSG00000105383,CHEMBL2108342,GEMTUZUMAB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cel,R-HSA-198933,https://reactome.org/PathwayBrowser/#/R-HSA-198933,CD33,ENSG00000105383,CHEMBL2109150,LINTUZUMAB,3.0,Unknown status,EFO_0000565,leukemia,,
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cel,R-HSA-198933,https://reactome.org/PathwayBrowser/#/R-HSA-198933,CD33,ENSG00000105383,CHEMBL2109267,M195,1.0,Completed,EFO_0000198,myelodysplastic syndrome,,
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cel,R-HSA-198933,https://reactome.org/PathwayBrowser/#/R-HSA-198933,CD33,ENSG00000105383,CHEMBL2109266,AVE-9633,1.0,Terminated,MONDO_0004643,myeloid leukemia,,
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
MAPK3 (ERK1) activatio,R-HSA-110056,https://reactome.org/PathwayBrowser/#/R-HSA-110056,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
MAPK1 (ERK2) activatio,R-HSA-112411,https://reactome.org/PathwayBrowser/#/R-HSA-112411,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
GAB1 signalosom,R-HSA-180292,https://reactome.org/PathwayBrowser/#/R-HSA-180292,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
PECAM1 interaction,R-HSA-210990,https://reactome.org/PathwayBrowser/#/R-HSA-210990,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Co-inhibition by CTLA,R-HSA-389513,https://reactome.org/PathwayBrowser/#/R-HSA-389513,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Co-inhibition by PD-,R-HSA-389948,https://reactome.org/PathwayBrowser/#/R-HSA-389948,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Signal regulatory protein family interaction,R-HSA-391160,https://reactome.org/PathwayBrowser/#/R-HSA-391160,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Netrin mediated repulsion signal,R-HSA-418886,https://reactome.org/PathwayBrowser/#/R-HSA-418886,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Platelet sensitization by LD,R-HSA-432142,https://reactome.org/PathwayBrowser/#/R-HSA-432142,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
PI-3K cascade:FGFR,R-HSA-5654695,https://reactome.org/PathwayBrowser/#/R-HSA-5654695,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Regulation of IFNG signalin,R-HSA-877312,https://reactome.org/PathwayBrowser/#/R-HSA-877312,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
MET activates PTPN1,R-HSA-8865999,https://reactome.org/PathwayBrowser/#/R-HSA-8865999,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Interleukin-37 signalin,R-HSA-9008059,https://reactome.org/PathwayBrowser/#/R-HSA-9008059,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Regulation of IFNA/IFNB signalin,R-HSA-912694,https://reactome.org/PathwayBrowser/#/R-HSA-912694,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
Co-inhibition by BTL,R-HSA-9927353,https://reactome.org/PathwayBrowser/#/R-HSA-9927353,PTPN11,ENSG00000179295,CHEMBL4650521,BATOPROTAFIB,1.0,Recruiting,EFO_0000616,neoplasm,,C[C@@H]1OCC2(CCN(c3cnc(Sc4ccnc(N)c4Cl)c(N)n3)CC2)[C@@H]1N
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL1171837,PONATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL255863,NILOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL288441,BOSUTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL4297524,RADOTINIB,3.0,Recruiting,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RHOA GTPase cycl,R-HSA-8980692,https://reactome.org/PathwayBrowser/#/R-HSA-8980692,BCR,ENSG00000186716,CHEMBL4130229,VODOBATINIB,2.0,Recruiting,HP_0000726,Dementia,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL1171837,PONATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL255863,NILOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL288441,BOSUTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL4297524,RADOTINIB,3.0,Recruiting,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RHOB GTPase cycl,R-HSA-9013026,https://reactome.org/PathwayBrowser/#/R-HSA-9013026,BCR,ENSG00000186716,CHEMBL4130229,VODOBATINIB,2.0,Recruiting,HP_0000726,Dementia,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL1171837,PONATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL255863,NILOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL288441,BOSUTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL4297524,RADOTINIB,3.0,Recruiting,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RHOC GTPase cycl,R-HSA-9013106,https://reactome.org/PathwayBrowser/#/R-HSA-9013106,BCR,ENSG00000186716,CHEMBL4130229,VODOBATINIB,2.0,Recruiting,HP_0000726,Dementia,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL1171837,PONATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL255863,NILOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL288441,BOSUTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL4297524,RADOTINIB,3.0,Recruiting,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
CDC42 GTPase cycl,R-HSA-9013148,https://reactome.org/PathwayBrowser/#/R-HSA-9013148,BCR,ENSG00000186716,CHEMBL4130229,VODOBATINIB,2.0,Recruiting,HP_0000726,Dementia,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL1171837,PONATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL255863,NILOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL288441,BOSUTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL4297524,RADOTINIB,3.0,Recruiting,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RAC1 GTPase cycl,R-HSA-9013149,https://reactome.org/PathwayBrowser/#/R-HSA-9013149,BCR,ENSG00000186716,CHEMBL4130229,VODOBATINIB,2.0,Recruiting,HP_0000726,Dementia,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL1171837,PONATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL255863,NILOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL288441,BOSUTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL4297524,RADOTINIB,3.0,Recruiting,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RAC2 GTPase cycl,R-HSA-9013404,https://reactome.org/PathwayBrowser/#/R-HSA-9013404,BCR,ENSG00000186716,CHEMBL4130229,VODOBATINIB,2.0,Recruiting,HP_0000726,Dementia,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL1421,DASATINIB ANHYDROUS,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL2105708,PONATINIB HYDROCHLORIDE,4.0,,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12.Cl
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL1201740,NILOTINIB HYDROCHLORIDE MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1.Cl.O
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL4297220,ASCIMINIB HYDROCHLORIDE,4.0,,EFO_0000339,chronic myelogenous leukemia,,Cl.O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL1642,IMATINIB MESYLATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL2095206,BOSUTINIB MONOHYDRATE,4.0,,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl.O
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL4208229,ASCIMINIB,4.0,,EFO_0000616,neoplasm,,O=C(Nc1ccc(OC(F)(F)Cl)cc1)c1cnc(N2CC[C@@H](O)C2)c(-c2cc[nH]n2)c1
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL1171837,PONATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL941,IMATINIB,3.0,Recruiting,EFO_0000209,T-cell acute lymphoblastic leukemia,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL2316582,OLVEREMBATINIB,3.0,Recruiting,EFO_0000220,acute lymphoblastic leukemia,,Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2[nH]ncc2c1
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL255863,NILOTINIB,3.0,"Active, not recruiting",EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL288441,BOSUTINIB,3.0,Completed,EFO_0000339,chronic myelogenous leukemia,,COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL4297524,RADOTINIB,3.0,Recruiting,EFO_0000339,chronic myelogenous leukemia,,Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cnccn5)n4)c3)cc(C(F)(F)F)c2)cn1
RAC3 GTPase cycl,R-HSA-9013423,https://reactome.org/PathwayBrowser/#/R-HSA-9013423,BCR,ENSG00000186716,CHEMBL4130229,VODOBATINIB,2.0,Recruiting,HP_0000726,Dementia,,Cc1ccc(C(=O)NNC(=O)c2c(C)cccc2Cl)cc1C#Cc1cnc2ccccc2c1
Transcriptional Regulation by E2F,R-HSA-8953750,https://reactome.org/PathwayBrowser/#/R-HSA-8953750,EZH2,ENSG00000106462,CHEMBL4594260,TAZEMETOSTAT HYDROBROMIDE,4.0,,EFO_0000691,sarcoma,,Br.CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Transcriptional Regulation by E2F,R-HSA-8953750,https://reactome.org/PathwayBrowser/#/R-HSA-8953750,EZH2,ENSG00000106462,CHEMBL3414621,TAZEMETOSTAT,4.0,,EFO_0000616,neoplasm,,CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1
Transcriptional Regulation by E2F,R-HSA-8953750,https://reactome.org/PathwayBrowser/#/R-HSA-8953750,EZH2,ENSG00000106462,CHEMBL3287735,GSK2816126,1.0,Terminated,EFO_0000616,neoplasm,,CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
IL-6-type cytokine receptor ligand interaction,R-HSA-6788467,https://reactome.org/PathwayBrowser/#/R-HSA-6788467,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-35 Signallin,R-HSA-8984722,https://reactome.org/PathwayBrowser/#/R-HSA-8984722,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Signaling by Erythropoieti,R-HSA-9006335,https://reactome.org/PathwayBrowser/#/R-HSA-9006335,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-12 signalin,R-HSA-9020591,https://reactome.org/PathwayBrowser/#/R-HSA-9020591,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-23 signalin,R-HSA-9020933,https://reactome.org/PathwayBrowser/#/R-HSA-9020933,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Interleukin-27 signalin,R-HSA-9020956,https://reactome.org/PathwayBrowser/#/R-HSA-9020956,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Erythropoietin activates Phosphoinositide-3-kinase (PI3K,R-HSA-9027276,https://reactome.org/PathwayBrowser/#/R-HSA-9027276,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Erythropoietin activates Phospholipase C gamma (PLCG,R-HSA-9027277,https://reactome.org/PathwayBrowser/#/R-HSA-9027277,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1287853,FEDRATINIB,4.0,,EFO_0000616,neoplasm,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2105759,BARICITINIB,4.0,,EFO_0000685,rheumatoid arthritis,,CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL5315119,UPADACITINIB HEMIHYDRATE,4.0,,EFO_0000685,rheumatoid arthritis,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1789941,RUXOLITINIB,4.0,,EFO_0000616,neoplasm,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2035187,PACRITINIB,4.0,,EFO_0000616,neoplasm,,C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1795071,RUXOLITINIB PHOSPHATE,4.0,,EFO_0002429,polycythemia vera,,N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL5095049,PACRITINIB CITRATE,4.0,,EFO_0002429,polycythemia vera,,C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1.O=C(O)CC(O)(CC(=O)O)C(=O)O
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4297216,FEDRATINIB HYDROCHLORIDE,4.0,,EFO_0002430,primary myelofibrosis,,Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1.Cl.Cl.O
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2103743,TOFACITINIB CITRATE,4.0,,EFO_0000685,rheumatoid arthritis,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4298167,FILGOTINIB MALEATE,4.0,,EFO_0000685,rheumatoid arthritis,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1.O=C(O)/C=C\C(=O)O
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL603469,LESTAURTINIB,3.0,"Active, not recruiting",EFO_0000220,acute lymphoblastic leukemia,,C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3622821,UPADACITINIB,3.0,"Active, not recruiting",EFO_0000274,atopic eczema,,CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3301607,FILGOTINIB,3.0,Completed,EFO_0000384,Crohn's disease,,O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL221959,TOFACITINIB,3.0,,EFO_0000540,immune system disease,,C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3137308,PEFICITINIB,3.0,,EFO_0000540,immune system disease,,NC(=O)c1cnc2[nH]ccc2c1N[C@@H]1[C@@H]2CC3C[C@H]1C[C@@](O)(C3)C2
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1078178,MOMELOTINIB,3.0,Completed,EFO_0002430,primary myelofibrosis,,N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4297507,DELGOCITINIB,3.0,Recruiting,HP_0000964,Eczematoid dermatitis,,C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4594275,GUSACITINIB,2.0,Terminated,EFO_0000274,atopic eczema,,N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4650343,IZENCITINIB,2.0,Terminated,EFO_0000384,Crohn's disease,,Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL2107823,GANDOTINIB,2.0,"Active, not recruiting",EFO_0000616,neoplasm,,Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)n[nH]1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL495727,AT-9283,2.0,Completed,EFO_0001378,multiple myeloma,,O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1944698,ZOTIRACICLIB,1.0,Withdrawn,EFO_0000182,hepatocellular carcinoma,,CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL1231124,AZD-1480,1.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3545241,AC-430,1.0,Completed,EFO_0000685,rheumatoid arthritis,,Cc1cc(Nc2nc(C(O)c3ccc(F)cc3)nc3ccccc23)n[nH]1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3545328,XL-019,1.0,Terminated,EFO_0000479,essential thrombocythemia,,O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4802163,NEZULCITINIB,1.0,Completed,EFO_0004610,acute lung injury,,CCc1cc(O)ccc1-c1ccc2c(-c3nc4c([nH]3)C[C@@H](C(=O)N3CC(N(C)C)C3)N(C(C)C)C4)n[nH]c2c1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL4303389,NS-018,1.0,Completed,EFO_0002430,primary myelofibrosis,,C[C@H](Nc1cc(-c2cnn(C)c2)cc(Nc2cnccn2)n1)c1ccc(F)cc1
Potential therapeutics for SAR,R-HSA-9679191,https://reactome.org/PathwayBrowser/#/R-HSA-9679191,JAK2,ENSG00000096968,CHEMBL3545215,BMS-911543,1.0,Terminated,MONDO_0004992,cancer,,CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Imatinib-resistant PDGFR mutant,R-HSA-9674396,https://reactome.org/PathwayBrowser/#/R-HSA-9674396,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Sunitinib-resistant PDGFR mutant,R-HSA-9674401,https://reactome.org/PathwayBrowser/#/R-HSA-9674401,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Regorafenib-resistant PDGFR mutant,R-HSA-9674403,https://reactome.org/PathwayBrowser/#/R-HSA-9674403,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
Sorafenib-resistant PDGFR mutant,R-HSA-9674404,https://reactome.org/PathwayBrowser/#/R-HSA-9674404,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL608533,MIDOSTAURIN,4.0,,EFO_0000222,acute myeloid leukemia,,CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL4204794,AVAPRITINIB,4.0,,EFO_0000616,neoplasm,,Cn1cc(-c2cc3c(N4CCN(c5ncc([C@@](C)(N)c6ccc(F)cc6)cn5)CC4)ncnn3c2)cn1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL4216467,RIPRETINIB,4.0,,EFO_0000616,neoplasm,,CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1743049,OLARATUMAB,4.0,,EFO_0000616,neoplasm,,
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL535,SUNITINIB,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1201733,PAZOPANIB HYDROCHLORIDE,4.0,,EFO_0000691,sarcoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O.Cl
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL3039504,NINTEDANIB ESYLATE,4.0,,EFO_0000768,idiopathic pulmonary fibrosis,,CCS(=O)(=O)O.COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1908391,MASITINIB,4.0,,EFO_0000616,neoplasm,,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1946170,REGORAFENIB,4.0,,EFO_0000616,neoplasm,,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1567,SUNITINIB MALATE,4.0,,EFO_0000681,renal cell carcinoma,,CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1201556,BECAPLERMIN,4.0,,HP_0200042,Skin ulcer,,
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL223360,LINIFANIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL274654,ORANTINIB,3.0,Terminated,EFO_0000182,hepatocellular carcinoma,,Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL2105728,CRENOLANIB,3.0,Recruiting,EFO_0000222,acute myeloid leukemia,,CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL576982,QUIZARTINIB,3.0,Completed,EFO_0000222,acute myeloid leukemia,,CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL477772,PAZOPANIB,3.0,"Active, not recruiting",EFO_0000349,clear cell renal carcinoma,,Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1278146,FAMITINIB,3.0,Completed,EFO_0000365,colorectal adenocarcinoma,,CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL502835,NINTEDANIB,3.0,,EFO_0000616,neoplasm,,COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL491473,CEDIRANIB,3.0,Completed,EFO_0000519,glioblastoma multiforme,,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL522892,DOVITINIB,3.0,Completed,EFO_0000681,renal cell carcinoma,,CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL572881,MOTESANIB,3.0,Terminated,EFO_0003060,non-small cell lung carcinoma,,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL4650333,SERALUTINIB,3.0,Not yet recruiting,EFO_0001361,pulmonary arterial hypertension,,COc1ccc(-c2cncc(N[C@@H](C)c3cccc(NC(=O)c4cncc(C)c4)c3)n2)cc1OC
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL101253,VATALANIB,3.0,Completed,EFO_0004288,colonic neoplasm,,Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL5314391,XL-999,2.0,Terminated,EFO_0000222,acute myeloid leukemia,,CCN1CCC(Nc2ccc3c(c2)/C(=C(\c2cccc(F)c2)c2nc(C)c[nH]2)C(=O)N3)CC1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL2364651,TOVETUMAB,2.0,Completed,EFO_0000519,glioblastoma multiforme,,
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1230609,FORETINIB,2.0,Completed,EFO_0000681,renal cell carcinoma,,COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL2103851,AMUVATINIB,2.0,Completed,EFO_0000702,small cell lung carcinoma,,S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL3545401,X-82,2.0,Terminated,EFO_0001365,age-related macular degeneration,,
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1721885,SU-014813,2.0,Completed,EFO_0003869,breast neoplasm,,Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL52885,ENMD-981693,2.0,Completed,EFO_0002618,pancreatic carcinoma,,Cn1cc(C2=C(c3cn(C)c4cc([N+](=O)[O-])ccc34)C(=O)NC2=O)c2ccccc21
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL1980297,ILORASERTIB,2.0,Terminated,MONDO_0004992,cancer,,Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL3545402,XL-820,2.0,Completed,MONDO_0011719,gastrointestinal stromal tumor,,
PDGFR mutants bind TKI,R-HSA-9674428,https://reactome.org/PathwayBrowser/#/R-HSA-9674428,PDGFRA,ENSG00000134853,CHEMBL2180604,TAK-593,1.0,Completed,EFO_0000616,neoplasm,,Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1
